

AD _____

Award Number: DAMD17-04-1-0783

TITLE: Breast Cancer in three dimensions: Revealing telomere dysfunction in Breast Cancer

PRINCIPAL INVESTIGATOR: William Foulkes, Ph.D.

CONTRACTING ORGANIZATION: McGill University Health Center
Montreal, Qc H3G 1A4

REPORT DATE: September 2006

TYPE OF REPORT: Final Addendum

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE (DD-MM-YYYY) 01/09/06		2. REPORT TYPE Final Addendum		3. DATES COVERED (From - To) 1 Jul 2003 – 30 Jun 2006	
4. TITLE AND SUBTITLE Breast Cancer in three dimensions: Revealing telomere dysfunction in Breast Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER DAMD17-04-1-0783	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) William Foulkes, Ph.D. E-Mail: william.foulkes@mcgill.ca				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) McGill University Health Center Montreal, Qc H3G 1A4				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT: The structural re-modeling of the mammalian nucleus is a key feature of cancer cells. Such reorganization of the nucleus impacts the genomic integrity of the cell. Our focus is on the genetic alterations that affect the telomeres (the ends of chromosomes) in breast cancer. In this study, we wished to determine if mutations in either of the two main breast cancer susceptibility genes, known as BRCA1 and BRCA2 can influence the way in which telomeres are organized. To do this, we studied the three-dimensional (3D) organization of telomeres in breast cancers derived from BRCA1 and BRCA2 gene mutation carriers. We used breast cancers arising in non-BRCA1/2 mutation carriers as controls. In addition, we studied three cancer cell lines derived from BRCA1-, BRCA2- and non-carriers to see if we found the same effect. There were two main measures- the length of the telomeres and the aggregation of the telomeres (i.e. to what extent telomeres were found 'stuck together')- this is usually the result of chromosomes with broken ends becoming fused. To summarize, the results were not conclusive. It was clear that the BRCA1 and BRCA2 cell lines had shorter telomeres and more aggregations compared with the controls, but in the tumors, the results were less clear. There was, however, a non-significant trend in the same direction as observed in the cell lines. This work is now continuing, and we aim to submit this work for publication in the coming year. The role of MYC in this process is of particular interest, as many BRCA1 tumours show amplification of MYC, and MYC is known to interact with other proteins in the maintenance of telomere length. We are currently analyzing the same set of tumours for MYC amplification by FISH.					
15. SUBJECT TERMS No subject terms provided					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	144	19b. TELEPHONE NUMBER (include area code)

Table of Contents

Cover	1
SF 298	2
Introduction	4
Body	4
Key Research Accomplishments	4
Reportable Outcomes	4-5
Conclusions	5
References	6
Appendices	6-143
Supporting Data	144

INTRODUCTION:

Telomeres are the ends of chromosomes. By capping the chromosomes, they are responsible for chromosomal integrity to prevent genomic instability. Two-dimensional studies of interphase nuclei have been unable to precisely describe the position of telomeres in either normal or cancer cells. Recent three-dimensional (3-D) imaging of the mammalian interphase nucleus, followed by highly sophisticated computerized image analysis, has resulted in the description of organized, dynamic telomere territories (TT) in normal cells. These TT are cell-cycle dependent: in G2, the telomeres are organized into telomeric disc (TD). TT, and in particular, the TD, are disrupted as a result of c-Myc deregulation¹. In some tumor cells, the same disruption of TT is seen. Notably, *BRCA1*-related breast cancers often show c-Myc deregulation²: the role of c-Myc alterations in *BRCA2*-related breast cancer is less clear, but in general, more aggressive breast cancers are more likely than quiescent tumors to have elevated levels of c-Myc protein. Thus, we postulate that disorganization of telomeres in *BRCA1* and/or *BRCA2*-related breast cancer is a key step in the development of these cancers.

BODY:

Task 1: To conduct telomere hybridizations and examination of 3D telomeric organization

This work was completed.

Task 2: To determine whether regulatable *BRCA1* and *BRCA2* mutations alter the levels of telomeric aggregation and genomic instability in 3D nuclei

This work was commenced, is on-going but has not been completed.

Task 3: To examine whether *BRCA1* and *BRCA2* mutations in conjunction with c-Myc deregulation accelerate aggregation and genomic instability.

This work is just starting now, and will be completed over the next year. Grants have been awarded on the basis of our preliminary findings that will allow us to complete this work.

KEY RESEARCH ACCOMPLISHMENTS:

- More than 25 breast tumours were analysed in detail
- Cell lines with and without *BRCA1* and *BRCA2* mutations were also analysed.
- *BRCA1* and *BRCA2* mutations appear to influence telomere structure
- Further studies on this subject have been made possible because of this award.

REPORTABLE OUTCOMES:

1. Presentations (by Soumya Panigrahi):

September 9-13, 2006

Sherif F. Louis, Bart Vermolen, Soumya Panigrahi, William D. Foulkes, Yuval Garini and Sabine Mai

Title: *Telomeric aggregates in c-Myc-dependent genomic instability and tumorigenesis in general.*

Fifth Annual Symposium of Hormonal Carcinogenesis
Montpellier, FRANCE

May 11-14, 2006

Panigrahi S, Wark L, Vermolen B, Watson P, Snell L, Chuang A, Kotar K, Garini Y, Foulkes W, Mai S.

Title: *Three Dimensional Organization of Telomeres in Human Breast Cancer.*

Canadian Telomere Symposium
Calgary, CANADA

October 20-21, 2005

CME: *The First International Symposium on the Hereditary Breast and Ovarian Cancer Susceptibility Genes*
Montreal, CANADA

June 2004

Panigrahi et al.

Title: *Three Dimensional Organizations of Telomeres in Human Breast Cancer*

(Poster presentation)

Canadian Telomere Group

2. Cell lines: we developed 2 new BRCA1 cell lines to allow us to look at telomere organization in BRCA1 heterozygotes.

3. Sabine Mai (co-PI) was awarded a Susan G Komen breast cancer grant (with the PI) on the basis of the preliminary work done here.

4. Members of the research community have visited Dr. Mai's lab on CIHR-funded short training grants; some of these awards were made possible because of this and similar work that has been carried out in Dr. Mai's laboratory.

5. Patent: Mai, S., Chuang, T., Moshir, S, Garini, Y. Method of monitoring genomic instability by 3D microscopy and analysis. – Serial No. 9157-51.

CONCLUSION:

This study has shown that cell lines derived from BRCA1 and BRCA2 carriers are statistically significantly more likely to show telomere aggregations than cell lines derived from non-carriers. Results from formalin-fixed, paraffin-embedded breast tumors support these findings, but the results are not conclusive. Our main focus now will be to study more tumors, and to look at the interaction between MYC and BRCA1 or BRCA2 in determining the extent of telomere aggregations. This work is important, as recent research suggests that MYC and BRCA1 may have an important joint role in sporadic breast cancer.³

REFERENCES:

1. Chuang TCY, Moshir S, Garini Y, Chuang AYC, van den Doel R, Mougey V, Kerr DP, Fest T, Boukamp P, Mai S. c-Myc deregulation alters the three-dimensional organization of telomeres and chromosomes of the interphase nucleus. *BMC Biol.* **2**:12. (2004)
2. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrío D, Barroso A, Rodríguez S, Cigudosa JC, Díez O, Alonso C, Lerma E, Sánchez L, Rivas C, Benitez J. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. *Clin Cancer Res* **9**, 3606-3614. (2003)
3. Kennedy RD, Gorski JJ, Quinn JE, Stewart GE, James CR, Moore S, Mulligan K, Emberley ED, Lioe TF, Morrison PJ, Mullan PB, Reid G, Johnston PG, Watson PH, Harkin DP. BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene. *Cancer Res.* **65**(22):10265-72 (2005)

APPENDICES:

Journal Articles

Garini Y and Mai S. The Significance of Telomeric Aggregates in the Interphase Nuclei of tumor Cells. *Journal of Cellular biochemistry*, 97: 904-915, 2006.

Caporali A, Wark L, Vermolen BJ, Garini Y, Mai S. Telomeric aggregates and end-to-end chromosomal fusions require myc box II. *Oncogene*, 1-6, 2006.

Mai S and Garini Y. Oncogenic remodeling of the Three-dimensional organization of the interphase nucleus. *Cell cycle*, 4:10, 1327-1331, 2005.

Vermolen BJ, Garini Y, Mai S, Mougey V, Fest T, Chuang TC-Y, Chuang AY-C, Wark L, Young IT. Characterizing the three-dimensional organisation of telomeres. *Int. Society for Analytical Cytology*, 67A:144-150, 2005.

Louis SF, Vermolen BJ, Garini Y, Young IT, Guffei A, Lichtensztein Z, Kuttler F, Chuang TC-Y, Moshir S, Mougey V, Chuang AY-C, Kerr PD, Fest T, Boukamp P, Mai S. c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus. *Proc. of the National Academy of Science*, 102; 27: 9613-9618, 2005.

Chuang TC-Y, Moshir S, Garini Y, Chuang AY-C, Young IT, Vermolen B, van den Doel R, Mougey V, Perrin M, Braun M, Kerr PD, Fest T, Boukamp P, Mai S. The three-dimensional organisation of telomeres in the nucleus of mammalian cells. *BMC Biology*, 1-8, 2004.

The Significance of Telomeric Aggregates in the Interphase Nuclei of Tumor Cells

Sabine Mai^{1*} and Yuval Garini²

¹Manitoba Institute of Cell Biology, CancerCare Manitoba, University of Manitoba, Winnipeg, Manitoba, Canada R3E 0V9

²Department of Imaging Science & Technology, Faculty of Applied Sciences, Delft University of Technology, Quantitative Imaging Group, 2628 CJ Delft, The Netherlands

Abstract Telomeres are TTAGGG repetitive motifs found at the ends of vertebrate chromosomes. In humans, telomeres are protected by shelterin, a complex of six proteins (de Lange [2005] *Genes Dev.* 19: 2100–2110). Since (Müller [1938] *Collecting Net.* 13: 181–198; McClintock [1941] *Genetics* 26: 234–282), their function in maintaining chromosome stability has been intensively studied. This interest, especially in cancer biology, stems from the fact that telomere dysfunction is linked to genomic instability and tumorigenesis (Gisselsson et al. [2001] *Proc. Natl. Acad. Sci. USA* 98: 12683–12688; Deng et al. [2003] *Genes Chromosomes Cancer* 37: 92–97; DePinho and Polyak [2004] *Nat. Genetics* 36: 932–934; Meeker et al. [2004] *Clin. Cancer Res.* 10: 3317–3326). In the present overview, we will discuss the role of telomeres in genome stability, recent findings on three-dimensional (3D) changes of telomeres in tumor interphase nuclei, and outline future avenues of research. *J. Cell. Biochem.* 97: 904–915, 2006. © 2006 Wiley-Liss, Inc.

Key words: oncogenes; 3D nucleus; genomic instability; telomeres; telomeric aggregates; chromosomes; breakage-bridge-fusion cycle; genomic instability

SIGNIFICANT EARLY WORK ON TELOMERE BIOLOGY

Müller [1938] and McClintock [1941] were the first to observe breakage-bridge-fusion (BBF) cycles. These are cycles where chromosomal end-to-end fusions contribute to the onset of chromosomal rearrangements and genomic instability. Studying broken chromosomes in

Zea mays, McClintock [1942] observed the formation of dicentric and ring chromosomes, rearrangements, terminal deletions, and chromatin bridges at anaphase that then broke apart unequally (“non-median breaks”). She also observed continuous cycles of these events, that is cycles of new fusions followed by new breakages in the following anaphases [McClintock, 1941, 1942]. Focusing on chromosome 9 in *Zea mays*, she was able to follow distinctive types of variegation and to link them to specific rearrangements on previously broken chromosomes. Broken chromosomes were then able to fuse with sister chromatids or with other chromosomes. This affected not only kernel color but also starch formation, growth conditions, and propagation of the plants [McClintock, 1942].

The questions McClintock asked then are still valid today. “(1) Must two chromosomes or more chromosomes be in intimate contact at the time of breakage in order that fusions may occur? (2) If no intimate contact is necessary at the time of breakage, are the broken ends “unsaturated,” that is capable of fusion with any other

Grant sponsor: Canadian Institutes of Health Research; Grant sponsor: Canada Foundation for Innovation; Grant sponsor: National Cancer Institute of Canada; Grant sponsor: CancerCare Manitoba Foundation; Grant sponsor: Physics for Technology program of the Foundation for Fundamental Research in Matter; Grant sponsor: The Delft Inter Faculty Research Center Life Tech; Grant sponsor: The Delft Research program Life Science and Technology.

*Correspondence to: Sabine Mai, Manitoba Institute of Cell Biology, CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada R3E 0V9.
E-mail: smai@cc.umanitoba.ca

Received 14 November 2005; Accepted 16 November 2005
DOI 10.1002/jcb.20760

© 2006 Wiley-Liss, Inc.

unsaturated broken end? (3) If question (2) can be answered in the affirmative, what forces are involved which lead to the contact and subsequent fusion of the two unsaturated ends? Likewise, (4) how long will these broken ends remain unsaturated, that is, capable of fusion?" [McClintock, 1942]. We found it important to use Barbara McClintock's own words to summarize some of the key questions in the field. Please note that these questions were formulated in 1942. Today, the concept of chromosomal localization is still under intense debate with respect to specific rearrangement of chromosomes. The "unsaturated ends" are indeed broken chromosomal ends that are free of telomeres and therefore able to fuse with sister chromatids or other chromosomes, and yes, chromosome ends can "be healed."

STRUCTURAL ORGANIZATION OF TELOMERES IN MAMMALIAN NUCLEI

Most studies with telomeres have been performed on metaphase chromosomes. Metaphase chromosomes reflect events that occurred prior to the metaphase being examined and, with respect to some aberrations, researchers infer from studying the metaphase chromosomes that 'telomere dysfunctions' were likely. For example, unbalanced translocations, dicentric chromosomes, and terminally deleted chromosomes suggest a defect in telomeres that may involve capping defects, DNA damage affecting the telomeric ends, oncogene activation or other stimuli [Artandi et al., 2000; Gisselsson et al., 2001; Lo et al., 2002; Deng et al., 2003; Murnane and Sabatier, 2004; Louis et al., 2005].

Advances in imaging allow us to now focus on the events that occur prior to the metaphase, namely in preceding cell cycle stages of interphase nuclei. While two-dimensional (2D) imaging of nuclei did not allow us to visualize the spatial organization of telomeres, three-dimensional (3D) and live cell imaging permit the analysis of the structural organization of telomeres in the nucleus of mammalian cells. Studies in recent years have then shown us that telomeres in normal nuclei have a dynamic cell cycle- and tissue-dependent organization. For example, in G0/G1 nuclei, telomeres are widely distributed throughout the whole nuclear space [Weierich et al., 2003; Chuang et al., 2004]. Measurements of telomere

positions in the 3D space of primary mouse lymphocyte nuclei have given a precise value to telomeres in this phase of the cell cycle. The a/c ratio indicates that telomeric positions in interphase nuclei is small in G0/G1 lymphocytes, and one usually measures values of 1.4 ± 0.1 [Vermolen et al., 2005a]. This number is indicative of the distribution of telomeres throughout the entire nuclear space of primary lymphocytes, which is roughly spherical. Similarly, in S phase, the a/c ratio is small (1.5 ± 0.2 ; [Vermolen et al., 2005a]). The nuclear distribution of telomeres changes when cells enter into G2: telomeres align in the center of the nucleus and form a telomeric disk [Chuang et al., 2004]. At this time, the a/c ratio is large due to the organization of the telomeres in a disk-like volume, and the a/c ratio measurements usually are 14 ± 2 [Vermolen et al., 2005a]. Telomere dynamics in interphase nuclei of human osteosarcoma (U2OS), human cervical carcinoma (HeLa), and mouse MS5 cells has been carefully measured by live cell imaging approaches. Long ranging as well as short movements were observed over a time period of 20 min [Molenaar et al., 2003]. Telomere dynamics has also been observed in interphase nuclei of human keratinocytes [Ermler et al., 2004]. Telomere movement is not only dependent on cell cycle but also on cell shape [Chuang et al., 2004; Ermler et al., 2004]. Thus, we conclude that telomeres are not static in mammalian nuclei but perform cell cycle and cell-type specific movements.

Another important feature of telomeres in normal interphase nuclei is the fact that the telomeres do not overlap. Each telomere of a normal nucleus is found in its specific 3D space and does not form clusters or aggregates with other telomeres [Chuang et al., 2004]. Normal cells have a limited life span [Hayflick, 1965]. Their mitotic clock is linked to telomere length. Telomere length is known to be shortening linearly with each cell division (approximately 50–200 base pairs per division [Lansdorp, 2000]). When the telomeres become too short, normal cells will eventually stop division cycles and enter into a state of replicative arrest that is also called senescence. The senescent phenotype has been extensively studied [for review, see Campisi, 2000]. Senescence is bypassed during tumor development [Campisi, 2000; Romanov et al., 2001].

TELOMERE ORGANIZATION IN TUMOR CELLS

Telomeres in tumor cells are different from telomeres in normal cells; they are generally shorter, even critically short [Vukovic et al., 2003; Meeker et al., 2004]. However, they may also be elongated or different subpopulations of telomere lengths may be present [Meeker et al., 2004]. It was shown that telomeres in tumor cells commonly manifest telomere dysfunction, and chromosomal aberrations indicative of these defects are observed. Telomerase is activated in 85% of the tumors, while it is not present in the rest of the tumors, some of which have demonstrated alternative lengthening of telomeres (ALT) [Muntoni and Reddel, 2005].

A remarkable difference between normal and tumor cells becomes apparent when 3D imaging approaches are applied. 3D imaging revealed a specific 3D telomeric signature for tumor cells. In contrast to the non-overlapping nature of telomeres in normal nuclei, telomeres of tumor nuclei tend to form aggregates. Various numbers and sizes of such telomeric aggregates (TAs) can be found in tumor nuclei [Chuang et al., 2004]. The formation of TAs is independent of telomere length and telomerase activity [Louis et al., 2005].

There are at least two types of telomeric dysfunction in tumor cells. One type of telomere dysfunction involves critically short telomeres [DePinho and Polyak, 2004]. The other one involves the formation of TAs and is independent of telomere size or telomerase activity [Chuang et al., 2004; Louis et al., 2005]. Both types of telomeric dysfunction can lead to BBF cycles that contribute to deletions, gene amplification, non-reciprocal translocation, and overall genetic changes that are associated with tumorigenesis [Artandi et al., 2000; DePinho and Polyak, 2004; Murnane and Sabatier, 2004].

MEASUREMENT OF TELOMERE DYSFUNCTION (3D VOLUMES AND POSITIONS)

Quantitative measurement of the telomeres parameters is based on 3D data that are usually captured by acquiring many optical sections of the nucleus with a high numerical aperture oil-immersed objective lens followed by an appropriate deconvolution algorithm. The most reliable one uses constrained iterative deconvolution [Schaefer et al., 2001; Vermolen et al., 2005b]. Telomere measurements are done with

a special algorithm and software package that we developed, TeloViewTM [Chuang et al., 2004; Vermolen et al., 2005a]. First, the position of each telomere is identified by using a threshold. Then, the center of gravity and the integrated intensity of each telomere are calculated. The integrated intensity of each telomere is the appropriate parameter for determining the length of the telomere, or the telomere copy number, which estimates the number of telomeres that are taking part in an aggregate. Aggregates are easily observed when looking at a 3D visualization of the nucleus and it can be quantitatively calculated by analyzing the integrated intensity of each telomere (Fig. 1).

IMPACT OF TELOMERE AGGREGATES ON CHROMOSOMAL ORGANIZATION

It is not just a transient aberration in the 3D organization of the nucleus when telomeres aggregate. Since some of the aggregates represent fusions, dicentric chromosomes can form. These end-to-end fused chromosomes cannot appropriately separate during cell division, but will first generate anaphase bridges and then break apart, leaving one chromosome too short (with a terminal deletion) and the other one with




Fig. 1. Histogram illustrating the concept of telomeric aggregates (TAs) and their quantitative analysis. This histogram demonstrates how TAs are found using TeloViewTM [Vermolen et al., 2005a]. Each point represents the copy number of a telomere that is found in the nucleus. The intensity of an average telomere is calculated by analyzing the smaller telomeres in the nucleus (which are the majority of telomeres). See the change in the graph slope at about telomere number 37. All the telomeres smaller than telomere number 37 are interpreted as single copies while telomeres that are larger are interpreted as aggregated copies. The copy number is calculated by dividing the integrated intensity of each telomere by that of telomere number 37. The telomeres are sorted for convenience from smallest to largest (based on their integrated intensity).

a new piece (generating an unbalanced translocation). Both chromosomes are 'new' structures and both are unable to persist the way they were left after this cell division. Since both new chromosomes have telomere free ends and represent a double-strand break, they will each find a new chromosome partner, and they will fuse with it to heal their broken ends. This series of events is termed a BBF cycle and goes back to Müller and McClintock's seminal findings [Müller, 1938; McClintock, 1941]. Importantly, a BBF cycle is not a single event. One BBF cycle initiates the next and so forth until no more free ends persist to permit fusions with other chromosomes [McClintock, 1941, 1942; Louis et al., 2005].

Once aggregates form and fusions occur, BBF cycles result and with such BBF cycles, the genetic information of the chromosomes will be remodeled [Louis et al., 2005]. TAs and fusions are different from the reversible telomeric associations that have been reported for Chinese hamster embryonic cells [Slijepcevic et al., 2000]. Which events lead to such telomere-mediated nuclear remodeling? We have studied oncogenic remodeling of the 3D telomere organization. The deregulation of the oncoprotein c-Myc was able to remodel the telomeric organization from non-overlapping telomeres to TAs of various numbers and sizes [Louis et al., 2005]. A single deregulation event of c-Myc, where the oncogene was overexpressed in the nucleus for 2 h, was sufficient to initiate the formation of TAs. Moreover, TAs/fusions caused the formation of dicentric, end-to-end fused chromosomes. The latter generated anaphase bridges and broke apart as anaphase progressed, leaving behind terminal deletions and unbalanced translocations. Two hours of c-Myc deregulation initiated three BBF cycles. Twelve hours of c-Myc deregulation led to five such cycles. Thus, the time of c-Myc deregulation was directly proportional to the number of BBF cycles observed [Louis et al., 2005]. The scoring of chromosomal aberrations over a 120-h period documented the BBF cycles: from fusion to breakage with terminal deletions and non-reciprocal translocations to telomere-free ends and new fusions (*ibid*).

WHICH ABERRATIONS ARE GENERATED WHEN TELOMERES ARE REMODELED IN THE 3D SPACE OF THE NUCLEUS?

Two sets of parallel experiments involving chromosome painting to determine the 3D

organization of chromosomes in interphase nuclei and spectral karyotyping (SKY) of metaphase chromosomes were carried out to examine the effects of TA formation on chromosomal positions and aberrations [Louis et al., 2005]. SKY data showed non-random chromosomal rearrangements affecting chromosomes 5 + 13, 7 + 10, 7 + 17. Other chromosomes were sometimes, but not regularly involved and judged as random aberrations. When examining the positions of chromosomes 5 + 13, 7 + 10, and 7 + 17 in interphase nuclei, we found no overlap between these pairs prior to Myc activation, while they changed their positions over the time course of c-Myc deregulation and showed substantial overlap [Louis et al., 2005].

MEASUREMENTS OF CHROMOSOMAL OVERLAPS IN THE INTERPHASE NUCLEUS

Chromosomal overlaps measurements are performed after 3D image acquisition and constrained iterative deconvolution. First, the 3D boundary of the nucleus is determined based on the DAPI counterstain image. Within this volume, a threshold level is determined for each chromosome and the total volume V_1 and V_2 of each chromosome pair is calculated (by counting only the voxels that has an intensity value above the threshold). The total volume that is occupied by both chromosome pairs is also measured (V_0). By dividing V_0 by the total volume of each one of the chromosome pairs, the relative overlap ratio is calculated, V_0/V_1 and V_0/V_2 . By following the same procedure for each time point since c-Myc deregulation, we finally get the relative overlap as a function of time.

SIGNIFICANCE OF OVERLAPPING CHROMOSOMES

Chromosomal overlap is a problem for genome stability if the overlapping chromosomes fuse at their telomeric ends or are involved in illegitimate recombination events. TAs brings chromosomes into close vicinity. If TAs represent fusions, then BBF cycles will occur. This was found after experimentally-induced c-Myc deregulation [Louis et al., 2005; Mai and Garini, 2005].

There are two possibilities for the initiation of BBF cycles after TA formation and chromosome overlap. The occurrence of non-random chromosomal aberrations suggests either a non-random formation of chromosomal overlaps

resulting in end-to-end chromosomal fusions. Alternatively, one may argue that there is a non-random occurrence of TA formation resulting in chromosomal overlaps and causing the initiation of BBF cycles. At the present time, we cannot distinguish between both possibilities and both remodeling events may coexist.

TAs AND TUMORS

Genomic instability is viewed as an event through which genetic changes occur or have occurred [Hanahan and Weinberg, 2000; Gollin, 2005; Mitelman et al., 2005]. These changes can be structural and numerical, and this is the classical view of genomic instability. We would like to expand this view and include epigenetic changes that coincide with genetic alterations and/or precede them, point mutations, and alterations in nuclear organization that affect the genome. Organizational changes in the 3D space of the nucleus need to be considered as an important factor not only in tumors but also much earlier that is during the initiation of

genomic instability and the establishment of tumorigenic potential.

The analysis of primary tumors revealed that TAs are common [Chuang et al., 2004]. Various cell types and tissues were examined, including primary head and neck cancer, primary mouse plasmacytoma, human neuroblastoma, and colon carcinoma cell lines [Chuang et al., 2004]. While normal cells do not show TAs, tumor cells (primary tumor cells and tumor cell lines) consistently display TAs (Fig. 2).

Importantly, being a feature of tumor cells makes one wonder if such changes in the telomeric organization of the interphase nucleus do not occur earlier, that is when cells become tumorigenic. Early data suggest that this is indeed the case. For example, in cervical cancer, non-invasive lesions, such as CIN I, show TAs in some of cells (Fig. 3). During the development of mouse plasmacytoma, early plasmacytotic foci display TAs in a subpopulation of the foci (Fig. 4). Additional analyses are ongoing and will help us understand the earliest




Fig. 2. Telomere organization in primary nuclei of a B cell, a primary mouse plasmacytoma and a Burkitt lymphoma line (Raji). The **top panel** shows two-dimensional (2D) representations of the above nuclei; the **bottom panel** shows the three-dimensional (3D) organization of telomeres in the above nuclei. Telomeres are shown in red, nuclei are shown in blue. Arrows point to TAs. Hybridizations were performed as described [Chuang et al., 2004; Louis et al., 2005].




Fig. 3. Telomere organization in cervical biopsy tissue of a CIN 1 lesion. **a:** 2D image of a section showing the identical nuclei (blue) and their telomeric signals (red) that are shown in **(b)** and **(c)** as 3D images. Black arrows point to TAs that are observed in some of the cells. Frozen sections of 5- μ m thickness were hybridized as described [Chuang et al., 2004; Louis et al., 2005].

time point during tumor development *in vivo* that show TA formation. *In vitro*, in a model of c-Myc-induced genomic instability in PreB and Ba/F3 mouse lymphocytes, we have shown that c-Myc deregulation elicits TA formation within 12 h [Louis et al., 2005]. Additional studies propose even earlier time points (unpublished data). Taken together, the above data indicate that the formation of TAs is an intrinsic factor in the transformation of the normal cell into a malignant one. Therefore, in the future, the knowledge of TA formation during tumor development can be used as a diagnostic tool and for monitoring of treatment success.

MECHANISMS OF TA FORMATION

How do these aggregates form? This is an area that requires intense research. At this point, nothing is known about the mechanisms that cause TA formation. One may speculate that one of the shelterin proteins [de Lange, 2005] is causally involved in TA formation. However, this has not been demonstrated in tumor models. We know from studies of de Lange and colleagues that the absence of TRF2 leads to the formation of telomeric fusions which lead to cell death and senescence [van Steensel et al., 1998; Celli and de Lange, 2005]. Whether these

fusions involve TA formation and can be linked to genomic instability and cancer has not been investigated.

BOVERI'S LEGACY: IN SEARCH OF THE MECHANISMS THAT REGULATE ABERRANT NUCLEAR AND GENOMIC ORGANIZATION

Although we described the formation of TAs in tumors and after c-Myc deregulation for the first time [Chuang et al., 2004; Louis et al., 2005], the concept of the nucleus and its chromosomal order has been studied long before. Theodore Boveri (1862–1915) was the first researcher who linked nuclear organization and genome stability. Studying *Ascaris* and sea urchin eggs, he described for the first time 'chromosomal regions' ('chromosome territories' [Cremer and Cremer, 2001]). Chromosomal regions are regions within the 3D nuclear space in which chromosomes tend to be found in normal cells. Boveri also noted that an aberrant chromosome constitution leads to aberrant cell division cycles and mis-segregation of chromosomes. He found that aberrant chromosome constitution resulted in aberrant embryo development or cell death [Boveri, 1902, 1914]. From the simple organisms he studied, he inferred for tumor development that similar pathways are




Fig. 4. Plasmacytotic focus examined by telomere hybridization. Telomere hybridizations were performed on 5- μ m sections of paraffin-embedded tissues. **A:** Overview of plasmacytotic focus in 2D. Nuclei are shown in blue, telomeres in red. White box indicates area of the section that is shown in **(b)**. **B:** Insert from **(a)** showing 2D and 3D organization of the telomeres. Black arrows point to TAs seen in front view **(b)** and in side view **(c)**. The blue arrow points to a structure that appears to be a replicating telomere.

in operation [Boveri, 1914]. The centrosome cycles and aberrations thereof were also described by Boveri [1914] for the first time and later translated into English by his wife [Boveri, 1929]. Since his time, more details about the 3D organization of the nucleus and the genome have been investigated. However, the big picture that he first put forward is as valid today as it was in his time.

CURRENT CONCEPTS AND OPEN QUESTIONS

In the following paragraphs, we will discuss some of the issues that are important for future research in the area of the 3D organization of the nucleus and its alteration in the contribution to tumor development.

WHICH STIMULI LEAD TO THE FORMATION OF TAs?

Due to the impact of telomeric remodeling on genome stability, it will be important to characterize the conditions that lead to the formation of TAs. We have recently studied c-Myc-dependent TA formation and the effects of TAs on genomic instability [Louis et al., 2005]. We anticipate that other oncogenes may cause similar effects. One candidate is Ha-Ras. This oncogene was already studied with respect to its ability to alter chromatin organization [Fischer et al., 1998]. A more recent study using Balb/3T3 cells spontaneously immortalized and transfected with mutated c-Ha-Ras-1 found that Ha-Ras increased the level of chromosomal rearrangements involving telomeric sequences threefold [Peitl et al., 2002]. However, it is not known whether these rearrangements followed TA formation. It is also not known whether additional genetic changes occurred in these immortalized cells that contributed to the above results.

Other stimuli that converge at the chromosomal ends and elicit genomic instability may involve viruses that are able to immortalize or transform the host cells. Wan et al. [1997] examined telomeres after human papilloma viral infection and found a high frequency of telomeric associations and rearrangements. Using human ovarian epithelial cells immortalized by human papilloma oncoproteins, E6 and E7, the authors observed that 30–100% of all metaphases examined displayed telomeric associations (ibid). Whether these associations

followed TA formation has not been investigated. However, one may postulate that this is very likely if the c-Myc-mediated remodeling of telomeres and chromosomes can be considered a general pathway to nuclear remodeling of the genome. The impact of viruses on telomeric organization and genomic instability requires further investigation. The above effects may be cell-type, host, and/or virus-specific since work by Argilla et al. [2004] demonstrates that transgenic mice expressing SV40 or HPV16 in the absence of telomerase do not exhibit telomere dysfunction or increased genomic instability.

TELOMERES AND EVOLUTION

It has been reported that human subtelomeric sequences are recombination and duplication hot spots [Linardopoulou et al., 2005]. Subtelomeric sequences are involved in inter-chromosomal recombinations and segmental duplications. This not only is a feature of tumor cells, but also occurs frequently during evolution. For example, half of the known subtelomeric sequences have formed recently during primate evolution. Interestingly, the subtelomeric gene duplication rate is significantly higher than the genome average. Thus, the authors conclude that this is both advantageous for evolution and may also have pathological consequences [Linardopoulou et al., 2005]. In the context of our discussion, we emphasize that telomeres and subtelomeric sequences are hot spots of evolution and genomic instability. The formation of TAs may contribute to both.

DO TAs AFFECT THE CHROMOSOMAL ORDER IN VIVO?

Since previous studies were done in established tumors or tumor cell lines [Chuang et al., 2004], one cannot say whether the chromosomal order changed due to tumor formation or due to TA formation or both. While data are emerging that TAs occur early in tumor development (Figs. 3 and 4), it is still unclear whether this is mechanistically linked to the remodeling of the nuclear order of chromosomes and to rearrangements in vivo. Thus, the cause-relationship in vivo is not yet established and needs to be examined carefully.

The closest cause-relationship study to date involved oncogenic remodeling of the telomeres and chromosomes in the nucleus [Louis et al.,

2005]. In this *in vitro* study using mouse lymphocytes, c-Myc deregulation led to TA formation that preceded chromosomal rearrangements via BBF cycles [Louis et al., 2005; Mai and Garini, 2005].

WHEN IS THE EARLIEST TIME POINT FOR TA FORMATION AND WHEN IS THE TUMORIGENIC POTENTIAL ESTABLISHED?

This question is critical for our understanding of the impact of nuclear remodeling in tumor development. We speculate that TA formation may be the earliest event in tumor development and occur subsequent to oncogene deregulation. This is solely based on our *in vitro* studies and on studies we performed with pre-neoplastic and non-invasive lesions. More detailed studies in several tumor models will be necessary to establish this point. Is it enough for a cell to carry TAs to be tumorigenic? Are TAs and chromosomal rearrangements required before a cell becomes tumorigenic? Is a specific genetic background more susceptible to TA formation? Is the formation of TAs reversible? Can cells repair TAs? When do TAs become irreversible? Appropriate cell culture and mouse models will allow researchers to address such questions in the future.

WILL CELLS UNDERGO APOPTOSIS WHEN A CRITICAL THRESHOLD OF TAs IS REACHED?

Data on repeated c-Myc inductions suggest this may be the case. When mouse Pre B lymphocytes are stimulated to overexpress c-Myc every 12 h, >96% of all nuclei display large or several TAs. In this experimental set-up, all cells die of apoptosis within 30 h [Louis et al., 2005]. In contrast, a single activation of c-Myc deregulation for 2 h or for 12 h led to the formation of three or five TA cycles, respectively, which represent BBF cycles, without significant elevation in cell death (*ibid*). Thus, we propose that a critical threshold of TAs is tolerated by the cells and leads to genomic instability through chromosome remodeling by TA-induced BBF cycles. A low level of TAs allows for cell survival and cell proliferation while genomic rearrangements can occur. The latter situation is the critical one, since it contributes to the propagation of genomically unstable cells.

REMODELING OF THE NUCLEUS THROUGH TAs

In c-Myc deregulated cells, TAs form and chromosomes change their positions. Not only are there more chromosomal overlaps, but also more chromosomal ends become linked through TAs and fusions [Louis et al., 2005]. Several questions arise from these findings. Do chromosomes move normally? This is an open question, since the available data do not allow for a consensus in interpretation. While some research groups do not find substantial chromosomal movements [Abney et al., 1997; Gerlich et al., 2003], others find chromosomal reorganization during the cell cycle [Ferguson and Ward, 1992; Vourc'h et al., 1993; Bridger et al., 2000; Chubb et al., 2002; Walter et al., 2003; Essers et al., 2005], cellular differentiation [Stadler et al., 2004], and during quiescence and senescence [Bridger et al., 2000].

Whether chromosomes move normally or not, there are conditions that induce movement, such as c-Myc deregulation [Louis et al., 2005]. In the presence or absence of pre-existing movements, the potentially dynamic nature of chromosome order is a very complex issue. For example, are there specific neighborhood relationships that become established due to specific stimuli (such as oncogenic activation, viral infection, DNA damage)? Or do chromosomes that are observed in specific chromosomal neighborhoods come closer to each other diminishing the intrachromosomal space? Would this favor fusions, illegitimate recombinations, and/or non-homologous end joining?

There is evidence that a non-random nuclear order of chromosomes with specific chromosomal neighborhood relationships is important for specific rearrangements. Data by Neves et al. [1999] suggest this for *bcr/abl* in chronic myeloid leukemia. Chromosomes 9 and 22 are in close enough proximity to permit this translocation. This finding is supported by Kozubek et al. [1999] who state that the positions of chromosomes 9 and 22 have a determinative role in the induction of t(9;22) and in the development of t(9;22) leukemias. For mouse B cells, chromosomes 12 and 15 are found in a close neighborhood in lymphocytes (where they are involved in balanced translocations in mouse plasmacytoma) but are found more distant in mouse hepatocytes [Parada et al., 2004]. There are more studies that support this

chromosome neighborhood concept. Thomas and Diehl [2003] state that the proximity between translocating chromosomes is a prerequisite for their rearrangement. Roix et al. [2003] support this interpretation.

In a survey of >11,000 constitutional translocations, Bickmore and Teague [2002] concluded that the frequency of constitutional translocations depended on three main factors, and these included the chromosome positions, chromosome sizes, and specific DNA sequences.

We conclude from the above that chromosome specific neighborhood relationships exist in a cell-type specific manner and are consistent with the resulting chromosomal translocations. However, the experimental proof for this concept is lacking. For example, if a chromosome involved in translocations was moved to a new nuclear position would it still be involved in the same translocations or not? Do approaching gene loci or gene loci in the same nuclear compartment contribute to possible illegitimate recombination events? To date, these questions remain unanswered and await future investigation.

It is now possible to view all chromosomes in a nucleus [Bolzer et al., 2005]. Such 3D localization of all chromosomes needs to be combined with 3D FISH studies to assess potential gene and chromosomal region-associated movements.

CONCLUSIONS

Further research is required to fully understand the complexity of nuclear organization in normal cells and during malignancy. Studies using various approaches are required to investigate the complexity of 3D nuclear space that is crucial for understanding genome organization and stability. Geneticists, evolutionary biologists, cancer researchers, cell biologists, program developers, physicists, mathematicians, and biostatisticians are all necessary in a multidisciplinary effort to understand and model the nuclear structure and its regulation in normal and tumor cells. Only when we fully understand who the key players are, will we be able to learn how to modulate them for patient-specific treatments.

ACKNOWLEDGMENTS

We thank our lab members, especially Mrs. Cheryl Taylor-Kashton, and many colleagues

for comments and discussions. We are grateful to Dr. Michael Mowat and Dr. Francis Wiener for stimulating discussions and critical reading. Work in the Mai lab was supported by the Canadian Institutes of Health Research, the Canada Foundation for Innovation, the National Cancer Institute of Canada, and CancerCare Manitoba Foundation. Work in the Garini lab was supported by the Physics for Technology program of the Foundation for Fundamental Research in Matter, the Delft Inter Faculty Research Center Life Tech, Cyttron, and the Delft Research program Life Science and Technology (Delft, The Netherlands).

REFERENCES

- Abney JR, Cutler B, Fillback ML, Axelrod D, Scalettar BA. 1997. Chromatin dynamics in interphase nuclei and its implication for nuclear structure. *J Cell Biol* 137:1459–1468.
- Argilla D, Chin K, Singh M, Hodgson JG, Bosenberg M, de Solorzano CO, Lockett S, DePinho RA, Gray J, Hanahan D. 2004. Absence of telomerase and shortened telomeres have minimal effects on skin and pancreatic carcinogenesis elicited by viral oncogenes. *Cancer Cell* 6:373–385.
- Artandi SE, Chuang S, Lee S-L, Alson S, Gottlieb GJ, Chin L, DePinho RA. 2000. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. *Nature* 406:641–644.
- Bickmore WA, Teague P. 2002. Influences of chromosome size, gene density and nuclear position on the frequency of constitutional translocations in the human population. *Chromosome Res* 10:707–715.
- Bolzer A, Kreth G, Solovei I, Koehler D, Saracoglu K, Fauth C, Muller S, Eils R, Cremer C, Speicher MR, Cremer T. 2005. Three-dimensional maps of all chromosomes in human male fibroblast nuclei and prometaphase rosettes. *PLoS Biol* 3:1–17.
- Boveri T. 1902. Über mehrpolige Mitosen als Mittel zur Analyse des Zellkerns. *Verh Phys Med Gesellschaft Würzburg* 35:67–90.
- Boveri T. 1914. Zur Frage der Entstehung maligner Tumoren. Jena: Fischer.
- Boveri T. 1929. The origin of malignant tumors. Translated by Marcella Boveri. Baltimore: The Williams & Wilkins Company.
- Bridger JM, Boyle S, Kill IR, Bickmore WA. 2000. Remodelling of nuclear architecture in quiescent and senescent human fibroblasts. *Curr Biol* 10:149–152.
- Campisi J. 2000. Cancer, aging and cellular senescence. *In vivo* 14:183–188.
- Celli GB, de Lange T. 2005. DNA processing is not required for ATM-mediated telomere damage response after TRF2 deletion. *Nat Cell Biol* 7:712–718.
- Chuang TCY, Moshir S, Garini Y, Chuang AY-C, Young IT, Vermolen B, Doel Rvd, Mougey V, Perrin M, Braun M, Kerr PD, Fest T, Boukamp P, Mai S. 2004. The three-dimensional organization of telomeres in the nucleus of mammalian cells. *BMC Biology* 2:12.

- Chubb JR, Boyle S, Perry P, Bickmore WA. 2002. Chromatin motion is constrained by association with nuclear compartments in human cells. *Curr Biol* 12:439–445.
- Cremer C, Cremer T. 2001. Chromosome territories, nuclear architecture and gene regulation in mammalian cells. *Nat Rev Genet* 2:292–301.
- de Lange T. 2005. Shelterin: The protein complex that shapes and safeguards human telomeres. *Genes Dev* 19:2100–2110.
- Deng W, Tsao SW, Guan X-Y, Lucas JN, Cheung ALM. 2003. Role of short telomeres in inducing preferential chromosomal aberrations in human ovarian surface epithelial cells: A combined telomere quantitative fluorescence in situ hybridization and whole-chromosome painting study. *Genes Chromosomes Cancer* 37:92–97.
- DePinho RA, Polyak K. 2004. Cancer chromosomes in crisis. *Nat Genetics* 36:932–934.
- Ermiler S, Kronic D, Knoch TA, Mai S, Greulich-Bode KM, Moshir S, Boukamp P. 2004. Cell cycle-dependent 3D distribution of telomeres and TRF2 in HaCaT and HaCaT-myc cells. *European J Cell Biol* 83:681–690.
- Essers J, van Cappellen WA, Theil AF, van Drunen E, Jaspers NG, Hoeijmakers JH, Wyman C, Vermeulen W, Kanaar R. 2005. Dynamics of relative chromosome position during the cell cycle. *Mol Biol Cell* 16:769–775.
- Ferguson M, Ward DC. 1992. Cell cycle dependent chromosomal movement in pre-mitotic human T-lymphocyte nuclei. *Chromosoma* 101:557–565.
- Fischer AH, Chadee DN, Wright JA, Gansler TS, Davie JR. 1998. Ras-associated nuclear structural change appears functionally significant and independent of the mitotic signaling pathway. *J Cell Biochem* 70:130–140.
- Gerlich D, Beaudouin J, Kalbfuss B, Daigle N, Eils R, Ellenberg J. 2003. Global chromosome positions are transmitted through mitosis in mammalian cells. *Cell* 112:751–764.
- Gisselsson D, Jonsons T, Petersen A, Strömbeck B, Dal Cin P, Höglund M, Mitelman F, Mertens F, Mandahl N. 2001. Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors. *Proc Natl Acad Sci USA* 98:12683–12688.
- Gollin SM. 2005. Mechanisms leading to chromosomal instability. *Semin Cancer Biol* 15:33–42. Review.
- Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. *Cell* 100:57–70. Review.
- Hayflick L. 1965. The limited in vitro lifetime of human diploid cell strains. *Exp Cell Res* 37:614–636.
- Kozubek S, Lukasova E, Mareckova A, Skalnikova M, Kozubek M, Bartova E, Kroha V, Krahulcova E, Slotova J. 1999. The topological organization of chromosomes 9 and 22 in cell nuclei has a determinative role in the induction of t(9,22) translocations and in the pathogenesis of t(9,22) leukemias. *Chromosoma* 108:426–435.
- Lansdorp PM. 2000. Repair of telomeric DNA prior to replicative senescence. *Mech Ageing Dev* 118:23–34.
- Linardopoulou EV, Williams EM, Fan Y, Friedman C, Young JM, Trask BJ. 2005. Human subtelomeres are hot spots of interchromosomal recombination and segmental duplication. *Nature* 437:94–100.
- Lo AWI, Sabatier L, Fouladi B, Pottier G, Ricoul M, Murnane JP. 2002. DNA amplification by breakage/fusion/bridge cycles initiated by spontaneous telomere loss in a human cancer cell line. *Neoplasia* 4:531–538.
- Louis SF, Vermolen BJ, Garini Y, Young IT, Guffei A, Lichtensztejn Z, Kuttler F, Chuang TCY, Moshir S, Mougey V, Chuang AYC, Kerr PD, Fest T, Boukamp P, Mai S. 2005. c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus. *Proc Natl Acad Sci USA* 102:9613–9618.
- Mai S, Garini Y. 2005. Oncogenic remodeling of the three-dimensional organization of the interphase nucleus. *Cell Cycle* 4:1327–1331.
- McClintock B. 1941. The stability of broken ends of chromosomes in *Zea mays*. *Genetics* 26:234–282.
- McClintock B. 1942. The fusion of broken ends of chromosomes following nuclear fusion. *Proc Natl Acad Sci USA* 28:458–463.
- Meeker AK, Hicks JL, Iacobuzio-Donahue CA, Montgomery EA, Westra WH, Chan TY, Ronnett BM, De Marzo AM. 2004. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. *Clin Cancer Res* 10:3317–3326.
- Mitelman F, Johansson B, Mertens F. 2005. Mitelman database of chromosome aberrations in cancer. <http://cgap.nci.nih.gov/Chromosomes/Mitelman>.
- Molenaar C, Wiesmeijer K, Verwoerd NP, Khazen S, Eils R, Tanke HJ, Dirks RW. 2003. Visualizing telomere dynamics in living mammalian cells using PNA probes. *EMBO J* 22:6631–6641.
- Muntoni A, Reddel RR. 2005. The first molecular details of ALT in human tumor cells. *Hum Mol Genet* 14 Suppl 2:R191–196.
- Murnane JP, Sabatier L. 2004. Chromosome rearrangements resulting from telomere dysfunction and their role in cancer. *BioEssays* 26:1164–1174.
- Müller HJ. 1938. The remaking of chromosomes. *Collecting Net* 13:181–198.
- Neves H, Ramos C, da Silva MG, Parreira A, Parreira L. 1999. The nuclear topography of ABL, BCR, PML, and RAR α genes: Evidence for gene proximity in specific phases of the cell cycle and stages of hematopoietic differentiation. *Blood* 15:93(4):1197–1207.
- Parada LA, McQueen PG, Misteli T. 2004. Tissue-specific spatial organization of genomes. *Geno Biol* 5:R44.1–R44.9.
- Peitl P, Mello SS, Camparoto ML, Passos GA, Hande MP, Cardoso RS, Sakamoto-Hojo ET. 2002. Chromosomal rearrangements involving telomeric DNA sequences in Balb/3T3 cells transfected with the Ha-ras oncogene. *Mutagenesis* 17:67–72.
- Roix JJ, McQueen PG, Munson PJ, Parada LA, Misteli T. 2003. Spatial proximity of translocation-prone gene loci in human lymphomas. *Nat Genet* 34:287–291.
- Romanov SR, Kozakiewicz BK, Holst CR, Stampfer MR, Haupt LM, Tlsty TD. 2001. Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. *Nature* 409:633–637.
- Schaefer LH, Schuster D, Herz H. 2001. Generalized approach for accelerated maximum likelihood based image restoration applied to three-dimensional fluorescence microscopy. *J Microscop* 204:99–107.
- Slijepcevic P, Xiao Y, Natarajan AT. 2000. Chromosome-specific telomeric associations in Chinese hamster embryonic cells. *Genes Chromosomes Cancer* 28:98–105.
- Stadler S, Schnapp V, Mayer R, Stein S, Cremer C, Bonifer C, Cremer T, Dietzel S. 2004. The architecture of chicken

- chromosome territories changes during differentiation. *BMC Cell Biol* 5(1):44.
- Thomas RK, Diehl V. 2003. Unhappy neighbourhood: Spatial genome organization and lymphomagenesis in B cells. *Lancet* 362:1868–1870.
- van Steensel B, Smogorzewska A, de Lange T. 1998. TRF2 protects human telomeres from end-to-end fusions. *Cell* 92:401–413.
- Vermolen BJ, Garini Y, Mai S, Mougey V, Fest T, Chuang TC-Y, Chuang AY-C, Wark L, Young IT. 2005a. Characterizing the three-dimensional organization of telomeres. *Cytometry* 67A:144–150.
- Vermolen BJ, Mai S, Wark L, Fordyce CA, Miller CJ, Berman H, Chuang AY-C, Tlsty T, Young IT, Garini Y. 2005b. The effect of deconvolution algorithms on the automatic analysis of telomeres in three-dimensional imaging. (under review).
- Vourc'h C, Taruscio D, Boyle AL, Ward DC. 1993. Cell cycle-dependent distribution of telomeres, centromeres, and chromosome-specific subsatellite domains in the interphase nucleus of mouse lymphocytes. *Exp Cell Res* 205:142–151.
- Vukovic B, Park PC, Al-Maghrabi J, Beheshti B, Sweet J, Evans A, Trachtenberg J, Squire J. 2003. Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma. *Oncogene* 22:1978–1987.
- Walter J, Schermelleh L, Cremer M, Tashiro S, Cremer T. 2003. Chromosome order in HeLa cells changes during mitosis and early G1, but is stably maintained during subsequent interphase stages. *J Cell Biol* 160:685–697.
- Wan TS, Chan LC, Ngan HY, Tsao SW. 1997. t(High) frequency of telomeric associations in human ovarian surface epithelial cells transformed by human papilloma viral oncogenes. *Cancer Genet Cytogenet* 95:166–172.
- Weierich C, Brero A, Stein S, Hase Jv, Cremer C, Cremer T, Solovei I. 2003. Three-dimensional arrangements of centromeres and telomeres in nuclei of human and murine lymphocytes. *Chromosome Res* 11:485–502.

ORIGINAL ARTICLE

Telomeric aggregates and end-to-end chromosomal fusions require myc box IIA Caporali^{1,2,4}, L Wark^{2,4}, BJ Vermolen³, Y Garini³ and S Mai²

¹Dipartimento di Medicina Sperimentale, Sezione di Biochimica, Biochimica Clinica e Biochimica dell'Esercizio Fisico, Università degli Studi di Parma, Parma, Italy; ²Manitoba Institute of Cell Biology and The Genomic Center for Cancer Research and Diagnosis, CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada and ³Department of Imaging Science and Technology, Faculty of Applied Sciences, Delft University of Technology, Delft, The Netherlands

Telomeres of tumor cells form telomeric aggregates (TAs) within the three-dimensional (3D) interphase nucleus. Some of these TAs represent end-to-end chromosomal fusions and may subsequently initiate breakage–bridge–fusion cycles. Wild-type (wt) and myc box II mutant (mt) Myc induce different types of genomic instability when conditionally expressed in mouse proB cells (Ba/F3). Only wt Myc overexpressing Ba/F3 cells are capable of tumor formation in severe combined immunodeficient mice. In this study, we investigated whether telomere dysfunction leading to TA formation is linked to the genetic changes that permit wt c-Myc-dependent transformation of Ba/F3 cells. To this end, we examined the 3D organization of telomeres after the deregulated expression of deletion myc boxII mutant (Δ 106) or wt Myc. Δ 106-Myc overexpression did not induce TAs, whereas wt-Myc deregulation did. Instead, Δ 106-Myc remodelled the 3D telomeric organization such that telomeres aligned in the center of the 3D interphase nucleus forming a telomeric disk owing to a Δ 106-induced G1/S cell cycle arrest. In contrast, wt-Myc overexpression led to distorted telomere distribution and TA formation. Analysis of chromosomal alterations using spectral karyotyping confirmed Δ 106-Myc and wt-Myc-associated genomic instability. A significant number of chromosomal end-to-end fusions indicative of telomere dysfunction were noted in wt-Myc-expressing cells only. This study suggests that TAs may play a fundamental role in Myc-induced tumorigenesis and provides a novel way to dissect tumor initiation.

Oncogene advance online publication, 4 September 2006; doi:10.1038/sj.onc.1209928

Keywords: three-dimensional nuclear organization; telomere aggregates; c-Myc; genomic instability; telomeric fusions

Introduction

Chromosomes are organized into discrete territories in the interphase nucleus. This nonrandom organization of chromosomes, conserved during evolution, suggests a role for a spatial organization in the control of gene expression and replication (for reviews, see Cremer and Cremer, 2001; Parada *et al.*, 2002). A number of reports describe an architectural stability of the chromosomal positions in the nucleus (Gerlich *et al.*, 2003), whereas other studies described considerable changes in chromosomal positions during the cell cycle (Gasser, 2002; Essers *et al.*, 2005). In particular, chromosome motility increases during mitosis and early-stage G1, but it is limited to local diffusion during the rest of cell cycle (Walter *et al.*, 2003). The spatial organization of chromosomes might contribute to chromosomal translocations found in many tumors (Kozubek *et al.*, 1999; Neves *et al.*, 1999).

Three-dimensional (3D) fluorescent *in situ* hybridization (FISH) is an innovative approach to study the nuclear architecture in fixed cultured cells during cell cycle, cell differentiation and malignant transformation (Solovei *et al.*, 2002; Cremer *et al.*, 2003).

Using 3D FISH experiments with peptide-nucleic-acid (PNA)-telomeric probes, we demonstrated that telomeres of normal cells are organized in a nonoverlapping manner in the 3D interphase nucleus (Chuang *et al.*, 2004; Louis *et al.*, 2005). In contrast, tumor cells display an aberrant organization of telomeres and form clusters of telomeres, the so-called telomeric aggregates (TAs) (Chuang *et al.*, 2004; Mai and Garini, 2005, 2006).

The position of telomeres during the cell cycle is an important indicator of the stage at which these fusions may occur. It has been shown previously that the 3D telomere organization varies during different phases of the cell cycle and displays a highly ordered, dynamic assembly in the interphase nucleus. During G0/G1 and S phases, telomeres are widely distributed throughout the nucleus, whereas in late G2 phase, they align in the middle of the nucleus forming a telomeric disk (Chuang *et al.*, 2004; Vermolen *et al.*, 2005).

The deregulation of Myc protein is found in a wide range of human cancers and is associated with disease progression. The deregulated expression of Myc can

Correspondence: Dr S Mai, Manitoba Institute of Cell Biology, Physiology, Biochemistry and Medical Genetics, 675 McDermot, Winnipeg, MB, Canada R3E 0V9.

E-mail: smai@cc.umanitoba.ca

⁴These two authors contributed equally to this work.

Received 21 March 2006; revised 26 June 2006; accepted 7 July 2006

drive cells into proliferation (Deb-Basu *et al.*, 2006), reduce cell adhesion (Frye *et al.*, 2003), promote metastasis (Pelengaris *et al.*, 2002) and genomic instability (for a review see Mai and Mushinski 2003; Kuttler and Mai, 2005).

The N-terminus of Myc has three highly conserved elements, known as Myc boxes. Of these, Myc box I has been implicated in Myc turnover (Bahram *et al.*, 2000). Myc box I is essential for Myc function *in vivo* and is required for full transactivation and repression of many target genes (Oster *et al.*, 2003). Myc box II is required for all the known biological functions of Myc (Stone *et al.*, 1987) but not all Myc target genes require the integrity of this box for activation, which shows that there are other mechanisms of Myc-dependent activation (Nikiforov *et al.*, 2002).

The conditional expression of wild-type (wt) Myc and deleted box II mutant-Myc ($\Delta 106$ -Myc) in spontaneously immortalized mouse Ba/F3 pro-lymphocytes was previously characterized (Fest *et al.*, 2002). Mutant Myc protein induced lower level of apoptosis but higher level of genomic instability than its wt counterpart. It is of note that in these cells, genomic instability and tumorigenesis are two separable events: Only wt-Myc but not $\Delta 106$ -Myc-expressing cells induced tumor formation in the severe combined immunodeficient mouse model (Fest *et al.*, 2005).

We have recently reported that c-Myc deregulation induces cycles of TA formation and remodels the interphase nucleus by changing the organization of telomeres and chromosomes (Louis *et al.*, 2005, for reviews, see Mai and Garini, 2005, 2006). In addition, the presence of TAs in cells constitutively expressing Myc contributed to genomic instability by forcing abnormal chromosome segregation during mitosis (Ermler *et al.*, 2004).

Telomere function is essential for the preservation of chromosomal integrity (for a review see Feldser *et al.*, 2003). Loss of various telomere-capping proteins or critical shortening of the telomeric repeats led to dysfunctional telomeres. The formation of dicentric chromosomes that led to specific rearrangements was observed more than 60 years ago by Barbara McClintock. Dicentric chromosomes can initiate ongoing chromosomal instability via breakage-bridge-fusion (BBF) cycles (McClintock, 1941). During mitotic segregation, the two centromeres of a dicentric chromosome are pulled to opposite poles and chromosomes can break. These breaks generate telomere-free ends and new chromosome fusions, nonreciprocal translocations and overall genetic changes that contribute to genomic instability. Our previous study showed that c-Myc is one key factor that initiates chromosomal rearrangements through BBF cycles (Louis *et al.*, 2005).

In the present study, we investigated whether Myc box II is required for TA formation in Ba/F3 cells. In order to evaluate the difference in initiating and promoting tumorigenesis between wt-Myc and $\Delta 106$ -Myc-expressing cells, we analysed the organization of telomeres in the interphase nucleus and the presence of chromosomal rearrangements resulting from BBF cycles.

Results

Telomere disk after cell cycle synchronization

It has been shown previously that varying telomere organization is observed during different phases of the cell cycle with telomeric disks forming in the G2 phase of the cell cycle (Chuang *et al.* 2004). Telomere positions in the 3D nucleus were calculated by using a program (Teloview) and algorithms that we have developed for this purpose (Chuang *et al.* 2004; Vermolen *et al.*, 2005). Briefly, using an adequate threshold, the program calculates the center of gravity, the volume and intensity for each telomere. Using the quick-hull algorithm (Barber *et al.* 1996), the distribution of the telomeres in the nucleus volume is found by fitting the smallest set of polygons that contains all the telomeres. In general, this volume is an ellipsoid with two similar radii ($a = b$) and one dissimilar radius (c) (i.e. spheroid). Therefore, the level of flatness of the volume occupied by the telomeres can be described by an a/c ratio. The larger the ratio, the more disk-like is the shape of the volume occupied by the telomeres.

In order to confirm the position of telomeres during different phases of the cell cycle and the presence of telomeric disk, mouse diploid immortalized Pre-B lymphocytes were synchronized in late G2 with 0.5 $\mu\text{g/ml}$ of nocodazole. Synchronized cells were reintroduced into culture and harvested again after 8 h at G1 phase (Figure 1a).

Using PNA-FISH hybridization in 3D fixed Pre-B lymphocytes, we confirmed the formation of a telomeric disk at the time of synchronization (Figure 2b). Eight hours after release from synchronization, telomeres returned to a wide distribution throughout the interphase nucleus (Figure 2c). The calculated a/c ratios in the cells arrested in G2/M phase and in the cells in G1 phase were 11.8 ± 2.9 and 8.1 ± 1.7 , respectively (Table 1).

To detect telomere positions after G1/S synchronization, Pre-B cells were incubated for 42 h in RPMI 1640 that had been depleted of the amino acids methionine, cysteine and L-glutamine, and then returned to complete RPMI 1640 with mimosine at a concentration of 0.4 $\mu\text{g/ml}$ 8 h (Kuschak *et al.*, 2002). The G1/S block was confirmed by fluorescent-activated cell sorter (FACS) analysis (Figure 1a). Eight hours after release from the G1/S block, Pre-B cells returned to normal cycling conditions (Figure 1b). Under conditions of G1/S synchronization, the telomeres aligned in the center of 3D interphase nucleus and formed a telomere disk (Figure 2d). The high value of the a/c ratio (9.6 ± 2.9 time 0), calculated for G1/S synchronized cells, confirmed the flatness of the volume occupied by the telomeres. Eight hours after release from the G1/S arrest, the telomeres were widely distributed in 3D interphase nucleus with a calculated a/c ratio of 7.7 ± 1.4 (Table 2, Figure 2e).

The 3D organization of telomeres in wt-Myc and $\Delta 106$ -Myc-induced Ba/F3 cells

To study the organization of telomeres in the nucleus after conditional wt-Myc and $\Delta 106$ -Myc induction in




Figure 1 FACS analysis for Pre-B cells. Control group proliferated normally with no detectable sign of cell cycle arrest (a). Cells were harvested 0h after having been synchronized at G2/M with nocodazole and 8 h after release from synchronization with nocodazole. (b) For G1/S synchronization, Pre-B cells were incubated for 42 h in RPMI media that had been depleted of the amino acids methionine, cysteine and L-glutamine, released from G1/S synchronization and placed in normal media. Cells were then harvested at 0h after synchronization and once every hour for 8 h. The cell cycle profile was expressed as the percentage (\pm s.d.) of cells in each phase (G0/G1; S; G2/M). These values were calculated from data collected from three independent experiments.

immortalized mouse pro-B lymphocytes (Ba/F3) stably transfected with MycER (Fest *et al.*, 2002), we performed PNA-telomere FISH hybridization. After addition of a single dose of 4-hydroxytamoxifen (4HT), nuclear c-Myc signal was quantified by quantitative fluorescent immunostaining (Kuschak *et al.*, 1999). In nontreated control cells, MycER was found in the cytoplasm. The nuclear signal of both wt and Δ 106-Myc proteins increased threefold over a 2–4-h period and decreased to the levels of nontreated cells after 6 h (data not shown).

Consistent with our previous results (Louis *et al.*, 2005), Ba/F3 cells without MycER activation showed nonoverlapping telomere positions (Figure 3a). At 24 h after wt-Myc activation, Ba/F3 cells displayed a wide spatial telomere distribution and the presence of TAs (Figure 3b). At the same time point, in Δ 106-myc-induced Ba/F3 cells, telomeres were aligned in the center of the 3D interphase nucleus (Figure 3c).

To better describe telomere distribution in 3D nucleus, we measured *a/c* ratios after wt and Δ 106-Myc activation (Table 3). Telomeres were widely




Figure 2 Three-dimensional analysis of telomere position after G2/M and G1/S synchronization. (a) Fixed control cell untreated. (b) Fixed cells harvested 0 h after having been synchronized at G2/M with nocodazole. (c) Fixed cells harvested 8 h after release from synchronization with nocodazole. (d) Fixed cells harvested 0 h after synchronization at G1/S with depleted medium/mimosine. (e) Fixed cells harvested 8 h after release from synchronization with depleted medium/mimosine. Telomeres are shown in red; nuclei were stained with DAPI (blue). 3DF (3D front view), 3DS (3D side view).

Table 1 Effect of G2/M synchronization on telomeres distribution in 3D nucleus

Cell culture conditions	<i>a/c</i> ratio	Telomere distribution in 3D
Pre-B control	6.3 \pm 2.3	Widely distributed throughout the nucleus
Pre-B 0 h + nocodazole	11.8 \pm 2.9	Disk formation
Pre-B 8 h – nocodazole	8.1 \pm 1.7	Widely distributed throughout the nucleus

3D, three-dimensional. Thirty nuclei were analysed for each time point. These values were calculated from data collected from three independent experiments. Values are means of three experiments \pm s.d.

Table 2 Effect of G1/S synchronization on telomeres distribution in 3D nucleus

Cell culture conditions	a/c ratio	Telomere distribution in 3D
Pre-B 0 h (amino-acid deprivation plus mimosine)	9.6±2.9	Disk formation
Pre-B 8 h after release from G1/S block	7.7±1.4	Widely distributed throughout the nucleus

Thirty nuclei were analysed for each time point. These values were calculated from data collected from three independent experiments. Values are means of three experiments ± s.d. 3D, three-dimensional.




Figure 3 Telomere distribution in 3D interphase nuclei of Ba/F3 cells at 24 h after wt-Myc and $\Delta 106$ -Myc activation. (a) Control (non-4HT treated) Ba/F3 cells; (b) wt-Myc-activated Ba/F3 cells with a wide distribution of telomeres and with TAs formation (yellow arrow); (c) in $\Delta 106$ -Myc expressing cells, telomeres are aligned in the center of the interphase nucleus, forming a disk-like structure without TAs. Telomeres are shown in red; nuclei were stained with DAPI (blue). 3DF (3D front view), 3DS (3D side view).

distributed throughout the nucleus after wt-Myc induction with a calculated a/c ratio of 4.1 ± 1.1 at 24 h and 4.9 ± 0.7 at 48 h, which means a spherical-like volume of distribution. However, after $\Delta 106$ -Myc induction, the a/c ratio was 10.1 ± 4.3 at 24 h and 9.2 ± 2.9 at 48 h.

The possible relationship between telomere distribution and cell cycle in this model was investigated by flow cytometry. Propidium iodide staining of cellular DNA indicated that non-4HT-treated Ba/F3 cells proliferated normally with no detectable sign of cell cycle arrest (Figure 4, 0 h). As expected, the overexpression of wt-Myc increased G1/S transition after 24 and 48 h (Figure 4a). In contrast, the $\Delta 106$ -Myc-expressing cells accumulated at G1/S phase of the cell cycle. By 24 h, over 80% of the cells were arrested in G1/S (Figure 4b).

Table 3 Effect of wt-Myc and $\Delta 106$ -Myc expression on telomeres distribution in 3D nucleus

Cell culture conditions in the presence of 4HT	a/c ratio	Telomere distribution in 3D
BaF3 wt-Myc 0 h	6.7±1.3	Widely distributed throughout the nucleus
BaF3 wt-Myc 24 h	4.1±1.1	Widely distributed throughout the nucleus
BaF3 wt-Myc 48 h	4.9±0.7	Widely distributed throughout the nucleus
BaF3 $\Delta 106$ -Myc 0 h	6.7±1.1	Widely distributed throughout the nucleus
BaF3 $\Delta 106$ -Myc 24 h	10.1±4.3	Disk formation
BaF3 $\Delta 106$ -Myc 48 h	9.2±2.9	Disk formation

Thirty nuclei were analysed for each time point. These values were calculated from data collected from three independent experiments. Values are means of three experiments ± s.d. 3D, three-dimensional.




Figure 4 Effect of wt-Myc and $\Delta 106$ -Myc expression on cell cycle profiles. Cell cycle analysis of Ba/F3 cells at 24 and 48 h after wt-MycER (a) and $\Delta 106$ -MycER (b) activation. The cells were collected, permeabilized and DNA was stained with propidium iodide. The overexpression of wt-Myc increased G1/S transition after 24 and 48 h. The $\Delta 106$ -Myc-expressing cells accumulated at G1/S phase of the cell cycle. The cell cycle profile was expressed as the percentage (\pm s.d.) of cells in each phase (G0/G1, S, G2/M). These values were calculated from data collected from three independent experiments.

$\Delta 106$ -Myc expression does not induce TA formation in interphase nuclei

In tumor cells, the ordered and nonoverlapping 3D nuclear space that telomeres normally occupy is compromised and telomeres can form aggregates that

may fuse their respective chromosomes, favoring structural chromosomal aberrations. In order to investigate whether the mutation in Myc box II impacted on the formation of TAs, we analysed wt and $\Delta 106$ -Myc-expressing cells. To this end, cells were harvested every 6 h over a time period of 48 h. Measurement of TAs was performed after 3D image acquisition and constrained iterative deconvolution (Louis *et al.*, 2005).

This time course experiment confirmed that only wt-Myc expression in Ba/F3 cells induced TAs. Representative images showed that TAs varied in number in wt-Myc-expressing cells at 24 h (Figure 5B, b). In contrast, TAs were not detectable in the 3D nucleus at 24 h, with control Ba/F3 cells (non-4HT treated cells) and $\Delta 106$ -Myc-expressing cells (Figure 5B, a and c, respectively). A single dose of 4HT induced the highest levels of TA formation after 24 h in wt-Myc-expressing cells. Thus, only a single TA cycle is observed in Ba/F3 after wt-Myc activation (Figure 5A). In Ba/F3 cells, the nuclear localization of Myc completely disappeared 6 h after 4HT-induced MycER activation (data not shown). As reported previously (Louis *et al.*, 2005), the number of TA cycles was directly linked to the duration of

wt-Myc deregulation. As wt-Myc but not $\Delta 106$ -Myc-expressing cells induced tumorigenesis *in vivo* (Fest *et al.*, 2005), the presence of TAs seems to be linked to the initiation and/or progression of tumorigenic potential seen in Ba/F3 cells with deregulated wt-Myc expression.

A significant number of chromosomal fusions were noted only in wt-Myc-expressing cells

To determine whether the formation of TA was associated with BBF events, spectral karyotyping (SKY) analysis on metaphase chromosomes was performed at different times: prior (6 h), during (24 h) and after (42 h) the peak of TA formation in both wt and $\Delta 106$ -Myc-expressing cells. Table 4 summarizes the genomic aberrations detected in wt-Myc-expressing Ba/F3 cells. As expected for an immortalized cell line (Fest *et al.*, 2005), control Ba/F3 cells (non-4HT treated)




Figure 5 Overview of TA formation in nuclei of Ba/F3 cells expressing wt-Myc or $\Delta 106$ -Myc. (A) Fold increase in TAs over control level during a period of 48 h. The highest levels of TAs were observed at 24 h after wt-Myc activation. Error bars represent a 95% confidence interval of binomial distribution. (B) Representative individual images showing TA formation over the time frame shown in (A). (B, a) Control (non-4HT treated) Ba/F3 cells display nonoverlapping telomeres. (B, b) wt-Myc activated Ba/F3 show the formation of TAs (yellow arrow). (B, c) $\Delta 106$ -Myc-expressing cells do not show TAs.

Table 4 Chromosomal rearrangements in wt-Myc-activated Ba/F3 cells

Time point (h)	Aberrations	%	P-value
0	Fusions: none Translocation: T5;X, T4;9 Metaphase with translocations: 2/20 Average number of translocations per metaphase: 1 Metaphases with chromosomal fusions: 0/20 Fusions per metaphase: 0	10	0.1468
6	Fusions: none Translocation: T4;9, T5;X, T14;X Metaphase with translocations: 3/20 Average number of translocations per metaphase: 3 Metaphases with chromosomal fusions: 0/20 Fusions per metaphase: 0	15	0.0717
24	Fusions: 8;19, 14;11, X;X, 10;9, 19;X, 18 :18, 11;6 Translocation: T15;9, T15;2, T5;X, T15; 10 Metaphase with translocations: 6/20 Average number of translocations per metaphase: 5 Metaphases with chromosomal fusions: 7/20 Fusions per metaphase: 3	30 35	0.0101 0.0036
42	Fusions: 10;11, X;X Translocation: T5;X, T8;4, T4;10, T15;10 Metaphase with translocations: 2/20 Average number of translocations per metaphase: 3 Metaphases with chromosomal fusions: 6/20 Fusions per metaphase: 2	10 30	0.1468 0.0101

The table summarizes data obtained by spectral karyotyping. Metaphases were prepared and analysed after a single administration of 4-hydroxytamoxifen to wt-MycER Ba/F3 cells (Figure 3). End-to-end fusions were detected at 24 h in 30% of the metaphases ($P=0.0101$). Nonreciprocal translocation were also found at 24 h (in 35% of the metaphases) and reached significance. As time progresses, fusions decreased whereas translocations remained steady. The table shows the description of the aberrations found, their percentage of occurrence, average number of fusion and translocation per metaphase, and significance P -values. A minimum of 20 metaphases was examined per time point.

showed some chromosomal alterations. At 24 h, six out of 20 metaphases in wt-Myc-expressing cells showed a significant increase in end-to-end chromosomal fusions and nonreciprocal translocations over control levels. At 42 h after wt-Myc activation, the percentage of fusions and translocation decreased. The karyotype of spontaneously immortalized, tetraploid (Ba/F3) cells is shown in Figure 6a. Representative images (Figure 6b), 24 h after wt-Myc activation, show fusions at telomeric ends




Figure 6 SKY of Ba/F3 wt-MycER and $\Delta 106$ -MycER cells. Representative images of Ba/F3 cells control (non-4HT treated) (a), 24 h after MycER activation (+4HT) for (b) wt-Myc and $\Delta 106$ -Myc (c) are shown. Notice the presence of fusion between two chromosomes X and between chromosome 10 and 9 (see yellow arrows) after wt-Myc activation. No fusions were detected by SKY after $\Delta 106$ -Myc activation. For a detailed overview of the aberration detected by SKY, see Tables 4 (wt-Myc) and 5 ($\Delta 106$ -Myc). Each panel of the figure shows the following order of images, the raw spectral image of the metaphase (top left corner), the classified image of the identical metaphase (top middle panel), the inverted DAPI image of the identical metaphase (top right corner) and the classified karyotype of the identical metaphase is displayed in the bottom panel. A minimum of 20 metaphases was analysed per time point.

between two chromosomes X and between chromosomes 10 and 9. Nonreciprocal translocation between chromosomes 15 and 9 and broken chromosomes (4, 16 and 9) were observed. Other aberrations included the insertion of chromosome X material into chromosome 1 and of chromosome 19 material into chromosome 4.

The analysis of 20 metaphases from $\Delta 106$ -Myc-expressing cells revealed an increased number of nonreciprocal translocations over 42 h in comparison with control (non-4HT treated) Ba/F3 cells. In contrast to wt-Myc-overexpressing Ba/F3 cells, $\Delta 106$ -Myc-overexpressing cells did not show chromosomal end-to-end fusions. Nonreciprocal translocations were found in wt-Myc-expressing cells at 24 h in 30% of the metaphases ($P = 0.0101$). As time progressed, translocations increased (in 40% of metaphases $P < 0.001$) (Table 5). Figure 6c summarizes the most common aberrations seen in $\Delta 106$ -Myc-expressing cells at 24 h. SKY analysis confirmed the presence of unbalanced translocation involving chromosomes 2, 3, 4 and 15.

Both wt and $\Delta 106$ -Myc proteins showed high levels of significant karyotypic instability. The main difference between $\Delta 106$ -Myc and wt-Myc-expressing cells were that the latter exhibited a significant number of chromosome fusions related to telomere dysfunction.

Discussion

There are at least two types of telomere dysfunction in tumor cells. One type involves critically short telomeres (DePinho and Polyak, 2004). The other one involves the formation of TAs and is independent of telomere size and telomerase activity (Louis *et al.*, 2005). Telomeres of normal cells are organized in a nonoverlapping manner in the 3D interphase nucleus. In contrast, tumor cells display an aberrant organization of telomeres that impact on the numbers of TAs (Chuang *et al.*, 2004).

Telomere dynamics have been observed and measured by live cell imaging approaches in different cell lines. Long and short ranging movements were observed over a time period of 20 min (Molenaar *et al.*, 2003). 3D imaging has permitted to determine that the telomere organization in the nucleus is cell cycle dependent. As such the position of telomeres during the cell cycle is an important indicator of the stage at which these TAs may occur (Chuang *et al.*, 2004).

In the present study, we have investigated a possible correlation between telomere positions during the cell cycle and the formation of TAs and the different tumorigenic potential of wt and mutant Myc proteins (Fest *et al.*, 2005). At the G1/S boundary of a synchronized cell cycle, the telomeres of Pre-B cells have a tendency to align in the center of the nucleus, in a structure we had termed earlier a telomeric disk (Chuang *et al.*, 2004). This is the first time such a telomere organization has been found during an induced G1/S block. This alignment of telomeres dissociates and telomeres are observed throughout the nucleus when cells re-enter into the cycle after release from the synchronization event.

Table 5 Chromosomal rearrangements in $\Delta 106$ -Myc activated Ba/F3 cells

Time point (h)	Aberrations	%	P-value
0	Fusions: none Translocation: T5;X Metaphase with translocations: 2/20 Average number of translocations per metaphase: 1 Metaphases with chromosomal fusions: 0/20 Fusions per metaphase: 0	10	0.1468
6	Fusions: none Translocation: T5 ;1, T3 ;16, T 7 ;13 Metaphase with translocations: 3/20 Average number of translocations per metaphase: 3 Metaphases with chromosomal fusions: 0/20 Fusions per metaphase: 0	15	0.0717
24	Fusions: none Translocation: T5;X, T1;15, T15;4, T12;3, T2;10 Metaphase with translocations: 6/20 Average number of translocations per metaphase: 4 Metaphases with chromosomal fusions: 0/20 Fusions per metaphase: 0	30	0.0101
42	Fusions: none Translocation: T15;4, T7;13, T8;4, T14;X Average number of translocations per metaphase: 8/20 Translocations per metaphase: 4 Metaphases with chromosomal fusions: 0/20 Fusions per metaphase: 0	40	<0.001

The table summarizes data obtained by spectral karyotyping. Metaphases were prepared and analysed after a single administration of 4-hydroxytamoxifen at $\Delta 106$ -MycER Ba/F3 cells (Figure 3b). End-to-end fusions were not observed over the 42h of the experiment. Nonreciprocal translocations were found at 24h in 30% of the metaphases ($P=0.0101$). As time progressed, translocations increased (in 40% of metaphases $P<0.001$). The table shows the description of the aberrations found, their percentage of occurrence, average number of fusion and translocation per metaphase, and significance P -values. M, metaphase. A minimum of 20 metaphases was examined per time point.

The telomeric disk naturally reforms at the G2/M transition of the cell cycle (Chuang *et al.*, 2004). Thereafter, the telomeres resume their distribution throughout the nucleus. This feature of a dynamic telomeric organization throughout the cell cycle is mimicked by an experimental G2/M synchronization. Eight hours after release from the G2/M block, telomeres will assume their normal cell cycle-dependent organization.

The expression of wt-Myc stimulates the G1/S transition by regulating the levels and the activity of the cyclins (Trumpf *et al.*, 2001). In Ba/F3 cells, wt-Myc activation promotes G1/S transition and is accompanied by a distorted telomere distribution that results from the presence of TAs (Figure 3, yellow arrow). In contrast, Myc box II mutants expressing cells were blocked in

G1/S and the telomeres were aligned in the center of the 3D interphase nucleus, forming a telomere disk. These results agree with the data obtained in synchronized Pre-B cells in G1/S phase of the cell cycle.

Previous work had shown in Ba/F3 cells that wt and mutant Myc proteins induced genomic instability but only wt-Myc protein had the potential of initiating and promoting tumorigenesis *in vivo* (Fest *et al.*, 2005). Using PNA-telomere FISH hybridization in 3D-fixed cells, we demonstrated that the formation of TAs takes part in MYC-induced tumorigenesis.

TAs were detectable only in wt-Myc expressing and tumorigenic Ba/F3 cells (Fest *et al.*, 2005) reaching the highest peak after 24h after Myc activation, whereas $\Delta 106$ -Myc expressing and nontumorigenic Ba/F3 cells (Fest *et al.*, 2005) did not show a significant number of TAs. The presence of TAs in malignant cells is supported by data from different cell lines and human tumors (Chuang *et al.*, 2004).

SKY data show that conditional wt-Myc protein expression (Table 4) led to a higher level of chromosomes end-to-end fusions than conditional $\Delta 106$ -Myc protein expression (Table 5). These results are in agreement with the absence of TAs in the mutant Myc-expressing cells.

TAs are not just a transient aberration in the 3D organization of the nucleus, but these events precede the formation of BBF cycles. As reported in our previous work, once aggregates form and chromosome fusions occur, BBF cycles result and the genetic information of the chromosomes will be remodelled (Louis *et al.*, 2005).

Nothing is known about the mechanisms that cause TA formation in the context of c-Myc deregulation. Shelterin is a protein complex with DNA remodelling activity that, together with several DNA repair protein, such as WRN, the Mre11 complex and DNA-PK, protects the integrity of the chromosome ends (De Lange, 2005). In cells constitutively expressing Myc and characterized by the presence of TAs (Ermler *et al.*, 2004), the level of TRF2 protein, a shelterin subunit protein, was reduced. These data lend support to the hypothesis that Myc may somehow interact with proteins of the shelterin or DNA repair complexes to mediate TAs formation. This capacity is lost in myc box II mutant. Understanding whether TAs may be the earliest events in tumor development and which genetic background is more susceptible to TA formation will provide a novel way to dissect the benign-to-malignant transition in cancer.

Materials and methods

Cell cultures and treatments

Mouse Pre-B lymphocytes (Mai *et al.*, 1999) were grown in RPMI 1640 supplemented with 0.1% β -mercaptoethanol, 1% L-glutamine, 1% sodium-pyruvate, 1% penicillin/streptomycin and 10% fetal bovine serum (FBS; Gibco, Burlington ON, Canada) at 37°C, in a humidified atmosphere and in the presence of 5%CO₂.

For G2/M synchronization, Pre-B cells were incubated for 8h in standard RPMI 1640 medium (Gibco, Burlington ON,

Canada) with nocodazole (Sigma-Aldrich, Oakville ON, Canada) at a concentration of 1 $\mu\text{g}/\text{ml}$. Upon completion of synchronization, cells were removed from nocodazole and returned to nocodazole-free media and harvested at 0 and 8 h.

For G1/S synchronization, Pre-B cells were incubated for 42 h in RPMI 1640 that had been depleted of the amino acids methionine, cysteine and L-glutamine, and then returned to complete RPMI 1640 with mimosine at a concentration of 0.4 $\mu\text{g}/\text{ml}$ for 8 h (Kuschak *et al.*, 2002). Cells were then harvested at 0 h and once every hour for 8 h.

The two Ba/F3 cell lines with conditional wt-MycER (Littlewood *et al.*, 1995) and $\Delta 106$ -MycER used in this study have been previously described (Fest *et al.*, 2002). Cells were grown in RPMI 1640 containing 10% FBS, 1% WEHI cells supernatant (mouse myelomonocytic leukemia macrophage-like cells derived from a BALB/c mouse; the cells produce IL3 supernatant) and 0.21% of plasmocin (Cayla, Toulouse, France).

Wt-Myc and $\Delta 106$ -Myc cells were induced with 4-hydroxytamoxifen (4HT) (Sigma-Aldrich, Oakville ON, Canada) to a final concentration of 100 nM in 10^5 cells/ml to activate the c-Myc protein. Cells were split 24 h prior induction and every 48 h after 4HT induction.

Cells were grown and maintained at a density of 10^5 – 10^6 cells/ml. Cell viability was determined by hemocytometer counts using trypan blue (Sigma-Aldrich, Oakville ON, Canada).

Immunohistochemistry

Immunohistochemistry was performed as described previously (Fukasawa *et al.*, 1997). The primary antibody used was a rabbit polyclonal anti-c-Myc (N262) at a dilution of 1:100 (Santa Cruz, Santa Cruz, California, USA) visualized by using a secondary goat anti-rabbit IgG fluorescein isothiocyanate antibody at a dilution of 1:100 (Sigma-Aldrich, Oakville ON, Canada). Images were acquired using a Hamamatsu CCD SensiCam Camera and the Northern Eclipse v 6.0 software.

FACS analysis

For FACS analysis, Pre-B and Ba/F3 cells were fixed in 70% cold ethanol and stained with propidium iodide (Sigma-Aldrich, Oakville ON, Canada) (1 $\mu\text{g}/\text{ml}$) following RNase digestion (Sigma-Aldrich, Oakville ON, Canada) (20 $\mu\text{g}/\text{ml}$). The stained cells were analysed for DNA content by flow cytometry in an EPICS Altra cytometer (Beckman-Coulter, Mississauga, ON, Canada).

Telomere FISH and 3D image analysis

Cells were fixed using 3:1 methanol/acetic acid fixative (Fluka, Oakville, ON, Canada) and then placed on $26 \times 76 \text{ mm}^2$ microscope slides. Telomeres were stained using quantitative fluorescent FISH with a telomere-specific CY3-labeled PNA probe (DAKO, Mississauga, ON, Canada). Nuclear volumes did not significantly change during the denaturation protocol

References

- Bahram F, von der Lehr N, Cetinkaya C, Larsson LG. (2000). c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. *Blood* **95**: 2104–2110.
- Barber CB, Dobkin PD, Huhdanpaa H. (1996). The quick-hull algorithm for convex hulls. *ACM Transactions on Mathematical Software* **22**: 469–483.
- Chuang TC, Moshir S, Garini Y, Chuang AY, Young IT, Vermolen B *et al.* (2004). The three-dimensional organiza-

tion of telomeres in the nucleus of mammalian cells. *BMC Biol* **3**: 2–12.

Cremer T, Cremer C. (2001). Chromosome territories, nuclear architecture and gene regulation in mammalian cells. *Nat Rev Genet* **2**: 292–301 (Review).

Cremer M, Kupper K, Wagler B, Wizelman L, von Hase J, Weiland Y *et al.* (2003). Inheritance of gene density-related higher order chromatin arrangements in normal and tumor cell nuclei. *J Cell Biol* **162**: 809–820.

used for 3D telomere FISH. Counterstaining was performed with 4'-6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich, Oakville ON, Canada). Three independent experiments were performed and at least 30 nuclei were examined per time point.

Cells were imaged on a Zeiss Axioplan 2 microscope with a Zeiss Axiocam HRm and deconvolution module, including Axiovision (Zeiss, North York, ON, Canada) software v3.1. Images were deconvolved using a constrained iterative algorithm (Schaefer *et al.*, 2001). Analysis was performed with TeloView (Chuang *et al.*, 2004; Vermolen *et al.*, 2005).

By choosing a simple threshold for the telomeres, the volume, intensity and center of gravity are calculated. The integrated intensity of each telomere is calculated because it is proportional to the telomere length (Poon *et al.*, 1999). The integration region is determined by growing a sphere on top of the found coordinate. After every step of growth (iteration), the sum under this volume (the telomere) is subtracted by the sum immediately surrounding it (background level). When the process of the growth of the sphere does not contribute to an integrated intensity increase, the algorithm stops and the integrated intensity of the telomere with an automatic background correction is obtained.

The telomeric distribution inside the nucleus is described by fitting an ellipsoid to the volume occupied by the telomeres. The distributions were found to be either oblate or spherical. It is therefore convenient to describe the distribution volume as a spheroid (i.e. an ellipsoid having two axes of equal length). As such, it is simpler to describe the spheroid degree of variation from a perfect sphere by the ratio a/c where a and b are the similar semi-axes and c is the third dissimilar axis. Such a description reflects the degree to which the telomere's volume is oblate. Nuclear flattening that may affect a/c ratios was considered in this study. All cells (samples) in an experiment were processed at the same time. If nuclei on one slide consistently showed high a/c ratios, whereas nuclei on parallel processed slides did not, we assumed that the a/c ratio reflected the flatness of telomere distribution of nuclei within that specific sample. All experiments were performed three times.

SKY analysis

SKY was performed by using the ASI (Applied Spectral Imaging, Vista, CA, USA) kit for mouse and Spectra Cube on a Carl Zeiss Axioplan 2 microscope. At least 20 metaphases were examined per time points.

Acknowledgements

We thank Dr Ludger Klewes and Dr Ed Rector for assistance with FACS analysis, and Mary Cheang (Biostatistics Unit) for statistical analyses. We acknowledge support from CancerCare Manitoba Foundation, the National Cancer Institute of Canada (NCIC), and the Canadian Institutes of Health Research (CIHR). AC and LW were recipients of a Strategic Training Program stipend from CIHR.

- Deb-Basu D, Karlsson A, Li Q, Dang CV, Felsner DW. (2006). MYC can enforce cell cycle transit from G1 to S and G2 to S, but not mitotic cellular division, independent of p27-mediated inhibition of cyclin E/CDK2. *Cell Cycle* **5**: 1348–1355. Epub 2006 Jun 15.
- De Lange T. (2005). Shelterin: the protein complex that shapes and safeguards human telomeres. *Genes Dev* **19**: 2100–2110 (Review).
- DePinho RA, Polyak K. (2004). Cancer chromosomes in crisis. *Nat Genet* **36**: 932–934.
- Essers J, van Cappellen WA, Theil AF, van Drunen E, Jaspers NG, Hoeijmakers JH et al. (2005). Dynamics of relative chromosome position during the cell cycle. *Mol Biol Cell* **16**: 769–775.
- Ermler S, Kronic D, Knoch TA, Moshir S, Mai S, Greulich-Bode KM et al. (2004). Cell cycle-dependent 3D distribution of telomeres and telomere repeat-binding factor 2 (TRF2) in HaCaT and HaCaT-myc cells. *Eur J Cell Biol* **83**: 681–690.
- Feldser DM, Hackett JA, Greider CW. (2003). Telomere dysfunction and the initiation of genome instability. *Nat Rev Cancer* **3**: 623–627.
- Fest T, Guffei A, Williams G, Silva S, Mai S. (2005). Uncoupling of genomic instability and tumorigenesis in a mouse model of Burkitt's lymphoma expressing a conditional box II-deleted Myc protein. *Oncogene* **24**: 2944–2953.
- Fest T, Mougey V, Dalstein V, Hagerty M, Milette D, Silva S et al. (2002). c-MYC overexpression in Ba/F3 cells simultaneously elicits genomic instability and apoptosis. *Oncogene* **21**: 2981–2990.
- Frye M, Gardner C, Li ER, Arnold I, Watt FM. (2003). Evidence that Myc activation depletes the epidermal stem cell compartment by modulating adhesive interactions with the local microenvironment. *Development* **130**: 2793–2808.
- Fukasawa K, Wiener F, Vande Woude GF, Mai S. (1997). Genomic instability and apoptosis are frequent in p53 deficient young mice. *Oncogene* **15**: 1295–1302.
- Gerlich D, Beaudouin J, Kalbfuss B, Daigle N, Eils R, Ellenberg J. (2003). Global chromosome positions are transmitted through mitosis in mammalian cells. *Cell* **112**: 751–764.
- Gasser SM. (2002). Visualizing chromatin dynamics in interphase nuclei. *Science* **296**: 1412–1416.
- Kozubek S, Lukasova E, Mareckova A, Skalnikova M, Kozubek M, Bartova E et al. (1999). The topological organization of chromosomes 9 and 22 in cell nuclei has a determinative role in the induction of t(9,22) translocations and in the pathogenesis of t(9,22) leukemias. *Chromosoma* **108**: 426–435.
- Kuschak TI, Kuschak BC, Taylor CL, Wright JA, Wiener F, Mai S. (2002). c-Myc initiates illegitimate replication of the ribonucleotide reductase R2 gene. *Oncogene* **21**: 909–920.
- Kuschak TI, Taylor C, McMillan-Ward E, Israels S, Henderson DW, Mushinski JF et al. (1999). The ribonucleotide reductase R2 gene is a non-transcribed target of c-Myc-induced genomic instability. *Gene* **238**: 351–365.
- Kuttler F, Mai S. (2005). c-Myc, genomic instability and disease. In: Volf JN (ed). *Genome and Disease Genome dynamics*, vol. 1. Karger: Basel, pp 171–190.
- Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. (1995). A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. *Nucleic Acids Res* **23**: 1686–1690.
- Louis SF, Vermolen BJ, Garini Y, Young IT, Guffei A, Lichtensztejn Z et al. (2005). c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus. *Proc Natl Acad Sci USA* **102**: 9613–9618.
- Mai S, Garini Y. (2005). Oncogenic remodeling of the three-dimensional organization of the interphase nucleus: c-Myc induces telomeric aggregates whose formation precedes chromosomal rearrangements. *Cell Cycle* **10**: 1327–1331.
- Mai S, Garini Y. (2006). The significance of telomeric aggregates in the interphase nuclei of tumor cells. *J Cell Biochem* **5**: 904–915.
- Mai S, Mushinski JF. (2003). c-Myc-induced genomic instability. *J Environ Pathol Toxicol Oncol* **22**: 179–199.
- Mai S, Hanley-Hyde J, Rainey GJ, Kuschak TI, Paul JT, Littlewood TD et al. (1999). Chromosomal and extrachromosomal instability of the cyclin D2 gene is induced by Myc overexpression. *Neoplasia* **1**: 241–252.
- McClintock B. (1941). The stability of broken ends of chromosomes in *Zea mays*. *Genetics* **26**: 234–282.
- Molenaar C, Wiesmeijer K, Verwoerd NP, Khazen S, Eils R, Tanke HJ et al. (2003). Visualizing telomere dynamics in living mammalian cells using PNA probes. *EMBO J* **22**: 6631–6641.
- Neves H, Ramos C, da Silva MG, Parreira A, Parreira L. (1999). The nuclear topography of ABL, BCR, PML, and RARalpha genes: evidence for gene proximity in specific phases of the cell cycle and stages of hematopoietic differentiation. *Blood* **93**: 1197–1207.
- Nikiforov MA, Chandriani S, Park J, Kotenko I, Matheos D, Johnsson A et al. (2002). TRRAP-dependent and TRRAP-independent transcriptional activation by Myc family oncoproteins. *Mol Cell Biol* **22**: 5054–5063.
- Oster SK, Mao DY, Kennedy J, Penn LZ. (2003). Functional analysis of the N-terminal domain of the Myc oncoprotein. *Oncogene* **22**: 1998–2010.
- Parada LA, McQueen PG, Munson PJ, Misteli T. (2002). Conservation of relative chromosome positioning in normal and cancer cells. *Curr Biol* **12**: 1692–1697.
- Pelengaris S, Khan M, Evan GI. (2002). Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. *Cell* **109**: 321–334.
- Poon SS, Martens UM, Ward RK, Lansdorp PM. (1999). Telomere length measurements using digital fluorescence microscopy. *Cytometry* **36**: 267–278.
- Schaefer LH, Schuster D, Herz H. (2001). Generalized approach for accelerated maximum likelihood based image restoration applied to three-dimensional fluorescence microscopy. *J Microsc* **204**(Pt 2): 99–107.
- Solovei I, Cavallo A, Schermelleh L, Jaunin F, Scasselati C, Cmarko D et al. (2002). Spatial preservation of nuclear chromatin architecture during three-dimensional fluorescence *in situ* hybridization (3D-FISH). *Exp Cell Res* **1**: 10–23.
- Stone J, De Lange T, Ramsay G, Jakobovits E, Bishop JM, Varmus H et al. (1987). Definition of regions in human c-myc that are involved in transformation and nuclear localization. *Mol Cell Biol* **7**: 1697–1709.
- Trumpp A, Refaeli Y, Oskarsson T, Gasser S, Murphy M, Martin GR et al. (2001). c-Myc regulates mammalian body size by controlling cell number but not cell size. *Nature* **414**: 768–773.
- Vermolen BJ, Garini Y, Mai S, Mougey V, Fest T, Chuang TC et al. (2005). Characterizing the three-dimensional organization of telomeres. *Cytometry* **67**: 144–150.
- Walter J, Schermelleh L, Cremer M, Tashiro S, Cremer T. (2003). Chromosome order in HeLa cells changes during mitosis and early G1, but is stably maintained during subsequent interphase stages. *J Cell Biol* **160**: 685–697. Epub 2003 Feb 25.

Extra View

Oncogenic Remodeling of the Three-Dimensional Organization of the Interphase Nucleus

c-Myc Induces Telomeric Aggregates Whose Formation Precedes Chromosomal Rearrangements

Sabine Mai¹

Yuval Garini²

¹Manitoba Institute of Cell Biology; University of Manitoba; CancerCare Manitoba; Winnipeg, Manitoba Canada

²Delft University of Technology; Faculty of Applied Sciences; Department of Imaging Science & Technology; Quantitative Imaging Group; Delft, The Netherlands

*Correspondence to: Sabine Mai; Manitoba Institute of Cell Biology; University of Manitoba; CancerCare Manitoba; 675 McDermot Avenue; Winnipeg, Manitoba R3E 0V9 Canada; Tel.: 204.787.2135; Fax: 204.787.2190; Email: smai@cc.umanitoba.ca

Received 08/01/05; Accepted 08/05/05

Previously published online as a Cell Cycle E-publication:

<http://www.landesbioscience.com/journals/cc/abstract.php?id=2082>

KEY WORDS

oncogene, c-myc, 3D nucleus, genomic instability, telomeres, chromosomes, breakage-bridge-fusion cycle, translocation

ACKNOWLEDGEMENTS

We thank Dr. Michael Mowat and Cheryl Taylor Kashton for critical reading. This study was funded by the Canadian Institutes of Health Research, CancerCare Manitoba, and the Canada Foundation for Innovation, the Physics for Technology program of the Foundation for Fundamental Research in Matter, the Delft Inter Faculty Research Center Life Tech, Cyttron, and the Delft Research program Life Science and Technology (Delft, The Netherlands).

ABSTRACT

The three-dimensional (3D) organization of the normal interphase nucleus permits the regulated completion of transcription and replication and assures proper chromosome organization. Aberrations from the normal 3D structural order of the nucleus are found in tumor cells. When examining the 3D organization of telomeres in nuclei of normal and tumor cells, we found that telomeres of normal nuclei do not overlap, while telomeres of tumor cells form aggregates of various numbers and sizes. To understand how such changes occur and what their implications are we have recently examined the role of the oncoprotein c-Myc in inducing changes in the 3D nuclear organization of telomeres. We found that c-Myc remodels the organization of telomeres and chromosomes in the interphase nucleus. It induces the formation of telomeric aggregates and fusions that are followed by breakage-bridge fusion cycles, and lead to the onset of chromosomal rearrangements that are typical of tumor cells.

The three-dimensional (3D) organization of the nucleus has long been studied. It has become evident that replication and transcription occur at specific nuclear compartments.¹⁻³ Furthermore, the majority of laboratories have described a probable and nonrandom organization of chromosomes into chromosome territories.⁴⁻⁹ Chromosomes have frequent neighbors, and the proximity to other chromosomes is tissue-specific.^{8,10}

Chromosome territories are maintained during evolution.¹¹ Data collected over the past decades indicate that gene-dense human chromosomes are found in the center of the nucleus, while gene-poor chromosomes are found towards the periphery of the nucleus.^{6,8,12-15}

Taking all the available information together, it thus becomes evident that nuclear organization is highly specific and has functional relevance to the cell assuring proper gene expression, replication and the stability of the genome.

An altered picture is found in the nuclei of tumor cells. For pathologists, the morphology and shape of tumor nuclei have long been crucial hallmarks for diagnostic evaluation compared to normal nuclei.¹⁶⁻¹⁸ Research laboratories have been trying to define what causes this difference and whether it can be used to understand mechanisms of the structural changes that are relevant to the oncogenic process and to design new diagnostic tools. In the end, the best scenario would be the identification of changes that are diagnostically relevant and to define how they occur so that one can design proper means to interfere with these changes therapeutically.

We have recently examined the 3D organization of telomeres in nuclei of normal, immortalized and tumor cells.¹⁹ This study allowed us to conclude that telomeres of nuclei from normal cells do not overlap. Moreover, telomeres are organized in a cell cycle-dependent manner.¹⁹ In G₀/G₁, they are widely distributed throughout the nucleus of primary mouse and human lymphocytes. In S phase, they occupy this same space. In the G₂ phase, however, telomeres change their nuclear positions and form a new structure that we termed the telomeric disk (TD). In a TD, telomeres align in the center of the interphase nucleus. This novel disk structure is different from the metaphase plate. When the TD forms in G₂, the nucleus is not yet in pro-metaphase, and chromosome condensation has yet to begin. We have therefore proposed that the TD may align chromosomes prior to mitosis and may constitute a new checkpoint.¹⁹

In contrast to this organization in normal cells, tumor cells have distorted TDs. Tumor cell nuclei show telomeric aggregates (TAs) of various sizes and numbers. Thus, the ordered and non-overlapping 3D nuclear space that telomeres normally occupy is compromised.




Figure 1. The 3D nuclear organization of telomeres in control (A) and c-Myc activated mouse Pre B lymphocytes (B–D). Telomeres are shown in green. Note the formation of telomeric aggregates as a result of c-Myc deregulation. Arrows point to aggregates. Images were acquired as described.²⁰




Figure 2. Examples of fused and dicentric chromosomes that form as a result of c-Myc deregulation. (A) Spectral karyotyping (SKY) analysis. c-Myc-dependent formation of a dicentric chromosomes (see arrows). Left panel: raw spectral image of a metaphase, middle panel: spectral image of the same metaphase, right panel: inverted DAPI image of the same metaphase, bottom panel: spectral karyotype of the above metaphase. (B) Additional examples of chromosomal fusions as determined by SKY.

This striking difference between normal and tumor cells prompted us to investigate I) whether the formation of telomeric aggregates was associated with events linked to cellular transformation, and II) whether TAs impacted on the chromosomal organization and genome stability in the 3D interphase nucleus.²⁰

We chose to study the role of *c-Myc* in TA formation since this oncoprotein is associated with at least 70% of human cancers (see ref. 21, and <http://www.myc-cancer-gene.org/index.asp>). The role of *c-Myc* in promoting genomic instability has been studied for the past decade, and it is now clear that *c-Myc* induces a very complex network of genomic instability (reviewed in refs. 22 and 23). For example, *c-Myc* promotes locus-specific gene amplification²⁴⁻²⁸ chromosomal rearrangements,^{25,29,30} illegitimate DNA replication,³¹ karyotypic instability,^{29,32} DNA breakage,³³ and alters DNA repair.^{34,35} Since *Myc* is a multi-functional protein, it also affects transcription (reviewed in refs. 36 and 37), promotes angiogenesis,^{38,39} apoptosis^{40,41} and alters the immune response of the host so that cells can escape immune surveillance.⁴²

While deciphering the puzzle of how *c-Myc* alters genome stability, we have recently shown that *c-Myc* deregulation can remodel the interphase nucleus by changing the organization of telomeres and chromosomes. These two downstream effects are directly causal to the formation of *c-Myc*-dependent chromosomal rearrangements.²⁰ The following findings led to these conclusions.

(1) In cell lines with conditional *c-Myc* expression, we showed that a single dose 4-hydroxy-tamoxifen (4HT)-activation of MycERTM was sufficient to generate telomeric aggregates in diploid mouse preB cells and in tetraploid Ba/F3 lymphocytes. Both cell types are immortalized but nontumorigenic. In addition, in the absence of *c-Myc* deregulation, telomeric aggregates in these cells are rare (up to 5% of TAs can be detected). Figure 1 shows an example of telomeric aggregate formation in PreB cells.

(2) Variation of MycERTM activation was also carried out; for example, MycERTM activation was performed for two hours, for 12 hours, every 12 hours, or for the duration of the biological effectiveness of 4HT. All activation schemes lead to the formation of TAs. The formation of TAs was directly proportional to the time of *Myc* deregulation. *c-Myc* deregulation induced cycles of TA formation. Fewer cycles (three) were observed after a 2 h pulse of *Myc* activation than after a 12 h pulse (five cycles).

(3) The formation of TA cycles was most consistent with breakage-bridge-fusion (BBF) cycles as first described by Mueller⁴³ and McClintock.⁴⁴ Chromosomes that fuse at their telomeric ends may form dicentric chromosomes that will break apart during anaphase. The result of this breakage is an unbalanced translocation. Moreover, the ends of the translocation partners are now 'open DNA ends' and represent a double strand break. They are free of telomeres and will




Figure 3. Overview of *c-Myc*-dependent remodeling of the interphase nucleus. The figure illustrates the formation of telomeric aggregates that represent in part telomeric fusions and move chromosomes into closer vicinity to each other. In anaphase, dicentric chromosomes break generating unbalanced translocations and two telomere-free chromosomal ends. The latter will fuse with new chromosome partners, thus initiating breakage-bridge-fusion (BBF) cycles. *c-Myc* deregulation induces multiple such BBF cycles.²⁰

fuse with other chromosomes propagating the BBF cycles. Thus, a single deregulation of *c-Myc* that is as short as 2 hours already leads to the remodeling of the interphase nucleus. Figure 2 shows examples of fused and dicentric chromosomes that were observed as a result of *c-Myc* deregulation.

(4) As telomeres aggregate, their chromosomes come into closer vicinity. This was measured for the following chromosome pairs: chromosomes 5 and 13, chromosomes 7 and 10, and chromosomes 7 and 17. This close proximity may favor chromosomal rearrangements as we had documented by spectral karyotyping. However, close proximity alone is not sufficient to cause chromosomal rearrangements as chromosomes 11 and 15 that were also found in close proximity and showed mixed color signatures in 3D imaging were only occasionally involved in rearrangements. Figure 3 summarizes the series of events that lead to chromosomal rearrangements.

The previous findings are based on quantitative analyses of the 3D measurements that we have performed. The amount of data and its complexity requires quantitative, standardized and convenient image processing analysis, and it is based on a program and algorithms that we have developed for this purpose. Two main algorithms were developed and used, one for measuring the level of telomeric aggregates and one for measuring chromosome overlap in the nucleus as a function of time.

Telomere measurements were done with TeloViewTM.^{19,45} By using an adequate threshold, the position of each telomere is found. We then calculate the center of gravity and the integrated intensity of each telomere.¹⁹ The integration region is determined by taking into account the limited optical resolution of the microscope and therefore selecting the correct 3D volume that is occupied by each telomere.

Measurements of chromosomal overlaps were performed after 3D image acquisition and constrained iterative deconvolution.²⁰ Chromosomes were stained by FISH using two different fluorochromes for each of the two chromosome pairs, e.g., 5 and 13. The nuclear volume was determined based on the DAPI counterstain image and measurements are performed only within its volume. We then determined intensity threshold, and calculated the total volume for each chromosome and for each chromosome type, V_1 and V_2 . Each of these values is the sum of volumes of the single chromosomes that belong to the same chromosome type. The total volume that is occupied by both chromosome pairs is then calculated, V_0 . The ratio of the overlap with respect to each chromosome type is finally found as V_0/V_1 and V_0/V_2 . These overlap-ratios however, seems to follow the same trend for each chromosome pair.²⁰

Implications. The above data demonstrate that the 3D nuclear organization is altered as a result of c-Myc deregulation. Since similar telomeric alterations were seen in premalignant and tumor cells, we propose that c-Myc deregulation initiates nuclear remodeling consistent with a tumor phenotype in which, as documented,²⁰ a novel genomic order is brought about through resulting chromosomal rearrangements. Currently, it is not known whether other oncogenes have similar effects on the nuclear organization. Data by others, however, propose nuclear alterations that are observed in association with the *Ras* oncogene.^{46,47}

We propose that the remodeling of the nucleus can be used as a sensitive diagnostic for nuclear aberrations that are associated with diseases like cancer. This approach does not require the presence of metaphases and relies on the 3D organization of the interphase nucleus for its analysis of tumor vs. normal cells. Moreover, nuclear remodeling of telomeres may not only play a role in cancer but also in the generation of mental retardation and malformations in which subtelomeric regions are involved.⁴⁸

References

- Zaidi SK, Young DW, Choi J-Y, Pratap J, Javed A, Montecino M, Stein JL, van Wijnen AJ, Lian JB, Stein GS. The dynamic organization of gene-regulatory machinery in nuclear microenvironments. *EMBO Rep* 2005; 6:128-33.
- Gilbert N, Gilchrist S, Bickmore WA. Chromatin organization in the mammalian nucleus. *Int Rev Cytol* 2005; 242:283-336.
- Kennedy BK, Barbie DA, Classon M, Dyson N, Harlow E. Nuclear organization of DNA replication in primary mammalian cells. *Genes Dev* 2000; 14:2855-68.
- Nagele R, Freeman T, McMorrow L, Lee HY. Precise spatial positioning of chromosomes during prometaphase: Evidence for chromosomal order. *Science* 1995; 270:1831-5.
- Cremer M, von Hase J, Volm T, Brero A, Kreth G, Walter J, Fischer C, Solovei I, Cremer C, Cremer T. Nonrandom radial higher-order chromatin arrangements in nuclei of diploid human cells. *Chromosome Res* 2001; 9:541-67.
- Cremer T, Cremer C. Chromosome territories, nuclear architecture and gene regulation in mammalian cells. *Nat Rev Genet* 2001; 4:292-301.
- Parada LA, McQueen PG, Munson PJ, Misteli T. Conservation of relative chromosome positioning in normal and cancer cells. *Curr Biol* 2002; 12:1692-7.
- Parada L, Misteli T. Chromosome positioning in the interphase nucleus. *Trends Cell Biol* 2002; 12:425-32.
- Bolzer A, Kreth G, Solvei I, Koehler D, Saracoglu K, Fauth C, Muller S, Eils R, Cremer C, Speicher MR, Cremer T. Three-dimensional maps of all chromosomes in human female fibroblast nuclei and prometaphase rosettes. *PLOS Biol* 2005; 3:e157.
- Parada LA, McQueen PG, Misteli T. Tissue-specific spatial organization of genomes. *Genome Biol* 2004; 5(7):R44, (Epub 2004 Jun 21).
- Tanabe H, Muller S, Neusser M, von Hase J, Calcagno E, Cremer M, Solovei I, Cremer C, Cremer T. Evolutionary conservation of chromosome territory arrangements in cell nuclei from higher primates. *Proc Natl Acad Sci USA* 2002; 99:4424-9.
- Cremer T, Cremer C, Baumann H, Luedtke EK, Sperling K, Teuber V, Zorn C. Rabl's model of the interphase chromosome arrangement tested in Chinese hamster cells by premature chromosome condensation and laser-UV-microbeam experiments. *Hum Genet* 1982; 60:46-56.
- Ferguson M, Ward DC. Cell cycle dependent chromosomal movement in premitotic human T-lymphocyte nuclei. *Chromosoma* 1992; 101:557-65.
- Croft JA, Bridger JM, Boyle S, Perry P, Teague P, Bickmore WA. Differences in the localization and morphology of chromosomes in the human nucleus. *J Cell Biol* 1999; 145:1119-31.
- Cremer M, Kupper K, Wagler B, Wizelman L, von Hase J, Weiland Y, Kreja L, Diebold J, Speicher MR, Cremer T. Inheritance of gene density-related higher order chromatin arrangements in normal and tumor cell nuclei. *J Cell Biol* 2003; 162:809-20.
- Khan MA, Walsh PC, Miller MC, Bales WD, Epstein JI, Mangold LA, Partin AW, Veltri RW. Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy. *Cancer* 2003; 98:2583-91.
- Kazanowska B, Jelen M, Reich A, Tarnawski W, Chybicka A. The role of nuclear morphometry in prediction of prognosis for rhabdomyosarcoma in children. *Histopathology* 2004; 45:352-9.
- Nafe R, Schlote W, Schneider B. Histomorphometry of tumour cell nuclei in astrocytomas using shape analysis, densitometry and topometric analysis. *Neuropathol Appl Neurobiol* 2005; 31:34-44.
- Chuang TCY, Moshir S, Garini Y, Chuang AYC, IT Young, van den Doel R, Mougey V, Perrin M, Braun M, Kerr DP, Fest T, Boukamp P, Mai S. The three-dimensional organization of telomeres in the nucleus of mammalian cells. *BMC Biology* 2004; 2:12.
- Louis SF, Vermolen BJ, Garini Y, Young IT, Guffei A, Zeldi Lichtensztejn Z, Fabien Kuttler F, Chuang TCY, Moshir S, Mougey V, Chuang, AYC, Kerr PD, Fest T, Boukamp P, Mai S. c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus. *Proc Natl Acad Sci USA* 2005; 102:9613-8.
- Nesbit CE, Tersak JM, Prochownik EV. Related articles, links abstract MYC oncogenes and human neoplastic disease. *Oncogene* 1999; 18:3004-16.
- Mai S, Mushinski JF. c-Myc-dependent genomic instability. *J Environ Path Toxicol Oncol* 2003; 22:179-99.
- Kuttler F, Mai S. c-Myc, genomic instability and disease. In: Volff J-N, ed. *Genome dynamics. Vol 1: Genome and Disease*. Wuerzburg, Germany: Karger Publishers, 2005:In press.
- Mai S. Overexpression of c-myc precedes the amplification of the gene encoding the dihydrofolate reductase. *Gene* 1994; 148:253-60.
- Mai S, Hanley-Hyde J, Fluri M. c-Myc overexpression associated *DHFR* gene amplification in hamster, rat, mouse and human cell lines. *Oncogene* 1996; 12:277-88.
- Mai S, Hanley-Hyde J, Rainey GJ, Kuschak TI, Paul JT, Littlewood TD, Mischak H, Stevens LM, Henderson DW, Mushinski JF. Chromosomal and extrachromosomal instability of the *cyclin D2* gene is induced by Myc overexpression. *Neoplasia* 1999; 1:241-52.
- Kuschak TI, Taylor C, McMillan-Ward E, Israels S, Henderson DW, Mushinski JF, Wright JA, Mai S. The *ribonucleotide reductase R2* gene is a nontranscribed target of c-Myc-induced genomic instability. *Gene* 1999; 238:351-65.
- Smith G, Dushnicki L, Smith S, Wright JA, Mai S. c-Myc-induced extrachromosomal elements carry active chromatin. *Neoplasia* 2003; 5:110-20.
- Mai S, Fluri M, Siwarski D, Huppi K. Genomic instability in MycER activated Rat1A-MycER cells. *Chromosome Res* 1996; 4:365-71.
- Rockwood LD, Torrey TA, Kim JS, Coleman AE, Kovalchuk AL, Xiang S, Ried T, Morse IIIrd HC, Janz S. Genomic instability in mouse Burkitt lymphoma is dominated by illegitimate genetic recombinations, not point mutations. *Oncogene* 2002; 21:7235-40.
- Kuschak TI, Taylor C, Wright JA, Wiener F, Mai S. c-Myc initiates illegitimate replication of the *ribonucleotide reductase R2* gene. *Oncogene* 2002; 21:909-20.
- Felsher DW, Bishop JM. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. *Proc Natl Acad Sci USA* 1999; 96:3940-4.
- Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM, Wahl GM. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: A mechanism for oncogene-induced genetic instability. *Mol Cell* 2002; 9:1031-44.
- Hironaka K, Factor VM, Calvisi DF, Conner EA, Thorgeirsson SS. Dysregulation of DNA repair pathways in a transforming growth factor alpha/c-myc transgenic mouse model of accelerated hepatocarcinogenesis. *Lab Invest* 2003; 83:643-54.
- Karlsson A, Deb-Basu D, Cherry A, Turner S, Ford J, Felsher DW. Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. *Proc Natl Acad Sci USA* 2003; 100:9974-9.
- Luscher B. Function and regulation of the transcription factors of the Myc/Max/Mad network. *Gene* 2001; 277:1-14.
- Oster SK, Ho CS, Soucie EL, Penn LZ. The myc oncogene: Marvelously Complex. *Adv Cancer Res* 2002; 84:81-154.
- Ngo CV, Gee M, Akhtar N, Yu D, Volpert O, Auerbach R, Thomas-Tikhonenko A. An in vivo function for the transforming Myc protein: Elicitation of the angiogenic phenotype. *Cell Growth Differ* 2000; 11:201-10.
- Baudino TA, McKay C, Pendeville-Samain H, Nilsson JA, Maclean KH, White EL, Davis AC, Ihle JN, Cleveland JL. c-Myc is essential for vacuologenesis and angiogenesis during development and tumor progression. *Genes Dev* 2002; 16:2530-43.
- Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. *Oncogene* 2003; 22:9007-21.
- Pelengaris S, Khan M, Evan G. c-MYC: More than just a matter of life and death. *Nat Rev Cancer* 2002; 2:764-76.
- Staeger MS, Lee SP, Frisan T, Mautner J, Scholz S, Pajic A, Rickinson AB, Musci MG, Polack A, Bornkamm GW. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells. *Proc Natl Acad Sci USA* 2002; 99:4550-5.
- Mueller HJ. The remaking of chromosomes. *Collecting Net* 1938; 13:181-98.
- McClintock B. The stability of broken ends of chromosomes in *Zea mays*. *Genetics* 1941; 26:234-82.

45. Vermolen BJ, Garini Y, Mai S, Mougey V, Fest T, Chuang TCY, Chuang AYC, Wark L, Young IT. Characterizing the three-dimensional organization of telomeres. *Cytometry* 2005; In press.
46. Laitinen J, Sistonen L, Alitalo K, Holtta E. c-Ha-rasVal 12 oncogene-transformed NIH-3T3 fibroblasts display more decondensed nucleosomal organization than normal fibroblasts. *J Cell Biol* 1990; 111:9-17.
47. Mello ML, de Campos Vidal B, Russo J. Ha-ras oncogene effect on DNA content and chromatin supraorganization in benzo[a]pyrene-transformed human breast epithelial cells. *Anal Cell Pathol* 1999; 19:73-9.
48. Helias-Rodzewicz Z, Bocian E, Stankiewicz P, Oberstyn E, Kostyk E, Jakubow-Durska K, Kutowska-Kazmierczak A, Mazurczak T. Subtelomeric rearrangements detected by FISH in three of 33 families with idiopathic mental retardation and minor physical anomalies. *J Med Genet* 2005; 39:e53.

Characterizing the Three-Dimensional Organization of Telomeres

B. J. Vermolen,^{1*} Y. Garini,¹ S. Mai,² V. Mougey,⁴ T. Fest,^{4,5} T. C.-Y. Chuang,^{2,3}
A. Y.-C. Chuang,² L. Wark,² and I. T. Young¹

¹Delft University of Technology, Faculty of Applied Sciences, Department of Imaging Science and Technology, Delft, The Netherlands

²Manitoba Institute of Cell Biology, CancerCare Manitoba, University of Manitoba, Winnipeg, Manitoba, Canada

³Department of Otolaryngology Head and Neck Surgery, Health Sciences Centre, Winnipeg, Manitoba, Canada

⁴IETG Institut, University Hospital Jean Minjoz, Besançon, France

⁵Hematology-Immunology department, UPRES 3889, IFR GFAS, University Hospital Pontchaillou, Rennes, France

Received 12 November 2004; Revision Received 18 March 2005; Accepted 23 March 2005

Background: Quantitative analysis can be used in combination with fluorescence microscopy. Although the human eye is able to obtain good qualitative results, when analyzing the spatial organization of telomeres in interphase nuclei, there is a need for quantitative results based on image analysis.

Methods: We developed a tool for analyzing three-dimensional images of telomeres stained by fluorescence in situ hybridization in interphase nuclei with DNA counterstained with 4',6-diamidino-2-phenylindole. After deconvolution of the image, we segmented individual telomeres. From the location of the telomeres we derived a distribution parameter ρ_T , which indicated whether the telomeres were in a disk ($\rho_T \gg 1$) or not ($\rho_T \approx 1$). We sorted mouse lymphocyte nuclei and measured ρ_T . We also performed a bromodeoxyuridine synchronous cell sorting experiment on live cells and measured ρ_T at several instances.

Results: Measuring ρ_T for nuclei in G0/G1, S, and G2 produced 1.4 ± 0.1 , 1.5 ± 0.2 , and 14 ± 2 , respectively, showing a significant difference between G2 and G0/G1 or S. For the bromodeoxyuridine synchronous cell sorting experiment, we found a cell cycle dependency of ρ_T and a correlation between ρ_T and an observer.

Conclusions: In this study we present a quantitative method to characterize the organization of telomeres using three-dimensional imaging, image processing, and image analysis. © 2005 International Society for Analytical Cytology

Key terms: telomeres; three-dimensional imaging; image processing; fluorescence microscopy; fluorescence in situ hybridization

Mack Fulwyler was a pioneer in the introduction of modern technology for the analysis of cells and cellular constituents. His work was essential in turning qualitative descriptions in biology into quantitative ones. Further, he understood how it was possible to use these quantitative descriptions to study the dynamics of cellular processes. His interests were not limited to the use of fluorescence in flow cytometry; he realized how fluorescence digital imaging microscopy could provide the tools to answer many questions that were not approachable through fluorescence-activated cell sorting. He also saw how the combination of the two, flow cytometry and image cytometry, could provide an even more powerful mechanism for studying what we have come to know as system biology.

With the advent of sequence-specific DNA probes, the use of fluorescence microscopy in cancer and genetics research has steadily grown. Continuous improvements in fluorescence microscopic methods (hardware and software), specific labeling methods (wetware), and better understanding of the genome function and structure (bioinformatics) currently enable us to detect almost any

DNA sequence, gene, or chromosome region with high sensitivity and to address the central question: "What does it mean?"

Because fluorescence methods in most cases are based on digital imaging, quantitative analysis can be used and has become a crucial part of the methodologies. These

Contract grant sponsor: Delft Research Initiatives Information and Communication Technology; Contract grant sponsor: LifeTech; Contract grant sponsor: Life Science & Technology; Contract grant sponsor: Nano-electrophoresis, FOM; Contract grant number: 99TF13; Contract grant sponsor: MicroNed and Cyttron, Bsik; Contract grant sponsor: Canada Foundation for Innovation; Contract grant sponsor: Canadian Institutes of Health Research; Contract grant sponsor: CancerCare Manitoba; Contract grant sponsor: Fondation de France; Contract grant sponsor: Ligue Contre le Cancer du Doubs.

*Correspondence to: B. J. Vermolen, Delft University of Technology, Faculty of Applied Sciences, Department of Imaging Science and Technology, Lorentzweg 1, 2628 CJ Delft, The Netherlands.
E-mail: b.j.vermolen@tnw.tudelft.nl

Published online 12 September 2005 in Wiley InterScience (www.interscience.wiley.com).

DOI: 10.1002/cyto.a.20159

Table 1
*Characteristics of Microscope System**

FWHM _{lateral}	200 nm
FWHM _{axial}	400 nm
Δx	106 nm
Δy	106 nm
Δz	200 nm
M	63 \times
NA	1.4
Filters	DAPI, Cy3
Typical image size	200 \times 200 \times 100 pixels

*FWHM, full width at half maximum; M, magnification; NA, numerical aperture.

methods, therefore, require suitable quantitative image analysis procedures and algorithms. As one of the last links in the chain, the algorithms being used must take into account the entire procedure that is being used, including the optical properties of the microscope and system, nature of the probes, and instrument parameters for the acquisition.

The organization of the interphase nucleus has been studied since the late 19th century (1). It is now well accepted that the position of chromosomes in the nucleus plays an important role in gene regulation (2). Recently, interest has also focused on telomeres whose importance to genomic stability was recognized as early as in the 1930s (3).

We have developed a method of studying the spatial organization of the genome in the three-dimensional (3D) interphase nucleus using flow sorted living cells. We analyze digital images of the 3D organization of the telomeres and how their positions change during the cell cycle. This method enables us to determine for the first time that telomere organization is cell cycle dependent with assembly of telomeres into a telomeric disk in G2 phase. Further, this disk formation is disrupted in tumor cells (4).

In this work we describe in more detail the algorithms that have been developed for the quantitative analysis of the telomeres in interphase nuclei. It can be extended to include centromeres and whole chromosomes.

MATERIALS AND METHODS

Cell Preparation

We studied two different cell nuclei populations based on mouse B lymphocytes. In the first case, immortalized mouse B lymphocyte cells were sorted according to their DNA content for the determination of G0/G1, S, or G2 phase. Cell cycle fractions were quantified through fluorescent-activated cell sorted analysis (4). Flow analyses were performed on an EPICS Altra cytometer operating under Multicycle software (Beckman-Coulter, Paris, France). Approximately 10 to 15 nuclei from each phase were analyzed for this study, representing a total of 35 cell nuclei.

To further study the phase transition timing along the cell cycle, we used the synchronous bromodeoxyuridine (BrdU) sorting method (4). The mouse B lymphocytes were labeled in vivo with BrdU. All BrdU-positive cells (i.e., cells in S phase, replicating their DNA) were live

sorted and placed into culture. Populations of nuclei were then harvested at different times (3, 3.5, 4.5, 5.5, 6.5, 7.5, 8, 8.5, and 9.5 h) of which approximately 20 nuclei were analyzed, representing a total of 180 cell nuclei.

For measurement of the telomeric disk, cells were first fixed and then telomere fluorescence in situ hybridization (FISH) was performed as describe previously (5) using a Cy3-labeled peptide nucleic acid (PNA) probe (DAKO, Glostrup, Denmark). 4',6-Diamidino-2-phenylindole (DAPI) was used as a DNA-specific counterstain. Telomere hybridizations were specific and we verified the correct number of telomeric signals observed at the ends of chromosomes prepared from primary cells using two-dimensional (2D) FISH metaphase spreads. The lymphocytes were fixed in such a way that the 3D structure of the nuclei was conserved (4).

3D Image Acquisition

For analysis of the telomere distribution, images were acquired with a Zeiss Axioplan 2 with a cooled AxioCam HR CCD in combination with a PlanApo 63 \times 1.4 oil immersion objective (Zeiss). This gave a pixel (sampling) distance in the lateral plane of $\Delta x = \Delta y = 106$ nm. The axial sampling distance between planes was $\Delta z = 200$ nm. The point spread function (*psf*) of the objective, which determines the optical resolution, gave a full width at half maximum of approximately 200 nm in the lateral direction and 400 nm in the axial direction. Typical image size was 200 \times 200 \times 100 pixels. Table 1 shows a summary of these values for this imaging system.

Figure 1 illustrates the system resolution. An image of a pair of telomeres relatively far apart and an image of a pair close together are shown. It is clear that the telomeres at a distance of 1200 nm can be easily distinguished and telomeres at a distance of 400 nm are just barely separable.




Fig. 1. Demonstration of the spatial resolution of our measurements. Two pairs of telomeres are shown: 1200 nm apart (top), which can be easily separated, and 400 nm apart (bottom). Inserts show the original image and graphs show the line section through the telomeres.




Fig. 2. Demonstration of the effect of deconvolution. The left image is before deconvolution and the right after deconvolution. We clearly see that the left image has more blur and has less contrast than the right image. Both images are shown with a linear contrast stretch.

3D Image Processing

The 3D digital images were processed to improve the resolution by using constrained iterative maximum likelihood deconvolution (6), which is available in AxioVision 3.1 (Zeiss) software. This deconvolution method was chosen for this work because it has been shown to provide the best results (7). In this procedure we seek to find the most likely original image that could have produced the observed data. This devolves into minimizing a measurement between the recorded image and a blurred estimate of the object assuming (a) a certain model for the image noise (Poisson) and (b) separate estimates for the background and the *psf*. Poisson noise is an excellent model for the random variations found in fluorescent images acquired through high-quality CCD cameras. Our estimate for the *psf* was based on a theoretical calculation (8). In this specific case we work with the log-likelihood function $\phi(\mathbf{f})$ which is given by:

$$\phi(\mathbf{f}) = \sum \mathbf{H}\mathbf{f} - \mathbf{g}^T \ln(\mathbf{H}\mathbf{f} + \mathbf{b}) + \gamma|\mathbf{f}|^2 \quad (1)$$

where \mathbf{g} is the digital fluorescence image that was recorded, \mathbf{b} is an estimate of the digital image background, \mathbf{H} is the *psf* of the imaging system, γ is a scalar “regularization” parameter that we are free to choose, and \mathbf{f} is the original image that we would like to estimate. Equation 1 is a concatenation of equations 4 and 5 in Vermeer et al. (7). The iterative algorithm seeks an image \mathbf{f} that minimizes $\phi(\mathbf{f})$ and thereby produces the most likely \mathbf{f} that could have given rise to the measured \mathbf{g} .

Further, the deconvolution works with the constraint that the final restored image should consist of only non-negative numbers because we cannot have a negative number of photons. An example of the result of applying this procedure to telomere images is shown in Figure 2. After restoration, the image is interpolated in the axial (z) direction from Δz to $\Delta z'$ so that the sampling distance in all three directions is the same: $\Delta z' = \Delta x = \Delta y = 106$ nm.

3D Image Segmentation and Analysis

Image segmentation and analysis of deconvolved 3D images of cells with labeled telomeres have been performed with a sequence of procedures that we have bundled together and named TeloView. The procedures themselves are from our image software library DIPIImage, which is available as public domain software (<http://www.qi.tnw.tudelft.nl/DIPIlib/>). The version of DIPIImage used in this development operates under MatLab (The MathWorks, Natick, MA, USA).

TeloView loads the 3D image and displays a maximum projection along the three main optical axes. Although thresholds and other parameters can be adjusted for display purposes, the analysis is performed on the original 3D data. After segmentation the 2D display indicates the location of the automatically found spots for verification. The user interface is shown in Figure 3.




Fig. 3. Screenshot of the interface of TeloView. The screen shows three displays with maximum intensity projections along the three main axes. It also shows crosses at the locations where the software identified a telomere.

Segmentation Algorithm




FIG. 4. Working of the algorithm. First we see the raw “image data.” A line through the center of this image gives a line section seen in “original data.” After we “smooth,” we perform a “TopHat” transform. Note that shading is now removed. We “threshold” and end up with two spots. One last “erosion” is performed to make sure that there are no remaining noise spikes.

Segmentation

Before starting the segmentation we pre-process the data by smoothing with a 3D Gaussian kernel. Figure 4 shows how the data are transformed during the different steps of segmentation. For segmentation of the individual telomeres we have chosen an algorithm based on a morphologic TopHat transformation (9,10). The TopHat transform on an image A with structuring element B is defined as follows (11).

To find objects with high intensity (“light” objects):

$$\text{TopHat}(A, B) = A - \max_B(\min(A)) \quad (2)$$

To find objects with low intensity (“dark” objects):

$$\text{TopHat}(A, B) = \min_B(\max(A)) - A \quad (3)$$

The “structuring element,” B , can be a quite general 3D gray-value object, but in our case we have chosen for the simple case that B is spherical. B should be larger than the objects that are being sought but smaller than any shading in the background. For a gray-scale image of telomeres, the telomeres would be our objects and any nonspecific binding of Cy3 uniform spread over the nucleus gives us shading. Thus, for our case, this translates to a spherical B with radius 742 nm (7 pixels).

After the TopHat transform, the resulting image is thresholded with a user-chosen value to produce a binary mask. To eliminate noise spikes that may remain, we conclude with an erosion. This algorithm gives satisfying results for small telomeres. Using the binary image mask from the segmentation, the center of gravity of each dot is

found. This gives coordinates (x_i, y_i, z_i) for each individual dot, where i is the index number of the dot.

Analysis

Observing the organization of telomeres in many cells, we see that the envelope shape of the telomeres is usually a spheroid, as illustrated in Figure 5. A spheroid is a geo-




FIG. 5. The telomeric territory can be given by a convex body containing all the telomeres. In most cases this envelope can be approximated by a geometric figure called a spheroid.

Oblate Spheroid




FIG. 6. The telomeric territory is characterized as an oblate spheroid, where two of the main axes, a and b , are of equal length and the third main axis, c , is shorter. The ratio $\rho_T = a/c$ now gives a measure of the flatness of the spheroid.

metric figure, like an ellipsoid, where the two main axes, a and b , are equal, and the third axis c has a different length, c . This is shown in Figure 6. If $a = c$, we have a sphere; if $a < c$, we have a prolate spheroid; and if $a > c$, we have an oblate spheroid. We can therefore define a telomere ratio parameter, ρ_T , which gives us a measurement of the disk-like nature of this organization. If $\rho_T \approx 1$, then the telomeres are distributed in a spherical way within the cell. However, if $\rho_T > 1$, then the telomeric territory is more disk-like. In the following, we describe how we determine ρ_T .

Given the spatial coordinates of every spot ($x_i, y_i, z_i \mid i = 1, 2, \dots, N$), we rotate the original spatial coordinates (x, y, z) to a new orthogonal coordinate system such that the distance from the spots to the new axes is minimized. This procedure is known as a principal component analysis (12). To accomplish this, we calculate the singular values (eigenvalues) of the covariance matrix of the data points. The three singular values, $\lambda_1 \geq \lambda_2 \geq \lambda_3$, are real and positive and can be ordered. They are the variances of the distances from the spots to the new principal axes. The standard deviation for each new axis is then given by:

$$\sigma_i = \sqrt{\lambda_i} \quad (4)$$

From these standard deviations, we then define ρ_T as:

$$\rho_T = \frac{\sqrt{\sigma_1 \sigma_2}}{\sigma_3} \quad (5)$$

Given that we work with ordered λ s, we have:

$$\rho_T \geq 1 \quad (6)$$

RESULTS

Results of the analysis of the cell-sorted mouse lymphocytes are presented in Table 2. Here we see small values (close to 1) of ρ_T for nuclei in G0/G1 and S phases, which indicate that telomeres are distributed throughout the

Table 2
Results of Phase-Sorted Cells

Phase	ρ_T
G0/G1	1.4 ± 0.1
S	1.5 ± 0.2
G2	14 ± 2

cell. For the telomeres in G2, however, there is a high value of ρ_T , indicating that the telomeres form a disk. A statistical analysis, using a two-sample Student's t test with unequal variances, indicates a significant difference in ρ_T between G0/G1 and G2 phases ($P < 0.01$) and between S and G2 phases ($P < 0.01$). An example of typical distributions of telomeres in lymphocytes is shown in Figure 7.

The results of the BrdU synchronization experiment can be seen in Figure 8. In the left graph we see the results of nuclei counted by a human observer. The observer was presented with a 2D computer display of the 3D distribution. A display of the DAPI counterstain indicated the position of the total DNA.

The nuclei are divided into three groups: (a) nuclei with telomeres in a disk, (b) nuclei in mitosis, and (c) other nuclei (interphase nuclei without a telomeric disk). At 3.5 h, 90% of nuclei show a telomeric disk. Based on timing since S phase, most nuclei are believed to be in late G2. After this point, cells continue through the cell cycle, enter into prometaphase and metaphase (i.e., mitosis), and the number of cells in G2, accordingly, decreases. This correlates with the observation that the fraction of cells with a telomeric disk decreases and the number of cells going into mitosis increases.

In the right graph of Figure 8 we show the result of ρ_T calculations on the same population of nuclei. We also





FIG. 7. Three typical distributions of telomeres. A nucleus is seen in G0/G1 phase (top), S phase (middle), and G2 phase (bottom). Every nucleus is shown in top view (xy plane), in side view (xz plane), and as a 3D visualization. We clearly see that the telomeres in G0/G1 and S phases are distributed throughout the nucleus, whereas those in G2 phase line up into a disk.

FIG. 8. Results of synchronous BrdU sorting experiment. In the left graph we show the results obtained by a human observer. For each time point approximately 20 nuclei were analyzed and sorted into 3 categories: nuclei with a telomeric disk (black line with circles), nuclei in mitosis (dashed line with squares), and nuclei in interphase without a telomeric disk (dotted line with triangles). In the right graph we show a box plot of ρ_T calculations on the same population. Asterisks indicate the mean ρ_T at every time point and boxes and whiskers represent the 0th, 25th, 50th, 75th, and 100th percentiles of the measurement. Plus signs denote outliers.



observe that the *spread* of ρ_T increases and reaches a maximum at 7.5 h. This coincides with the left graph, where we see an increase in the number of cells without a telomeric disk relative to the number with a telomeric disk. The right graph, however, does not correspond exactly to the left graph calculated by the observer because it calculates the average ρ_T value of the complete population of nuclei at that time point; the nuclei can be in different cell phases. By using a threshold on the ρ_T value, it is possible to imitate the classification of nuclei in a disk. If we choose a threshold of 6.7 between nuclei in a disk ($\rho_T > 6.7$) and others, we can calculate the fraction of these nuclei and get approximately the same curve as the human observer got. Apparently this is the subjective threshold that was selected when the left graph of Figure 8 was created.

In Figure 8 we notice that the fraction of cells in mitosis at 7.5 h is twice as high as those with a disk. In Figure 9 we see the histogram of the data at 7.5 h, which suggests two populations with twice the amount of low ρ_T cells compared with high ρ_T cells. In the box plot in Figure 8, we also see outliers that are easily explained if the data within the box and whiskers are from the population with low ρ_T and the outliers are from the population with high ρ_T . The outliers in Figure 8 at $t = 8.5$ h, for example, are due to the last few cells from the G2 population that have not yet entered mitosis.

DISCUSSION

For the first time we show that the telomere organization in the nucleus can be characterized and is cell cycle dependent. It is very important to recognize the need for 3D image processing for quantification where objective measurements are preferable above the subjective view of an individual. We have developed an objective means to quantify and analyze the spatial arrangement of telomeres, a task that is, essentially, too difficult for ordinary human vision that can only do qualitative estimates. This is done by calculating a parameter, ρ_T , whose value measures the disk-like compactness of the telomere distribution. We show that ρ_T is significantly higher in cells in G2 than in G0/G1 or S, which suggests that the telomeres form a disk during G2. This is also observed in a synchronous BrdU sorted population, where high ρ_T values are observed after

3.5 h and where the disk phenomenon decreases as cells leave G2. Although a human observer can only threshold the data into fractions called “disk” or “no disk” with a subjective threshold, our method allows this threshold, but we can distill more information out of the data like the distribution of the ρ_T values. It may be valuable in the future to combine these data with the DAPI intensity distribution that may allow distinguishing nuclei in mitosis (based on intensity uniformity) from the other cell cycle phases.

These findings shed new light on the cell cycle mechanism. It remains to be determined whether the telomeric disk is a precursor structure that will later position the chromosomes into the equatorial disk.

Nevertheless, we have already observed that, in cancer cells, the telomeres tend to form aggregates (4), which is another indication to the large role that the organization of the genome in the nucleus has in cancer development.

We are developing methods to quantify the size of a telomere or telomere aggregates, where telomeres are found in close association, as previously shown (4). It is therefore important to quantify such aggregates and test their correlation with cancer progress. Aggregates are usually significantly larger than individual telomeres. As a result, our current algorithm tends to miss these spots because




FIG. 9. Histogram of measured ρ_T at 7.5 h after BrdU pulse labeling. The histogram suggests two populations: one with low ρ_T and one with high ρ_T .

the TopHat transform is sensitive to the size of the telomeres. Therefore, we are currently working on an improved segmentation procedure based on a scale-space algorithm (13) that looks most promising. Another suggested path of research is to follow telomeres through the entire cell cycle in living cells.

ACKNOWLEDGMENTS

T. C.-Y. Chuang and A. Y.-C. Chuang were supported through a Canadian Institutes of Health Research Strategic Training Program, "Innovative Technologies in Multidisciplinary Health Research Training" fellowship. V. Mougey and T. Fest were supported by Fondation de France and Ligue Contre le Cancer du Doubs.

LITERATURE CITED

1. Rabl C. Über Zellteilung. In: Gegenbauer C, editor. *Morphologisches Jahrbuch*. Volume 10. 1885. p 214-330.
2. Marshall WF. Order and disorder in the nucleus. *Curr Biol* 200;12: R185-R192, Wilhelm Engelmann, Leipzig.
3. McClintock B. The stability of broken ends of chromosomes in *Zea mays*. *Genetics* 1941;26:234-282.
4. Chuang TCY, Moshir S, Garini Y, Chuang AY-C, Young IT, Vermolen B, Doel Rvd, Mougey V, Perrin M, Braun M, et al. The three-dimensional organization of telomeres in the nucleus of mammalian cells. *BMC Biol* 2004;2(12).
5. Figueroa R, Lindenmaier H, Hergenbahn M, Nielsen KV, Boukamp P. Telomeres erosion varies during in vitro aging of normal human fibroblasts from young and adult donors. *Cancer Res* 2000;60:2770-2774.
6. Schaefer LH, Schuster D, Herz H. Generalized approach for accelerated maximum likelihood based image restoration applied to three-dimensional fluorescence microscopy. *J Microsc* 2001;204:99-107.
7. Verveer PJ, Gemkow MJ, Jovin TM. A comparison of image restoration approaches applied to three-dimensional confocal and wide-field fluorescence microscopy. *J Microsc* 1999;193:50-61.
8. Gibson SF, Lanni F. Experimental test of an analytical model of aberration in an oil-immersion objective lens used in three dimensional light microscopy. *J Opt Soc Am* 1991;8:1601-1613.
9. Meyer F, Beucher S. Morphological segmentation. *J Vis Commun Image Represent* 1990;1:21-46.
10. Meyer F. Iterative image transformations for an automatic screening of cervical smears. *J Histochem Cytochem* 1979;27:128-135.
11. Young IT, Gerbrands JJ, van Vliet LJ. *Fundamentals of Image Processing*. In: Madisetti VK, Williams DB, editors. *The digital signal processing handbook*. Boca Raton: CRC Press/IEEE Press; 1998. p 51.1-51.81.
12. Wall ME, Rechtsteiner A, Rocha LM. Singular value decomposition and principal component analysis. In: Berrar DP, Dubitzky W, Granzow M, editors. *A practical approach to microarray data analysis*. Norwell: Kluwer; 2003. p 91-109.
13. Olivo-Marin J-C. Extraction of spots in biological images using multiscale products. *Pattern Recogn* 2002;35:1989-1996.

c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus

Sherif F. Louis^{*†}, Bart J. Vermolen^{†‡}, Yuval Garini^{†‡}, Ian T. Young[†], Amanda Guffei^{*}, Zeldia Lichtensztein^{*}, Fabien Kuttler^{*}, Tony C. Y. Chuang^{*§¶}, Sharareh Moshir^{*||}, Virginie Mougey^{**}, Alice Y. C. Chuang^{*}, Paul Donald Kerr[§], Thierry Fest^{**††}, Petra Boukamp^{||}, and Sabine Mai^{**‡‡}

^{*}Manitoba Institute of Cell Biology, University of Manitoba, 675 McDermot Avenue, Winnipeg, MB, Canada R3E 0V9; [†]Department of Imaging Science and Technology, Faculty of Applied Sciences, Quantitative Imaging Group, Delft University of Technology, 2628 CJ Delft, The Netherlands; [§]Department of Otolaryngology Head and Neck Surgery, Health Sciences Centre, GB421-820 Sherbrook Street, Winnipeg, MB, Canada R3A 1R9; ^{||}Division of Genetics of Skin Carcinogenesis, German Cancer Research Centre, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany; ^{**}Hematology Department, IETG Laboratory, University Hospital Jean Minjoz, 25030 Besançon, France; and ^{††}Hematology Department, EA 3889, IFR140 GFAS, University Hospital Pontchaillou, 35033 Rennes, France

Edited by George Klein, Karolinska Institutet, Stockholm, Sweden, and approved May 9, 2005 (received for review October 11, 2004)

In previous work, we showed that telomeres of normal cells are organized within the 3D space of the interphase nucleus in a nonoverlapping and cell cycle-dependent manner. This order is distorted in tumor cell nuclei where telomeres are found in close association forming aggregates of various numbers and sizes. Here we show that c-Myc overexpression induces telomeric aggregations in the interphase nucleus. Directly proportional to the duration of c-Myc deregulation, we observe three or five cycles of telomeric aggregate formation in interphase nuclei. These cycles reflect the onset and propagation of breakage-bridge-fusion cycles that are initiated by end-to-end telomeric fusions of chromosomes. Subsequent to initial chromosomal breakages, new fusions follow and the breakage-bridge-fusion cycles continue. During this time, nonreciprocal translocations are generated. c-Myc-dependent remodeling of the organization of telomeres thus precedes the onset of genomic instability and subsequently leads to chromosomal rearrangements. Our findings reveal that c-Myc possesses the ability to structurally modify chromosomes through telomeric fusions, thereby reorganizing the genetic information.

genomic instability | 3D nucleus | breakage-bridge-fusion

Multiple alterations accompany tumor initiation and progression resulting in the modulation of gene expression and in genomic instability. These interconnected changes occur within nuclei that harbor an altered 3D organization (1–3). In agreement with this concept, recent reports suggest tumor-associated changes of chromosomal organization in an altered 3D nucleus (3–8). However, mechanisms leading to structural changes of telomeres and chromosomes remain elusive.

We recently reported that the normal interphase nucleus has a unique 3D telomeric organization that is cell cycle dependent (9, 10). Telomeres are organized in a nonoverlapping manner and align into a central telomeric disk during the late G₂ phase of the cell cycle (9). In contrast, tumor cells display an aberrant organization of telomeres that can be objectively measured in nuclei showing telomeric aggregates of various complexity and sizes (9).

Constitutive expression of c-Myc due to chromosomal translocations, mutation, or amplification contributes to the development and progression of many cancers (11, 12). c-Myc deregulation directly promotes genomic instability (13), causing locus-specific and karyotypic instability (14–18). Additionally, c-Myc induces illegitimate replication initiation (19, 20), DNA breakage (21), alterations of DNA repair (22, 23), and a low level of point mutations (24, 25). Effects of c-Myc on genomic instability are reversible after a transient experimental activation of c-Myc (15). However, c-Myc continues to generate instability after constitutive deregulation (16). *In vivo*, c-Myc deregulation directly initiates and

promotes tumorigenesis (26–30). When c-Myc deregulation is abolished, *in vivo* tumorigenesis is reversible, provided that no additional mutations had occurred (29–34).

Prompted by the complexity of downstream genetic alterations that result from c-Myc deregulation, we investigated whether c-Myc affected the 3D organization of the mammalian interphase nucleus and whether this remodeling had an impact on genomic stability. We show that c-Myc deregulation causes remodeling of the 3D nuclear organization of telomeres and chromosomes, thus creating the topological conditions that initiate genomic instability.

Materials and Methods

Cells and Conditional Myc Activation. Culture conditions have been described for Ba/F3 (35) and PreB (36) cells. The plasmacytoma cell line MOPC460D was a gift of J. Mushinski (National Institutes of Health, Bethesda). Cell viability was determined by hemocytometer counts by using trypan blue. The primary mouse plasmacytoma DCPC21 was isolated from a BALB/c mouse (37). *v-abl/myc*-induced plasmacytomas (38) and primary lymphocytes were collected from BALB/c mice (Central Animal Care protocol 02-039).

To activate MycER (39) in Ba/F3 or PreB cells, 10⁵ cells per ml were treated with 100 nM 4-hydroxytamoxifen (4HT). Cells were split 24 h before 4HT treatment. Non-4HT treated control cells were cultivated in ethanol, which is used to dissolve 4HT (25, 26, 39). Two different MycER activation schemes were performed. First, analyses of c-Myc-induced changes in 3D telomere organization were carried out after a single addition of 4HT that was left in the culture medium until its biological effects subsided (40–42). Nuclei were examined every 24 h over a 10-day period. A second time course was performed every 6 h for 120 h (Fig. 1). To enable a time-dependent analysis of Myc activation, 4HT was given for 2 or 12 h and was removed. Alternatively, 4HT was added every 12 h or was given once but left in the culture. MycER activation was determined by fluorescent immunohistochemistry.

Immunohistochemistry (IHC). Fluorescent IHC of Myc protein was performed as described in ref. 43 by using a polyclonal anti-c-Myc antibody (N262; Santa Cruz Biotechnology) and a goat anti-rabbit IgG FITC antibody, each at a dilution of 1:100. Analysis was

This paper was submitted directly (Track II) to the PNAS office.

Abbreviations: 4HT, 4-hydroxytamoxifen; SKY, spectral karyotyping; TA, telomeric aggregate.

[†]S.F.L., B.J.V., and Y.G. contributed equally to this work.

[¶]Present address: Department of Otolaryngology Head and Neck Surgery, Head and Neck Division, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.

^{‡‡}To whom correspondence should be addressed. E-mail: smai@cc.umanitoba.ca.

© 2005 by The National Academy of Sciences of the USA




Fig. 3. c-Myc deregulation induces TAs in interphase nuclei of PreB and Ba/F3 cells shown at 72 h after 4HT-treatment. (a) Mock-treated PreB cells show nonoverlapping telomeres (red). (b) MycER-activated PreB cells with TAs (green arrow). (c) Mock-treated Ba/F3 cells show nonoverlapping telomeres. (d) MycER-activated Ba/F3 cells show the formation of TAs (green arrow).

tions as determined by 3D imaging (Fig. 2*a*). Without MycER activation, both PreB and Ba/F3 interphase nuclei also displayed nonoverlapping telomere positions (Fig. 2*b* and *c*, respectively). Therefore, the above cell lines were appropriate to study the effects of conditional c-Myc activation on the 3D telomeric organization.

c-Myc-Dependent Disruption of the 3D Telomeric Organization: Formation of Telomeric Aggregates (TAs) in Interphase Nuclei. We next analyzed the effect of conditional c-Myc expression on the 3D organization of telomeres. After a transient MycER activation with 4HT, nuclear c-Myc signals were observed in both PreB and Ba/F3 cells (Fig. 9*b* and *d*). In non-4HT treated control cells, MycER was found in the cytoplasm (Fig. 9*a* and *c*; see also ref. 39).

To determine whether c-Myc deregulation affected the 3D organization of telomeres, we performed time course experiments. In the first set of experiments, c-Myc deregulation and 3D telomeric organization were investigated in both PreB and Ba/F3 cells after a single 4HT treatment. Nuclei were analyzed after c-Myc deregulation at 0, 24, 48, 72, and 96 h and at 10 days and compared with nuclei from mock-treated control cells. In both cell lines, analyses of the 3D nuclear organization of telomeres revealed that c-Myc deregulation induced the formation of TAs. TAs are group(s) of telomeres that are found in clusters and, thus, in close association in the interphase nucleus. This 3D telomeric organization is distinct from the normal 3D organization of non-MycER-activated PreB, Ba/F3 cells and primary mouse lymphocytes (Fig. 2). Fig. 3 illustrates the presence of TAs in interphase nuclei of MycER-activated PreB and Ba/F3 cells (Fig. 3*b* and *d*, respectively). Although such TAs had been observed in tumor cell nuclei previously (9), their presence in conditional c-Myc expressing cells is a previously uncharacterized finding.

c-Myc Induces Cycles of TAs in Interphase Nuclei. In subsequent experiments, we investigated the time relationship between c-Myc deregulation and the formation of TAs more closely. To this end, cells were harvested every 6 h over a time period of 120 h. We also varied the duration of conditional c-Myc expression (Fig. 1), confirming nuclear c-Myc staining as above (Fig. 9 and 11). Next, the 3D organization of telomeres was determined (Fig. 4). At this point, we focused on near diploid PreB cells only (49). Our positive controls were cells constitutively overexpressing c-Myc [mouse plasmacytomas (27) and a plasmacytoma line (Fig. 4*Ae*)]. Negative controls were mock-treated PreB cells (Fig. 4*Aa*).

This time course confirmed that c-Myc deregulation induced TAs. Representative images show that TAs varied in size and numbers per MycER-activated PreB cell nucleus (Fig. 4*A b–d*, red arrows). High induction levels of TAs were observed at 30, 48, 72, and 96 h declining after 96 h (Fig. 4*B*, arrows). The highest levels




Fig. 4. c-Myc-induced telomeric aggregates appear in cycles. (A) Conditional c-Myc deregulation causes TA formation. (A*a*) Negative control: non-Myc-deregulated PreB nucleus with nonoverlapping 3D telomeric nuclear positions. (A*b–d*) TAs of various sizes and numbers are present after conditional c-Myc expression at any given time point of TA formation. Telomeres are shown in green; TAs by red arrows. (A*e*) Positive control: plasmacytoma cell line, MOPC460D, with constitutive c-Myc deregulation due to T12;15, shows TAs. Similar results were obtained with primary plasmacytoma cells (data not shown). (B) c-Myc induces cycles of TAs. Fold increase in TAs over control levels during a period of 120 h. During this period, c-Myc had been up-regulated for different lengths of time (see Fig. 1). Black, 4HT given for 2 h and removed; red, 4HT administered for 12 h and removed; green, 4HT added once and not removed; blue, 4HT added at 0, 12, and 24 h; gray, control cells. The highest levels of TA formation and a single TA peak observed after consecutive activations of MycER are shown by arrows and an arrowhead, respectively. Error bars represent a 95% confidence interval of binomial distributions.

of TA formation will hereafter be referred to as peaks of TAs. The 6-h time course performed over 120 h indicated that TAs formed in a c-Myc-dependent manner and showed a cyclic appearance (Fig. 4*B*). The number of TA cycles was directly linked to the duration of c-Myc deregulation. For example, 2 h of Myc activation induced three such cycles, whereas 12 h led to five cycles (Fig. 4*B*, black and red lines, respectively). 4HT, left in the culture medium until its biological effects on our cells subsided (Fig. 1), also induced five TA cycles (Fig. 4*B*, green line). In this context, repeated consecutive activations of MycER given every 12 h caused TAs in 96% of all nuclei. These cells died after 30 h (Fig. 4*B*, blue line) because of repeated cycles of c-Myc deregulation and not due to toxicity exerted by 4HT (50). Thus, only a single TA cycle is observed in this experimental setting (Fig. 4*B*, arrowhead). The increase in TAs and 3D volumes was significant (Table 3).

The c-Myc-Induced TA Cycles Represent Breakage-Bridge-Fusion (BBF) Cycles and Chromosomal Rearrangements. The cycles of c-Myc induced TAs in PreB nuclei showed similar periodicity for all c-Myc activation periods (Fig. 4*B*). We reasoned that these cycles might reflect both ongoing associations and dissociations of telomeres or BBF cycles. The BBF cycle could be induced by the breakage of dicentric chromosomes during anaphase-inducing apoptosis of cells




Fig. 5. Molecular cytogenetic evidence of BBF cycles in MycER-activated PreB cells. (a) SKY analysis reveals telomeric fusions and chromosome breakage. (a Upper) Metaphase, raw image (Left); metaphase, classified image (Center); and metaphase, inverted DAPI image (Right). (a Lower) Spectral karyotype. End-to-end fusion of chromosomes 18 and 4 (red arrow) and fusion of chromosome 1 with a broken piece of chromosome 1 (green arrow) are shown. One broken chromosome 1 is circled. Note additional broken chromosomes 1, 2, 3, and 7. (b) End-to-end fusions of chromosomes revealed by telomere FISH. (Upper) Centromeric fusion (see arrow and insert). (Lower) Telomeric fusion (see arrow and insert). (c) Anaphase bridges. (Upper) Short exposure of DAPI stained nucleus (100 msec). (Lower) Longer exposure (500 msec) of same image makes anaphase bridge visible (white arrow) but overexposes nuclei. (d) SKY illustrating chromosomal fusions (red arrow) and nonreciprocal translocations (white arrows). Broken chromosomes are also present (chromosomes 4, 6, 12, and 17).

having multiple or large TAs per nucleus. To address these possibilities, we first examined metaphase chromosomes at different times: prior, during, and after the peaks of TA formation for a 120-h period. We used both whole-genome analysis by mouse SKY and telomeric FISH of metaphase chromosomes. A significant level of dicentric chromosomes was noted (Fig. 5). Control cells had normal karyotypes (Fig. 12). In MycER-activated PreB cells, however, fusions had occurred. We show as example fusions at the telomeric ends of chromosomes 18 and 4 (Fig. 5a), red and green arrows) and between two chromosomes 1 (Fig. 5a, green arrow). Chromosome 1 was probably broken in the previous anaphase (Fig. 5a, green circle). An additional terminally deleted chromosome 1 is in the center of the same metaphase plate, and chromosomes 2, 3, and 7 reveal terminal deletions (Fig. 5a). Telomeric fusions involving both ends of chromosomes as well as sister chromatids were confirmed

Table 1. Apoptosis levels in non-MycER and MycER-activated PreB cells

Time, h	% apoptosis		Fold increase
	Controls	MycER-activated PreB cells	
0	3.0	3.0	1.0
12	2.0	4.0	2.0
24	6.0	12.0	2.0
30	4.0	10.0	2.5
42	2.0	8.0	4.0
48	5.0	10.0	2.0
66	4.0	11.0	2.75
72	3.0	8.0	2.7
84	3.0	5.0	1.7
96	3.0	3.0	1.0
102	2.0	3.0	1.5

by telomeric FISH (Fig. 5b). Anaphase bridges and ring chromosomes were present (Fig. 5c) and data not shown).

The nature of c-Myc-induced 3D structural changes in interphase nuclei of conditionally Myc expressing cells was as follows: at peaks of TA formation and thereafter, a significant increase in end-to-end chromosomal fusions over control levels was observed. This result was followed by a significant increase in broken chromosomes and nonreciprocal translocations (Figs. 5d and 6 and Table 2). In conclusion, TA cycles unveil BBF cycles, namely the fusions of two chromosomes, consequently, the formation of dicentrics and their subsequent breakage in anaphase (Fig. 5). The cycles are induced by conditional Myc deregulation and lead to the onset of genomic instability, demonstrated by the chromosomal rearrangements resulting from these BBF cycles (Figs. 5 and 6 and Table 2).

Next, we investigated whether cells with TAs died during the course of the experiments. If this possibility was the case, we would expect a correlation of cell death in Myc-activated cells at the peak of TA formation or shortly thereafter. The level of apoptosis was ≈ 2 -fold higher in Myc-activated cells than in control cells (Table 1). There was no preference in apoptotic cell death for any specific time point during the 120 h. We concluded that BBF cycles, not apoptosis, contributed to the cycles of TA formation.

3D Organization of Chromosomes in c-Myc Activated Interphase Nuclei. TAs and the initiation of BBF cycles with subsequent chromosomal rearrangements prompted us to investigate whether chromosomes were affected in their 3D nuclear positions during MycER activation. To this end, we examined the overlap of specific chromosomes over the 120-h period. SKY of MycER-activated PreB cells suggested chromosomal rearrangements involving chromosomes 7, 13, and 17. Additional rearrangements were found but




Fig. 6. Chromosomal aberrations in MycER-activated PreB cells over a period of 120 h after a single administration of 4HT. End-to-end fusions (blue) increase to 40% in the first 12 h. Over time, the percentage of fusions decreases. Translocations (orange) appear at 12 h and reach a maximum of 35% at 42 h. Telomere-free chromosomal end(s) (green) increase over time peaking at 30 h with 75% of metaphases having at least one telomere-free chromosomal end. Subsequently, the percentage of telomere-free chromosomal end(s) decreases. Q-FISH experiments confirmed healing of telomeric ends at later time points. The error bars show the 95% confidence interval for binomial distributions (51). Because of a confidence interval, the error bars are larger than expected when a standard error would have been used, which was not applicable in this situation. For details on each time point and aberration, see Table 2.

Our study showed that c-Myc is one key factor that initiates genomic instability through BBF cycles. Such BBF cycles in telomerase-positive immortalized mouse PreB cells (unpublished data) with long telomeres are distinct from BBF cycles reported for critically short telomeres (61, 64). Some TAs (but not necessarily all) represent fusions, as evident by the analysis of metaphase chromosomes. TAs and end-to-end fusions depended on time and levels of c-Myc activation. Analysis of frequencies of both events showed that they are closely linked. As the fusions initiate BBF cycles, the frequencies of breakage and nonreciprocal translocations increase over time.

A previously uncharacterized pathway of c-Myc-dependent genomic instability thus starts at the telomeric ends of the chromosomes. Both TAs and BBF cycles are the manifestation of deregulated Myc expression, leading to chromosomal rearrangements and subsequently to genomic instability.

Local chromosome movement increases chromosomal overlap in the nucleus. This temporal change in local positioning may permit the direct contact of chromosomal ends and facilitate recombinations and/or fusions. Such movements were observed after c-Myc deregulation and suggested an impact of the oncoprotein on local nuclear positioning of chromosomes. Chromosome movements were previously studied and found by others as well (65–69).

Several regulatory pathways involving oncogene deregulation may affect the 3D nuclear organization. Oncoproteins, including

c-Myc, can alter the 3D nuclear organization and the organization of chromatin (70–72). They also affect the nuclear matrix. High mobility group protein I(Y) (HMG1(Y)) is a c-Myc-dependent nuclear matrix protein (73) with increased expression during neoplasia (2). The analysis of myc-binding sites in the human genome suggests that c-Myc binds to genes encoding nucleoskeletal components (74). Furthermore, constitutive c-Myc expression was shown to be associated with down-regulation of the telomere repeat binding protein TRF2 (10), a protein required for telomere capping and genome stability (75). Myc is also involved in the regulation of DNA repair (22, 23) and has been shown to induce DNA breakage (21). Thus taken together, many different c-Myc-dependent mechanisms could potentially affect the nuclear organization and, as shown here, converge at the telomeres.

We thank Dr. Michael Mowat for critical reading of this manuscript, Mary Cheang for statistical analyses, and Cheryl Taylor-Kashton and Landon Wark for deconvolution. The work was supported by the Canada Foundation for Innovation, the Canadian Institutes of Health Research, CancerCare Manitoba (S.M.), Fondation de France (Paris) and French Minister of Foreign Affairs (T.F.), Sander-Stiftung, and Deutsche Krebshilfe (P.B.), the Physics for Technology program of the Foundation for Fundamental Research in Matter, the Delft Inter-Faculty Research Center Life Tech, Cyttron, and the Delft Research program Life Science and Technology (Delft, The Netherlands).

- Pienta, K. J., Partin, A. W. & Coffey, D. S. (1989) *Cancer Res.* **49**, 2525–2532.
- Leman, E. S., Madigan, M. C., Brunagel, G., Takaha, N., Coffey, D. S. & Getzenberg, R. H. (2003) *J. Cell Biochem.* **88**, 599–608.
- Zink, D., Fischer, A. H. & Nickerson, J. A. (2004) *Nat. Rev. Cancer* **4**, 677–687.
- Parada, L. A., McQueen, P. G., Munson, P. J. & Misteli, T. (2002) *Curr. Biol.* **12**, 1692–1697.
- Parada, L. & Misteli, T. (2002) *Trends Cell Biol.* **12**, 425–432.
- Roix, J. J., McQueen, P. G., Munson, P. J., Parada, L. A. & Misteli, T. (2003) *Nat. Genet.* **34**, 287–291.
- Parada, L. A., McQueen, P. G. & Misteli, T. (2004) *Genome Biol.* **5**, R44.
- Neves, H., Ramos, C., da Silva, M. G., Parreira, A. & Parreira, L. (1999) *Blood* **93**, 1197–1207.
- Chuang, T. C., Moshir, S., Garini, Y., Chuang, A. Y., Young, I. T., Vermolen, B., van den Doel, R., Mougey, V., Perrin, M., Braun, M., et al. (2004) *BMC Biol.* **2**, 12.
- Ermiler, S., Kronic, D., Knoch, T. A., Moshir, S., Mai, S., Greulich-Bode, K. M. & Boukamp, P. (2004) *Eur. J. Cell Biol.* **83**, 681–690.
- Nesbit, C. E., Tersak, J. M. & Prochownik, E. V. (1999) *Oncogene* **18**, 3004–3016.
- Potter, M. & Marcu, K. B. (1997) *Curr. Top. Microbiol. Immunol.* **224**, 1–17.
- Mai, S. & Mushinski, J. F. (2003) *J. Environ. Pathol. Toxicol. Oncol.* **22**, 179–199.
- Mai, S. (1994) *Gene* **148**, 253–260.
- Mai, S., Hanley-Hyde, J. & Fluri, M. (1996) *Oncogene* **12**, 277–288.
- Mai, S., Fluri, M., Siwarski, D. & Huppi, K. (1996) *Chromosome Res.* **4**, 365–371.
- Felsher, D. W. & Bishop, J. M. (1999) *Proc. Natl. Acad. Sci. USA* **96**, 3940–3944.
- Rockwood, L. D., Torrey, T. A., Kim, J. S., Coleman, A. E., Kovalchuk, A. L., Xiang, S., Ried, T., Morse, H. C., 3rd, & Jantz, S. (2002) *Oncogene* **21**, 7235–7240.
- Kuschak, T. I., Kuschak, B. C., Taylor, C. L., Wright, J. A., Wiener, F. & Mai, S. (2002) *Oncogene* **21**, 909–920.
- Louis, S. F., Grubne, B. & Mai, S. (2005) *Prog. Oncog.*, in press.
- Vafa, O., Wade, M., Kern, S., Beeche, M., Pandita, T. K., Hampton, G. M. & Wahl, G. M. (2002) *Mol. Cell* **9**, 1031–1044.
- Hironaka, K., Factor, V. M., Calvisi, D. F., Conner, E. A. & Thorgeirsson, S. S. (2003) *Lab. Invest.* **83**, 643–654.
- Karlsson, A., Deb-Basu, D., Cherry, A., Turner, S., Ford, J. & Felsher, D. W. (2003) *Proc. Natl. Acad. Sci. USA* **100**, 9974–9979.
- Partlin, M. M., Homer, E., Robinson, H., McCormick, C. J., Crouch, D. H., Durant, S. T., Matheson, E. C., Hall, A. G., Gillespie, D. A. & Brown, R. (2003) *Oncogene* **22**, 819–825.
- Chiang, Y. C., Teng, S. C., Su, Y. N., Hsieh, F. J. & Wu, K. J. (2003) *J. Biol. Chem.* **278**, 19286–19291.
- Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D. & Brinster, R. L. (1985) *Nature* **318**, 533–538.
- Potter, M. & Wiener, F. (1992) *Carcinogenesis* **13**, 1681–1697.
- Pelengaris, S., Khan, M. & Evan, G. I. (2002) *Cell* **109**, 321–334.
- Felsher, D. W. & Bishop, J. M. (1999) *Mol. Cell* **4**, 199–207.
- Marinkovic, D., Marinkovic, T., Mahr, B., Hess, J. & Wirth, T. (2004) *Int. J. Cancer* **110**, 336–342.
- D’Cruz, C. M., Gunther, E. J., Boxer, R. B., Hartman, J. L., Sintasath, L., Moody, S. E., Cox, J. D., Ha, S. I., Belka, G. K., Golant, A., Cardiff, R. D. & Chodosh, L. A. (2001) *Nat. Med.* **7**, 235–239.
- Jain, M., Arvanitis, C., Chu, K., Dewey, W., Leonard, E., Trinh, M., Sundberg, C. D., Bishop, J. M. & Felsher, D. W. (2002) *Science* **297**, 102–104.
- Karlsson, A., Giuriato, S., Tang, F., Fung-Weier, J., Levan, G. & Felsher, D. W. (2003) *Blood* **101**, 2797–2803.
- Shachaf, C. M., Kopelman, A. M., Arvanitis, C., Karlsson, A., Beer, S., Mandl, S., Bachmann, M. H., Borowsky, A. D., Ruebner, B., Cardiff, R. D., et al. (2004) *Nature* **431**, 1112–1117.
- Fest, T., Mougey, V., Dalstein, V., Hagerty, M., Milette, D., Silva, S. & Mai, S. (2002) *Oncogene* **21**, 2981–2990.
- Mai, S., Hanley-Hyde, J., Rainey, G. J., Kuschak, T. I., Paul, J. T., Littlewood, T. D., Mischak, H., Stevens, L. M., Henderson, D. W. & Mushinski, J. F. (1999) *Neoplasia* **1**, 241–252.
- Wiener, F., Kuschak, T. I., Ohno, S. & Mai, S. (1999) *Proc. Natl. Acad. Sci. USA* **96**, 13967–13972.
- Wiener, F., Coleman, A., Mock, B. A. & Potter, M. (1995) *Cancer Res.* **55**, 1181–1188.
- Littlewood, T. D., Hancock, D. C., Danielian, P. S., Parker, M. G. & Evan, G. I. (1995) *Nucleic Acids Res.* **23**, 1686–1690.
- Grenman, S., Shapira, A. & Carey, T. E. (1988) *Gynecol. Oncol.* **30**, 228–238.
- Grenman, S. E., Roberts, J. A., England, B. G., Gronroos, M. & Carey, T. E. (1988) *Gynecol. Oncol.* **30**, 239–250.
- Mandlekar, S., Hebbar, V., Christov, K. & Kong, A. N. (2000) *Cancer Res.* **60**, 6601–6606.
- Fukasawa, K., Wiener, F., Vande Woude, G. F. & Mai, S. (1997) *Oncogene* **15**, 1295–1302.
- Figuerola, R., Lindenmaier, H., Hergenahm, M., Nielsen, K. V. & Boukamp, P. (2000) *Cancer Res.* **60**, 2770–2774.
- Schaefer, L. H., Schuster, D. & Herz, H. (2001) *J. Microsc.* **204**, 99–107.
- Vermolen, B. J., Garini, Y., Mai, S., Mougey, V., Fest, T., Chunag, T. C. Y., Chuang, A. Y. C., Wark, L. & Young, I. T. (2005) *Cytometry*, in press.
- Poon, S. S., Martens, U. M., Ward, R. K. & Lansdorp, P. M. (1999) *Cytometry* **36**, 267–278.
- Beatty, B., Mai, S. & Squire, J., eds. (2002) *FISH: A Practical Approach* (Oxford Univ. Press, Oxford).
- Benedek, K., Chudoba, I., Klein, G., Wiener, F. & Mai, S. (2004) *Chromosome Res.* **12**, 777–785.
- Smith, G., Taylor-Kashton, C., Dushnick, L., Symons, S., Wright, J. & Mai, S. (2003) *Neoplasia (Bratisl.)* **5**, 110–120.
- Wilson, E. B. (1927) *J. Am. Stat. Assoc.* **22**, 209–212.
- Mueller, H. J. (1938) *Collecting Net.* **13**, 181–198.
- McClintock, B. (1941) *Genetics* **26**, 234–282.
- Fest, T., Guffei, A., Williams, G., Silva, S. & Mai, S. (2005) *Oncogene* **24**, 2944–2953.
- Molenaar, C., Wiesmeijer, K., Verwoerd, N. P., Khazen, S., Eils, R., Tanke, H. J. & Dirks, R. W. (2003) *EMBO J.* **22**, 6631–6641.
- DePinho, R. A. & Polyak, K. (2004) *Nat. Genet.* **36**, 932–934.
- Artandi, S. E., Chang, S., Lee, S. L., Alson, S., Gottlieb, G. J., Chin, L. & DePinho, R. A. (2000) *Nature* **406**, 641–645.
- Artandi, S. E. (2002) *Trends Mol. Med.* **8**, 44–47.
- Smith, K. A., Stark, M. B., Gorman, P. A. & Stark, G. R. (1992) *Proc. Natl. Acad. Sci. USA* **89**, 5427–5431.
- Ciullo, M., Debily, M. A., Rozier, L., Autiero, M., Billault, A., Mayau, V., El Marhomy, S., Guardiola, J., Bernheim, A., Coullin, P., et al. (2002) *Hum. Mol. Genet.* **11**, 2887–2894.
- Hande, M. P., Samper, E., Lansdorp, P. & Blascoe, M. A. (1999) *J. Cell Biol.* **144**, 589–601.
- Murnane, J. P. & Sabatier, L. (2004) *Bioessays* **26**, 1164–1174.
- Gisselsson, D., Jonson, T., Petersen, A., Strombeck, B., Dal Cin, P., Hoglund, M., Mitelman, F., Mertens, F. & Mandahl, N. (2001) *Proc. Natl. Acad. Sci. USA* **98**, 12683–12688.
- Londono-Vallejo, J. A. (2004) *Cancer Lett.* **212**, 135–144.
- Zink, D. & Cremer, T. (1998) *Curr. Biol.* **8**, R321–R324.
- Walter, J., Schermelleh, L., Cremer, M., Tashiro, S. & Cremer, T. (2003) *J. Cell Biol.* **160**, 685–697.
- Vourc’h, C., Taruscio, D., Boyle, A. L. & Ward, D. C. (1993) *Exp. Cell Res.* **205**, 142–151.
- Ferguson, M. & Ward, D. C. (1992) *Chromosoma* **101**, 557–565.
- Bridger, J. M., Boyle, S., Kill, I. R. & Bickmore, A. (2000) *Curr. Biol.* **10**, 149–152.
- Fischer, A. H., Bond, J. A., Taysavang, P., Battles, O. E. & Wynford-Thomas, D. (1998) *Am. J. Pathol.* **153**, 1443–1450.
- Fischer, A. H., Chadee, D. N., Wright, J. A., Gansler, T. S. & Davie, J. R. (1998) *J. Cell Biochem.* **70**, 130–140.
- Chadee, D. N., Hendzel, M. J., Tylipski, C. P., Allis, C. D., Bazett-Jones, D. P., Wright, J. A. & Davie, J. R. (1999) *J. Biol. Chem.* **274**, 24914–24920.
- Takaha, N., Hawkins, A. L., Griffin, C. A., Isaacs, W. B. & Coffey, D. S. (2002) *Cancer Res.* **62**, 647–651.
- Fernandez, P. C., Frank, S. R., Wang, L., Schroeder, M., Liu, S., Greene, J., Cocito, A. & Amati, B. (2003) *Genes Dev.* **17**, 1115–1129.
- van Steensel, B., Smogorzewska, A. & de Lange, T. (1998) *Cell* **92**, 401–413.

Research article

Open Access

The three-dimensional organization of telomeres in the nucleus of mammalian cells

Tony Chih Yuan Chuang^{†1,3}, Sharareh Moshir^{†1,2}, Yuval Garini^{*†4}, Alice Ya-Chun Chuang¹, Ian T Young⁴, Bart Vermolen⁴, Richard van den Doel⁴, Virginie Mougey⁵, Mathilde Perrin⁵, Martina Braun¹, Paul Donald Kerr³, Thierry Fest^{5,6}, Petra Boukamp² and Sabine Mai¹

Address: ¹Manitoba Institute of Cell Biology, CancerCare Manitoba, University of Manitoba, 675 McDermot Avenue, Winnipeg, MB, R3E 0V9, Canada, ²German Cancer Research Centre, Division of Genetics of Skin Carcinogenesis, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany, ³Department of Otolaryngology Head and Neck Surgery, Health Sciences Centre, GB421-820 Sherbrook Street, Winnipeg MB, R3A 1R9, Canada, ⁴Delft University of Technology, Faculty of Applied Sciences, Department of Imaging Science & Technology, 2628 CJ Delft, The Netherlands, ⁵Hematology Department, IETG Laboratory, University Hospital Jean Minjoz, 25030 Besançon, France and ⁶Present address: Hematology Laboratory, University Hospital Pontchaillou, 35033 Rennes, France

Email: Tony Chih Yuan Chuang - tychuang@hotmail.com; Sharareh Moshir - s.moshir@dkfz.de; Yuval Garini* - Y.Garini@tnw.tudelft.nl; Alice Ya-Chun Chuang - alicechuang@hotmail.com; Ian T Young - young@ph.tn.tudelft.nl; Bart Vermolen - vermolen@ph.tn.tudelft.nl; Richard van den Doel - richard@ph.tn.tudelft.nl; Virginie Mougey - virginie.mougey@voila.fr; Mathilde Perrin - mathilde-perrin@caramail.com; Martina Braun - tina-braun@gmx.net; Paul Donald Kerr - pkerr@exchange.hsc.mb.ca; Thierry Fest - thierry.fest@univ-rennes1.fr; Petra Boukamp - P.Boukamp@dkfz-heidelberg.de; Sabine Mai - smai@cc.umanitoba.ca

* Corresponding author †Equal contributors

Published: 03 June 2004

Received: 10 March 2004

BMC Biology 2004, 2:12

Accepted: 03 June 2004

This article is available from: <http://www.biomedcentral.com/1741-7007/2/12>

© 2004 Chuang et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Abstract

Background: The observation of multiple genetic markers *in situ* by optical microscopy and their relevance to the study of three-dimensional (3D) chromosomal organization in the nucleus have been greatly developed in the last decade. These methods are important in cancer research because cancer is characterized by multiple alterations that affect the modulation of gene expression and the stability of the genome. It is, therefore, essential to analyze the 3D genome organization of the interphase nucleus in both normal and cancer cells.

Results: We describe a novel approach to study the distribution of all telomeres inside the nucleus of mammalian cells throughout the cell cycle. It is based on 3D telomere fluorescence *in situ* hybridization followed by quantitative analysis that determines the telomeres' distribution in the nucleus throughout the cell cycle. This method enables us to determine, for the first time, that telomere organization is cell-cycle dependent, with assembly of telomeres into a telomeric disk in the G2 phase. In tumor cells, the 3D telomere organization is distorted and aggregates are formed.

Conclusions: The results emphasize a non-random and dynamic 3D nuclear telomeric organization and its importance to genomic stability. Based on our findings, it appears possible to examine telomeric aggregates suggestive of genomic instability in individual interphase nuclei and tissues without the need to examine metaphases. Such new avenues of monitoring genomic instability could potentially impact on cancer biology, genetics, diagnostic innovations and surveillance of treatment response in medicine.

Background

Cancer is characterized by multiple alterations that affect the modulation of gene expression and the stability of the genome. These interconnected changes occur within the nuclei of cells that alter their three dimensional (3D) organization during tumor initiation and progression [1,2]. It seems reasonable to assume that the highly organized mammalian interphase nucleus is the structure that ascertains genomic stability. In line with these concepts, oncogenic activation remodels this nuclear order and sets the stage for genomic instability as we have recently measured for conditional c-Myc deregulation. The deregulated expression of c-Myc alters the 3D nuclear space of chromosomes and telomeres, and makes genomic rearrangements topologically feasible (Chuang *et al.*, in preparation).

Defining the structural organization of the interphase nucleus is, therefore, essential to our understanding of the 3D genome organization in the interphase nucleus. Such a study can be performed by fluorescence *in situ* hybridization (FISH). Two of the most attractive features of FISH measurements of the 3D nucleus organization are the ability to simultaneously visualize multiple targets and the structural organization of nucleus and cells, something that cannot be achieved by array-based methods.

The organization of the interphase nucleus has been studied since the late nineteenth century [3]. It is now well accepted that the position of chromosomes in the nucleus plays an important role in gene regulation [4]. Nevertheless, some controversy exists. Most laboratories have observed a non-random organization of chromosome territories [2,5,6] that has been conserved during evolution [7]. This has been further supported by studies that demonstrate an architectural stability of the chromosomal positions in the nucleus [8,9]. There are, however, different observations on chromosomal positions [10-15] as well as on positional changes of chromosomes during the cell cycle [16,17].

Recently, interest has also focused on telomeres, whose importance to genomic stability was recognized as early as the 1930s [18]. Capping the chromosomes, telomeres are responsible for chromosomal integrity [19] to prevent genomic instability [20]. Some reports have been published on the 3D organization of telomeres in the nucleus, mainly with regard to the distances of telomeres from the nuclear shell. Telomeres have been previously found at the nuclear edge [21], at the nuclear periphery [22], throughout the entire nucleus [13,23], in non-Rabl association [11], in association with the nucleolus [24] or in the nuclear matrix [25].

Telomere dynamics also have been studied in living human U2OS osteosarcoma cells [26]. Individual telomeres showed significant directional movements and telomeres were shown to associate with promyelocytic leukemia bodies in a dynamic manner. This means that telomere structure is dynamic, and may be important for both transcriptional processes and for stabilizing chromosome positions in the nucleus.

We have developed a method of studying the organization of the genome by analysis of the 3D organization of telomeres in the nucleus and their positional changes along the cell cycle, using flow-sorted living cells. This method enables us to determine, for the first time, that telomere organization is cell-cycle dependent, with assembly of telomeres into a telomeric disk in the G2 phase. Moreover, we show for tumor cells that the 3D telomere organization is distorted and that telomeric aggregates are formed. These results emphasize a non-random and dynamic 3D nuclear telomeric organization and its importance to genomic stability.

Results and discussion

To study the organization and structure of the genome in the nucleus, we took the approach of labelling only the telomeres and measuring their 3D organization as indicators for chromosomal distribution. After the 3D fluorescent measurements, the data were analyzed with a programme that was developed for this study. The programme finds all the telomeres in the nucleus; their size, intensity and shape; and determines the telomeric organization inside the volume of the nucleus. One crucial property that we analyzed was the distribution of the telomeres inside the nuclear volume. We first segmented the nucleus and found the centre of each telomere. We then found the smallest convex set of polygons that contains all the telomeres (Fig. 1). This was done by using the Quickhull algorithm [27]. In most cases, we found that the volume contained by the telomeres resembles either a sphere or a flattened sphere (disk). It can be described as an ellipsoid with two similar radii ($a \approx b$) and a different third one (c ; Fig. 2). Such a shape is called a spheroid. The level of flatness of the volume occupied by the telomeres can, therefore, be described by the ratio of the two radii that are different, a (or b) and $c - a/c$. The larger the ratio, the more oblate (or disk-like) is the shape of the volume occupied by the telomeres, while $a/c \approx 1$ means that the volume is spherical.

The optical resolution and signal-to-noise ratio are presented in Fig. 3. The images of two neighbouring telomeres that are 1200 nm and 400 nm apart, and the corresponding intensity along the line connecting the pair, indicates the smallest telomere distance that can still




Figure 1
The distribution of the telomeres in the nucleus volume is found by fitting a convex set of polygons that contains all the telomeres. This volume usually looks like either a sphere or a disk and can be described as an ellipsoid.




Figure 3
Demonstration of the signal-to-noise and spatial resolution of our measurements. The fluorescence intensity is bright (typical signal-to-noise ratio of 10:1). Two pairs of telomeres are shown, 1200 nm apart (top), which can be easily separated, and 400 nm apart (bottom). The inserts show the actual images.




Figure 2
In general, the ellipsoid's main axes along $x'y'z'$ do not coincide with the microscope-slide plane and optical axes xyz . Our programme finds an ellipsoid that contains all the telomeres and the size of its main axes a, b, c . In most of the cases the $x'y'$ axes of the ellipsoid are similar, i.e. $a \approx b$. Therefore, the ratio a/c is a good measure of the flatness level of the ellipsoid and of the telomere organization inside the nucleus.

be unambiguously distinguished (approximately 200 nm).

It is expected that 80 telomeres will be observed in the interphase nucleus for normal mouse cells (92 for a normal somatic human cell), however, in our measurements we were usually able to identify approximately 40 separated telomere regions in each mouse cell (50 in human cells). Similar results have been described before [23,28]. This is probably due to neighbouring telomeres that are closer than the optical resolution (see Fig. 3), but it does not affect the analysis of the telomere distribution in the nucleus as long as the hybridization efficiency is high. This was verified by two-dimensional measurements of all the telomeres in a metaphase spread (using the same probe), where at least 90% of the telomeres are unambiguously observed (Fig. 4).

We first described the major observation of primary BALB/c mouse B lymphocytes that were studied along the cell cycle. These studies were followed by the analysis of immortalized cells. The lymphocytes were sorted according to their DNA content for the determination of the G0/G1, S or G2/M phases (see *Methods*).




Figure 4
Metaphase plate prepared from fetal liver cells directly isolated from day 10 old mouse embryos. Metaphase chromosomes and spreads were prepared as described [30] and hybridized with a PNA-telomeric probe that was Cy3 labelled. More than 90% of the telomeres are clearly observed.

By analyzing cell-cycle sorted primary mouse lymphocytes we found that the 3D telomere organization changes during the cell cycle. Telomeres are widely distributed throughout the nucleus in the G0/G1 and S phases with a calculated a/c ratio of 0.9 ± 0.4 , which means a spherical-like volume of distribution. However, during G2, telomeres are not observed throughout the whole nucleus. Their 3D organization changes, with all the telomeres assuming a central structure that we call the telomeric disk, which has never been reported before. In this ordered structure, all the telomeres align in the centre of the nucleus as cells progress into the late G2 phase. The a/c ratio they assume is 6.0 ± 2.0 , which means a very flat disk (almost a coin shape).




Figure 5
The distribution of telomeres in the nucleus of three typical cells selected from the G0/G1 phase (upper row), S phase (middle row) and G2/M phase (lower row). Each telomere distribution is shown from a top view (the XY plane), along the optical axis Z (left column), from a side view (XZ plane) as observed along the Y axis (centre column) and as a 3D image of the telomeres in an open nucleus (right column). When shown from the top and side views, the telomeres are displayed on top of the projected image of the nucleus. This projection demonstrates the extent of the chromatin (and therefore chromosomes) and defines the volume and borderline of the nucleus.

Typical lymphocytes from different phases are shown in Fig. 5. The a/c ratio of these cells in the G0/G1, S and G2/M phases is 0.8, 0.8 and 6, respectively, and clearly shows the correlation of the a/c ratio with the telomere distribution and the organization of the telomeric disk that we found in the G2 phase. The elongation of the telomeres along the Z axis (the optical axis) relative to the XY plane has the same ratio as the point spread function of our system and results from the poorer optical resolution along the optical axis. However, this has a very small effect on the shape of the whole nucleus.

Similar results have been observed in primary human lymphocytes, primary human fibroblasts and in normal human epithelial tissue (see additional file for more data). This suggests that chromosomes assume a very precise order that pre-aligns them prior to the onset of mitosis. In order to ascertain that the telomeric disk was not the result of a distorted nucleus, our analysis programme




Figure 6

BrdU-positive cells were live sorted and synchronized in the S phase. They were harvested from a culture at time intervals of 3.5–9 hours. The cells were then fixed for 3D analysis. For each time point we have measured: 1. the fraction of nuclei with a telomeric disk; 2. the fraction of cells in mitosis; and 3. the fraction of cells with interphase nuclei but without a telomeric disk. Ninety percent of the cells formed a telomeric disk 3.5 hours after BrdU incorporation and were therefore interpreted as cells in the late G2 phase (black line and circles). Cells entering mitosis (dashed line and squares) peaked at 7.5 hours (65%) and cells in G1 (dotted line and triangles) peaked after 8.5 hours (57%). The increase in the number of metaphases at 9.5 hours cannot be explained and probably lies within the limits of experimental errors.

compared the telomere distribution volume and shape with that of the 4'-6-Diamidino-2-phenylindole (DAPI) – stained nucleus, and verified that the nucleus itself still had a spherical-like volume. We rarely found distorted nuclei and excluded these cells from the analysis. The nucleus shown in G2 is not fully spherical. Such a shape is expected, because when the telomeres forms a disk, it pools the chromosomes and forces them to be closer to the disk, which results in an oblate shape as well.

To further study the phase transition timing along the cell cycle we used the synchronous bromodeoxyuridine (BrdU) sorting method. The cell population was pulse-labelled with BrdU in the S phase and flow sorted. Cells were placed back into culture and sub-populations harvested at 3.5, 4, 5, 6, 7, 8, 8.5, 9 and 10 hours after labelling and sorting. The cells were then fixed for 3D analysis. A minimum of 20 cells from each of these sub-populations were measured, analyzed and divided into

the following three categories: 1) nuclei with a telomeric disk; 2) cells in mitosis; 3) cells in interphase without telomeric disk and mitotic figures (evaluated as G1 cells). The cell fractions as a function of time are shown in Fig. 6. Most cells (90%) form a telomeric disk 3.5 hours after BrdU incorporation. These cells are, therefore, interpreted as cells in the G2 phase. The fraction of metaphase cells peaks at 7.5 hours (65%) and the cell fraction of interphase cells that does not have a telomeric disk (and is interpreted as being in the G1 phase) peaks at 8.5 hours (57%).

These results reveal that the telomeric disk is formed in the late G2 phase. As cells progress from G2 to M, chromosomes organize into metaphases and, therefore, the number of cells in interphase with a telomeric disk decreases. Because there is no other state of transition between telomeric disk and mitosis, we conclude that the telomeric disk is the 3D telomeric organization assumed in late G2. Thus, it is also the final stage of the interphase nucleus that permits the organization of the genetic material prior to its entry into the M phase and prior to chromosome segregation. Cells in late G2 with a telomeric disk have additional characteristic features: i) they exhibit a larger overall nuclear volume than their G1 or S phase counterparts (this increase in size was also confirmed by fluorescent activated cell sorter [FACS] analysis); and ii) they begin to show signs of early re-organization of the chromatin into partially condensed areas (as visualized using the DAPI stained image).

At the end of the M phase, we observe cells that enter into the G1 conformation of telomeres, with a wide spatial distribution of telomeres throughout a smaller nucleus.

In conclusion, this data indicates that the telomeric disk is a novel structure within the interphase nucleus in late G2 that has not been previously described. Its existence points to the fundamental importance of ordered nuclear organization at the end of G2. The telomeric disk probably assures the proper organization of chromosomes prior to mitosis and their organized segregation during mitosis. Together with information that has been previously published on telomeric dynamics [26,28], it is tempting to speculate that telomeres take an active part in the process of chromosome organization into a unique structure, the telomeric disk, during G2. This alignment of telomeres and chromosomes would facilitate the proper subsequent organization of the chromosomes into an equatorial plane during cell division. This process may be driven by the telomeres themselves (that are free of the nuclear matrix) or through the nuclear matrix. The telomeric disk may also allow for a late G2 checkpoint.

Further work on the subject can also be performed *in vivo*, as has been shown by Molenaar *et al.* [26]. In such a way the full dynamic process can be observed, which is complementary to the single time-points that are shown in our work.

We have continued to observe the distribution of telomeres in cancer cells. Typical 3D images constructed from normal nuclei and from a Burkitt lymphoma cell line (Raji), as well as from primary mouse plasmacytoma (PCT) and primary human head and neck squamous cell carcinoma (HNSCC) stage IV (Fig. 7), show that telomeres form aggregates and thus a partially altered telomeric disk. Such telomeric aggregates are characterized by both a larger volume and larger integrated intensity than their normal non-overlapping and non-aggregated counterparts. They are not observed in normal cells. Similar results for altered telomeric organization have also been found in human neuroblastoma and colon carcinoma tumor cell lines.

In line with these concepts, oncogenic activation remodels this nuclear order and sets the stage for genomic instability as we have recently measured for conditional c-Myc deregulation. We have found that deregulated expression of c-Myc alters the 3D nuclear organization of chromosomes and telomeres, and makes genomic rearrangements topologically feasible (Chuang *et al.*, in preparation).

Conclusions

In summary, we have shown that 3D optical imaging followed by the analysis of telomeres in the interphase is an important tool for basic research and cancer biology. We have found cell-cycle dependence of the telomere organization in the nucleus, where telomeres align into a telomeric disk during the late G2 phase. Such an organization has never before been reported.

Telomeric aggregates are found in tumor cells and, therefore, an alteration of the telomeric disk is seen. Transient telomeric aggregations potentially cause irreversible chromosomal rearrangements.

The above findings indicate that it is now possible to examine the presence of telomeric aggregates suggestive of genomic instability in individual interphase nuclei and tissue, without the need to examine metaphases. Such new directions of monitoring genomic instability could potentially have an impact on cancer biology, genetics, diagnostic innovations and surveillance of treatment response in medicine.




Figure 7

Normal: A normal blood cell; RAJI: A Burkitt lymphoma cell line; PCT: A primary mouse plasmacytoma cell; HNSCC: A primary human head and neck squamous cell carcinoma (stage IV). The distribution of telomeres in cancer cells compared with a normal cell. Images are shown as explained in Fig. 5. Aggregates of telomeres are formed and the telomeric disk that appears in the G2 phase is distorted.

Methods

Cells

Mouse primary cells were directly isolated from BALB/c mice and stimulated with lipopolysaccharide to enter into the cell cycle [29]. Primary mouse fetal liver cells were also directly isolated from BALB/c mice. Mice were studied according to the protocols approved by Canadian Central Animal Care. Immortalized mouse pro B lymphocytes have been described elsewhere [30]. Human primary cells were obtained from healthy donors. Head and neck squamous cell carcinoma and control tissue were obtained from a patient at CancerCare Manitoba upon ethics approval and informed consent.

Fixation techniques

Pro B lymphocytes [30] were fixed in four ways: i) following cytospin preparations, cells were fixed in 3.7% formaldehyde (1×PBS/50 mM MgCl₂); ii) cells were allowed to

grow on glass slides and were fixed in 1% formaldehyde (3D fixation); iii) cells were fixed in suspension with 3.7% formaldehyde (3D fixation); and iv) cells were fixed in methanol:acetic acid (3:1) according to standard protocols [29]. Tissue was fixed following cryosection (5 μ m sections were used) in 1% formaldehyde (1 \times PBS/50 mM MgCl₂). All hybridizations shown in this report were carried out after 3D fixation.

Fluorescent activated cell sorter (FACS) analysis

For FACS analysis, primary lymphocytes were fixed in 70% cold ethanol and stained with propidium iodide (1 μ g/mL) following RNase (20 μ g/mL) digestion. The stained cells were analysed for DNA content by flow cytometry in a EPICS Altra cytometer (Beckman-Coulter). Cell cycle fractions were quantified with WinCycle software (Phoenix Flow Systems, San Diego, CA).

Cell sorting

Cells were stained with Hoechst 33342 (Molecular Probes) at a final concentration of 1 μ g/mL for 90 minutes at 37°C and 5% of carbon dioxide (CO₂). Cells were sorted according to their DNA content (G0/G1, S and G2/M phases) with a EPICS Altra cytometer (Beckman-Coulter) equipped with a UV laser (Coherent, excitation at 350 nm) and a 460 nm band-pass filter.

BrdU labelling

Pro B lymphocytes were labelled *in vivo* with 10 μ M of BrdU (5-Bromo-2'-deoxyuridine, SIGMA-ALDRICH, Lyon, France) for one hour at 37°C in humidified atmosphere (5% CO₂). BrdU was then detected with 5 μ L/1 \times 10⁶ cells of anti-BrdU-FITC (fluorescein isothiocyanate) antibody (TEBU, Le Perray-en-Yvelines, France) at identical conditions for 30 minutes. Thereafter, all BrdU (i.e. FITC)-positive cells were live sorted, placed into culture for different times and harvested at 3.5, 4, 5, 6, 7, 8, 8.5, 9 and 10 hours after labeling and sorting. The cells were then fixed for 3D analysis. For each time point we have measured: 1. the fraction of nuclei with a telomeric disk; 2. the fraction of cells in mitosis; and 3. the fraction of cells in interphase nuclei without telomeric disk and mitotic figures that were evaluated as G1 and S phase cells.

Telomere FISH using Cy3-labeled PNA probes

Telomere FISH was performed as described [31] using a Cy3-labelled PNA probe (DAKO, Glostrup, Denmark). Telomere hybridizations were specific as shown by metaphase hybridizations and the correct number of the telomeric signals observed at the ends of chromosomes prepared from primary cells (Fig. 4).

3D image acquisition

Unless stated otherwise, 20–30 cells were analyzed by 3D imaging from each cell type and phase type. Part of the

measurements were done with a confocal microscope (Leica AOBS-SP) and most of them with a conventional Axioplan 2 (Zeiss) with a cooled AxioCam HR CCD followed by deconvolution [30]. DAPI, FITC and Cy3 filters (Zeiss) were used in combination with Planapo 63 \times /1.4 oil (Zeiss). Axiovision 3.1 software with a deconvolution module and rendering module were used (Zeiss). Both methods gave similar results.

80–100 sections were acquired for each 3D nucleus, typically with 200 \times 200 pixels per section with a \sim 100 \times 100 nm nominal imaging area per pixel (steps of 200 nm along Z). The point-spread function of our system has a full width at half max of approximately 200 nm in the plane and 400 nm along the optical axis.

3D analysis of telomeres

In order to analyze the telomere distribution in the nucleus, we developed a special 3D image analysis programme. The main algorithmic part is described below. The programme (TeloView) is based on the Matlab computer language (The MathWorks, Natick, MA, USA) and some of the image processing algorithms are based on the DipImage library (developed at the Quantitative Imaging Group, Delft University of Technology, Delft, The Netherlands) [32].

The programme segments the nucleus volume by a derivative-based algorithm using a morphological top and bottom-hat algorithm [33]. The volume, intensity and centre of gravity are calculated for each spot. The programme then finds a principle plane in the nucleus ($x'y'$) that is the closest to all the telomeres (Fig. 2). This is especially important when a tissue section is analyzed, because this plane should not necessarily be parallel to the microscope slide plane.

The telomeric distribution inside the nucleus is described by fitting an ellipsoid to the volume occupied by the telomeres (three different main axes; Fig. 2). The distributions were found to be either oblate or spherical (i.e. the two principle axes along the main $x'y'$ plane of the spheroid are similar). It is, therefore, convenient to describe the distribution volume as a spheroid (i.e. an ellipsoid having two axes of equal length). As such, it is simpler to describe the spheroid degree of variation from a perfect sphere by the ratio a/c where a and b are the similar semi-axes and c is the third one. Such a description reflects the degree to which the telomere's volume is oblate.

Authors' contributions

TCYC performed the data analysis, wrote the discussion, performed the hybridizations, took all head and neck cancer samples from tumor collections during surgery to preparation of frozen sections, hybridization, analyses

and patient records. SMO performed some of the hybridizations and analyses while visiting SM's lab. YG developed the 3D analysis methods, 3D algorithms and the programme that analyses the nuclei, wrote the paper in its current version and acts as corresponding author. AYCC organized the data, tables, and G2 phase data. ITY, BV and RD took part in the development of the 3D analysis methods and algorithms, and the programme that analyses the nuclei. VM did the BrdU-labelling experiments and G2 study in France and in SM's lab. MP performed the G2 analysis in SM's lab. MB performed the metaphase telomere FISH. PDK directs the programme of head and neck surgery and provided some of the samples that were used for the study. TF supervised VM and MP in France. PB supervised SMO in Heidelberg. SM planned and carried out the project that was performed in SM's lab, and was supervisor for TCYC, SMO (while visiting SM's lab), AYCC, MB, MP and VM, and performed part of the experiments.

Acknowledgements

The authors wish to thank our colleagues and lab members for discussions and critical reading of this manuscript. This work was supported by the Canada Foundation for Innovation, the Canadian Institutes of Health Research (NSERC), CancerCare Manitoba, Fondation de France (Paris), the French Minister of Foreign Affairs, Sander-Stiftung and Verein zur Förderung der Krebsforschung e.V.

This work was also supported by the Physics for Technology programme of the Foundation for Fundamental Research in Matter (FOM), the Delft Inter-Faculty Research Center Life Tech and the Delft Research programme Life Science and Technology.

References

- Pienta KJ, Partin AW, Coffey DS: **Cancer as a disease of DNA organization and dynamic cell structure.** *Cancer Research* 1989, **49**:2525-2532.
- Cremer C, Cremer Thomas: **Chromosome territories, nuclear architecture and gene regulation in mammalian cells.** *Nature reviews Genetics* 2001, **2**:292-301.
- Rabl C: **Über Zellteilung.** *Morphologisches Jahrbuch Gegenbaur C (ed)* 1885, **10**:214-330.
- Marshall WF: **Order and Disorder in the Nucleus.** *Curr Biol* 2003, **12**:R185-R192.
- Nagele R, Freeman T, McMorro L, Lee H-y: **Precise spatial positioning of chromosomes during prometaphase: evidence for chromosomal order.** *Science* 1995, **270**:1831-1835.
- Parada LA, Misteli T: **Chromosome positioning in the interphase nucleus.** *Trends in Cell Biology* 2002, **12**:425-432.
- Tanabe H, Müller S, Neusser M, von Hase J, Calcagno E, Cremer M, Solovei I, Cremer C, Cremer T: **Evolutionary conservation of chromosome territory arrangements in cell nuclei from higher primates.** *Proc Nat Acad Sci USA* 2002, **99**:4424-4429.
- Gerlich D, Beaudouin J, Kalbfuss B, Daigle N, Eils R, Ellenberg J: **Global chromosome positions are transmitted through mitosis in mammalian cells.** *Cell* 2003, **112**:751-764.
- Abney JR, Cutler B, Fillback ML, Axelrod D, Scalettar BA: **Chromatin dynamics in interphase nuclei and its implication for nuclear structure.** *The Journal of Cell Biology* 1997, **137**:1459-1468.
- Holley WR, Mian IS, Park SJ, Rydberg B, Chatterjee A: **A model for interphase chromosomes and evaluation of radiation-induced aberrations.** *Radiation Research* 2002, **158**:568-580.
- Cerda MC, Berrios S, Fernandez-Donoso R, Garagna S, Redi C: **Organisation of complex nuclear domains in somatic mouse cells.** *Biology of the Cell* 1999, **91**:55-65.
- Cornforth Michael N., Greulich-Bode Karin M., Loucas Bradford D., Arsuaga Javier, Vazquez Mariel, Sachs Rainer K., Bruckner Martina, Molls Michael, Hahnfeldt Philip, Hlatky Lynn, Brenner David J.: **Chromosomes are predominantly located randomly with respect to each other in interphase human cells.** *J Cell Biol* 2002, **159**:237-244.
- Vourc'h Claire, Taruscio Domenica, Boyle Ann L., Ward David C.: **Cell cycle-dependent distribution of telomeres, centromeres, and chromosome-specific subsatellite domains in the interphase nucleus of mouse lymphocytes.** *Experimental Cell Research* 1993, **205**:142-151.
- Lopez-Velazquez G, Marquez J, Ubaldo E, Corkidi G, Echeverria O, Vazquez Nin GH: **Three-dimensional analysis of the arrangement of compact chromatin in the nucleus of G0 rat lymphocytes.** *Histochemistry and Cell Biology* 1996, **105**:153-161.
- Dong F, Jiang J: **Non-Rabl patterns of centromere and telomere distribution in the interphase nuclei of plant cells.** *Chromosome Research* 1998, **6**:551-558.
- Ferguson M, Ward DC: **Cell cycle dependent chromosomal movement in pre-mitotic human T-lymphocyte nuclei.** *Chromosoma* 1992, **101**:557-565.
- Gasser SM: **Visualizing chromatin dynamics in interphase nuclei.** *Science* 2002, **296**:1412-1416.
- McClintock Barbara: **The stability of broken ends of chromosomes in Zea Mays.** *Genetics* 1941, **26**:234-282.
- Blackburn EH: **Switching and signaling at the telomere.** *Cell* 2001, **106**:661-673.
- Maser RS, DePinho RA: **Connecting chromosomes, crisis, and cancer.** *Science* 2002, **297**:565-569.
- Cremer T, Cremer C, Baumann H, Luedtke EK, Sperling K, Teuber V, Zorn C: **Rabl's model of the interphase chromosome arrangement tested in Chinese hamster cells by premature chromosome condensation and laser-UV-microbeam experiments.** *Human Genetics* 1982, **60**:46-56.
- Zalensky AO, Allen MJ, Kobayashi A, Zalenskaya IA, Balhorn R, Bradbury EM: **Well-defined genome architecture in the human sperm nucleus.** *Chromosoma* 1995, **103**:577-590.
- Weierich Claudia, Brero Alessandro, Stein Stefan, Hase Johann von, Cremer Christoph, Cremer Thomas, Solovei Irina: **Three-dimensional arrangements of centromeres and telomeres in nuclei of human and murine lymphocytes.** *Chromosome Research* 2003, **11**:485-502.
- Armstrong SJ, Franklin FCH, Jones GH: **Nucleolus-associated telomere clustering and pairing precede meiotic chromosome synapsis in Arabidopsis thaliana.** *Journal of Cell Science* 2001, **114**:4207-4217.
- de Lange T: **Human telomeres are attached to the nuclear matrix.** *The EMBO Journal* 1992, **11**:717-724.
- Molenaar C, Wiesmeijer K, Verwoerd NP, Khazen S, Eils R, Tanke HJ, Dirks RW: **Visualizing telomere dynamics in living mammalian cells using PNA probes.** *The EMBO Journal* 2003, **22**:6631-6641.
- Barber C, Bradford, Dobkin P, David, Huhdanpaa Hannu: **The quick-hull algorithm for convex hulls.** *ACM Transactions on Mathematical Software* 1996, **22**:469-483.
- Nagele Robert G., Velasco Antonio Q., Anderson William J., McMahon Donald J., Thomson Zabrina, Fazekas Jessica, Wind Kelly, Lee Hsin-yi: **Telomere associations in interphase nuclei: possible role in maintenance of interphase chromosome topology.** *Journal of Cell Science* 2001, **114**:377-388.
- Beatty B, Mai S, Squire J: **FISH: A practical Approach.** Oxford University Press, USA.; 2002:274.
- Fest T, Mougey V, Dalstein V, Hagerty M, Milette D, Silva S, Mai S: **c-MYC overexpression in Ba/F3 cells simultaneously elicits genomic instability and apoptosis.** *Oncogene* 2002, **21**:2981-2990.
- Figuroa R, Lindenmaier H, Hergenbahn M, Nielsen KV, Boukamp P: **Telomere erosion varies during in vitro aging of normal human fibroblasts from young and adult donors.** *Cancer Research* 2000, **60**:2770-2774.
- DIPimage, a scientific image processing toolbox for MATLAB [<http://www.ph.tn.tudelft.nl/DIPlib/>]
- Meyer Frenand: **Iterative image transformations for an automatic screening of cervical smears.** *The Journal of Histochemistry and Cytochemistry* 1979, **27**:128-135.

Curriculum Vitae
Dr. William Foulkes
Dr. Sabine Mai

CURRICULUM VITAE

WILLIAM DAVID FOULKES

BIRTHPLACE

Penarth, Wales, UK.

ADDRESS BUSINESS

Division of Medical Genetics
Montreal General Hospital
1650 Cedar Avenue, Room L10-116
Montreal, Quebec, H3G 1A4
Tel: (514) 934-1934, local 44121
Fax: (514) 934 8273
Lab: (514) 937-6011, local 44201

Department of Medical Genetics
Cancer Prevention Centre
Sir M.B. Davis-Jewish General Hospital
3755 Cote Ste Catherine, Room C-107.1
Montreal, Quebec, H3T 1E2
Tel: (514) 340 8222, local 3851
Fax: (514) 340 8222, pause 2116/
(514) 340 8600Lab: (514) 340-8222, local 3361
Email: william.foulkes@mcgill.ca

HOME

45 Elmwood
Senneville, Quebec
H9X 1T6
Tel: (514) 457-6669

CITIZENSHIP

Canadian, British

MARITAL STATUS

Married - Norah Neylon
3 children: Eleanor, Gabriel and Sarah

EDUCATION & TRAINING

1980

B.Sc. - Upper second class honours, Anatomy
University of London

1984

MB.BS
University of London

1984 -1985 House officer in Medicine and Surgery,
Hackney and St. Bartholomew's Hospital,
London

EDUCATION & TRAINING (cont'd)

1985-1986 Senior House Officer
Emergency Medicine,
Whittington Hospital, London

1986 - 1987 Rotating Senior House Officer
Department of Medicine
St. Mary's and St. Charles Hospitals, London

1987 - 1988 Senior House Officer
Departments of Medicine and Radiotherapy
Royal Marsden Hospital, London

1988 - 1989 Registrar in General and Respiratory Medicine
Ealing Hospital, Middlesex

1989 - 1990 Registrar in Gastroenterology
Hammersmith Hospital, London

1990 – 1994 Ph.D.
A molecular genetic analysis of ovarian cancer
Completed as an external student of the
University of London, at the
Imperial Cancer Research Fund
(Internal: Galton Laboratory, UCL)

FELLOWSHIPS

1990 - 1994 Clinical Research Fellow
Human Immunogenetics Laboratory
Imperial Cancer Research Fund
London
and
Honorary Research Fellow,
Family Cancer Clinic - St. Mark's Hospital,
London

(affiliated with the Division of Medical
and Molecular Genetics, KGT Medical School,
University of London)

APPOINTMENTS

1994 -	Medical Scientist, Montreal General Hospital
1996- 2002	Assistant Professor, Department of Medicine, McGill University, Montreal.
1996- 2002	Assistant Professor, Department of Human Genetics, McGill University, Montreal
1996-	Senior Research Associate, Epidemiology Research Centre, Pavillon Hotel Dieu, Centre Hospitalier Université de Montréal (CHUM).
1996-	Project Director, Lady Davis Institute, Sir Mortimer B. Davis-Jewish General Hospital, Montreal
1996-	Assistant Physician, Montreal General Hospital
1996- Montreal	Assistant Physician, Royal Victoria Hospital,
1996-	Assistant Physician, Sir Mortimer B. Davis-Jewish General Hospital, Montreal
1998-	2002 Assistant Professor, Department of Oncology, McGill University, Montreal
2001-	Principal Investigator, Canadian Genetic Diseases Network
2001-	Director, Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University
2001-	Vice-Chair, Genetic VRC, Canadian Cancer Etiology Research Network
2002-	Associate Professor (tenure), Departments of Medicine, Human Genetics and Oncology, McGill University, Montreal

AWARDS RECEIVED

1979: Junior Scholarship in Anatomy, Physiology and Biochemistry, St Bartholomew's Hospital.

1983: Health Education Council Elective Scholarship "Diabetes in China".

1990-1994: Clinical Research Fellow Bursary, Imperial Cancer Research Fund, London.

1994-1997: Fast Foundation Award of the Montreal General Hospital Research Institute.

1997-1999: Fonds de la recherche en Santé du Québec: Chercheur-boursier clinicien. Junior 1

1997-2000: 175th Anniversary Bursary, Montreal General Hospital Research Institute.

1999-2002: Fonds de la recherche en Santé du Québec: Chercheur-boursier clinicien. Junior 2

2002-2007 : Fonds de la recherche en Santé du Québec: Chercheur-boursier clinicien. Senior

2003-2008: William Dawson Scholar, McGill University (equivalent Canada Research Chair, tier 2)

CURRENT COMPETITIVE GRANTS

Principal Investigator

Principal applicant: Foulkes, WD

CBCRA-IDEA: *BRCA1* splice variants and breast cancer risk: novel approaches using nanobiology.

(\$97,380 one year, 2006-2007)

Principal applicant: Foulkes, WD

Co-investigators: Bismar, T; Aloyz, R; Ghadirian, P

CBCRA: Toward the biological treatment of BRCA1-related breast cancer: EGF, EGFR and tyrosine kinase inhibitors

(\$413,834 over 3 years, 2006-2009)

Principal applicant: Foulkes, WD

Co-investigators: Nielsen, T; Mai, S

CBCRA: BRCA1, CDC4, Cyclin E, and chromosomal instability in breast cancer

(\$315,021 over 3 years, 2005-2008)

Co-investigator

Principal applicant: Mai, S

Co-investigators: Foulkes, WD; Watson, P

Susan G Komen Breast Cancer Foundation
The three-dimensional telomeric signature(s) of DCIS
(US \$249,000 over three years 2006-2009)

Principal applicant: Isaacs, W

Co-applicants: Foulkes, WD; Epstein, J; Partin, A; Easton, D; Eeles, R; Maehle, L; Giles, G; Hopper, J; Whittemore, AS; Halpern, J; Hsieh, CL; Cussenot, O; Cancel, G; Jarvik, G; Bdzioch, M; Stanford, J; Ostrander, E; Schaid, D; Thibodeau, S; Gronberg, H; Cooney, K; Lange, E; Schleutker, J; Vogel, W; Cannon-Albright, L; Camp, N; Jianfeng Xu, Meyers, D.
NIH (USA): *Prostate cancer susceptibility: the ICPCG study*.
(\$US 228,000 as personal award over 4 years, 2002-2006)

Principal applicant: Batista, R

Co-applicants: Foulkes, WD; Blancquaert, I; Cleret de Langavant, G; Gaudet, D; Godard, B; Laflamme, N; Marcoux, A; Rousseau, F
CIHR: *Programme de recherche en appui aux politiques de santé en génétique dans un souci de qualité, d'efficience et de bien-être social*.
(\$ 1,000,000 over 4 years, 2003-2007, no financial award to WDF)

Principal applicant: Bismar, T

Co-applicants: Foulkes, WD; Rubin, M.A
Prostate Cancer Research Foundation of Canada (PCRFC): *Defining aggressive phenotype of prostate cancer using a multiplex of 12 gene model*
(\$ 60,000 over 2 years, 2005-2007)

Principal applicant: Narod, S

Co-applicants: Foulkes WD
CBCRI(Canada): *Risk factor analysis of hereditary breast and ovarian cancer*
(\$ 1,250,000 over 5 years, 2004-2009)

CLINICAL RESEARCH FELLOWS

Pierre Chappuis MD (1998-2001)

Research: Cancer Genetics: in particular, treatment and outcome in hereditary breast cancer
Current position: Head, Hereditary cancer clinics, Divisions of Oncology and Medicine, University Hospital of Geneva, Switzerland.

Zhi Qi Yuan MD (1998-2000)

Research: Genetics of Colorectal Cancer
Current position: Instructor, Albert Einstein College of Medicine, Bronx, New York.

David Farber MD (2001-2002)

Research: Genetics of Colorectal Cancer
Current position: Staff Gastroenterologist, Cité de la Santé, Laval, Québec

John Goffin MD (2001-2002)

Research : Survival following breast cancer in *BRCA1/2* mutation carriers

Current position: Instructor, Tufts University Medical Center, Boston, MA

Rami Younan MD (2003)

Research: Genomic deletions in *MLH1* and *MSH2*

Current position: Staff surgeon, Université de Montréal

Polymnia Galiatsatos (2005)

Research: Genetics of Colorectal Cancer

Current Position: Staff gastroenterologist, SMBD-Jewish General Hospital

STUDENTS

Sophie Sun, MSc. Title: *CDKN2A/p16 and familial cancer*. FCAR scholar, 1995-1996.

Current position: Oncology Fellow, University of British Columbia.

Lucie Dupuis, MSc. Title: The incidence of cancer in the first degree relatives of women diagnosed with endometrial cancer before age 55. Genetic counselling Master's project (Brandeis University, MA, USA, 1998. *NB* Ms. Dupuis obtained permission to work with me while at Brandeis).

Current position: Genetic Counsellor, Hospital for Sick Children, Toronto, Ontario.

Isabelle Thiffault, MSc student, 2002-2004: Towards a molecular understanding of proteus syndrome.

Current Position: PhD student, Université de Montréal.

Susan McVety, MSc student, 2003- 2005: Characterisation of cDNA deletions in *MLH1* and *MSH2*.

Current Position: Laboratory Technician.

Ioli Makriyianni, MSc student, 2003-2005: Mitochondrial and somatic mutations in hereditary breast cancer.

Tayma Khalil, MSc student 2005-: *CDC4*, cyclin E and hereditary breast cancer.

McGILL UNIVERSITY SUMMER STUDENTS

(2 month projects)

Tamar Flanders 1996. Project: Familial studies of colorectal and endometrial cancer*

Kevin Sanders 1996. Project: Familial risks of Thyroid Cancer and Breast/Thyroid cancer*

Nathalie Ng Cheong 1997. Project: *PTEN* mutations in familial cancer*

Marie-Noelle Hébert-Blouin 1998. Project: *GSTT1* and risk of head and neck cancer*

Nicola Matthews 1998. Project: Lobular breast cancer and familial cancer risk*

Karen Buzaglo 2000. Project: Familial factors in fallopian tube cancer*

Maral Ouzounian 2000. Project: Germ-line mutations in hereditary breast cancer

Annick Wong 2002. Project: Claudins and cancer*

*work published as a result of their project

Ronald Lafreniere, June 17, 1997.

MSc, McGill Dept. Epidemiology and Statistics
Hela Makni, April 2000

MSc, McGill Dept. Biology
Sahar Sibani, January 2001

MSc, McGill Dept Epidemiology and Statistics
Nooshin Ahmadi Pour, January 2003

PhD, University of Toronto Faculty of Medicine
Alexander Liede, February 2003

PhD, McGill Dept. Experimental Medicine
Kevin Little, November 2004

MSc, University of Toronto, Faculty of Medicine
Sean Cleary, December 2004

INTERNATIONAL CONFERENCE ORGANISER

First International Symposium on Hereditary Breast and Ovarian Cancer, Montreal Oct 19-21, 2005. (www.odon.ca/brca/). Co-sponsored by the Program in Cancer Genetics and the Hereditary Breast and Ovarian Cancer Foundation (www.hboc.ca). Role: Scientific Director of Conference.

INTERNATIONAL COMMITTEES etc

Cancer Genetics Abstract Referee, ASHG meeting, San Francisco, CA, 1999.

Co-Chair, Breast Cancer Genetics Session, ASHG, Denver, CO, 1998.

Member, Steering Committee, International Prostate Cancer Genetics Collaborative Group (representing Eastern Canada) 1997-

Writing committee, Cancer Genetics Certification Examination, Institute for Clinical Evaluation, American Board of Internal Medicine, Philadelphia, PA 1999-2000

Scientific Organising Committee, UICC International Conference on Familial Cancer, Oklahoma City, OK, June 4-6, 2003.

NATIONAL and INTERNATIONAL PEER-REVIEW GRANT COMMITTEE etc

National Cancer Institute of Cancer, Epidemiology panel, 1997-2000

Canadian Breast Cancer Research Initiative, IDEA grant panel, 2002-2003

Canadian Institute for Health Research, Genetics Panel, 2003-

ad hoc external reviewer of grants for MRC (Canada) (6), Alberta Heritage Fund for Medical Research (1), Cancer Research Campaign (UK) (5) Research Grants Council of Hong Kong (3), Yorkshire Cancer Research (1).

Tenure review, Independent Investigator, National Human Genome Research Institute, January 2001.

Promotion review (to Assistant Professor) Memorial Sloan-Kettering Cancer Center, June 2001.

Tenure review (to Associate Professor), University of Vermont, September 2002

Tenure review (to Full Professor) Memorial Sloan-Kettering Cancer Center, January 2003

Tenure review (to Full Professor) Sloan Kettering Institute and Memorial Sloan-Kettering Cancer Center, January 2003

Promotion review (to Clinical Assistant Professor), Ohio State University, July 2003

Promotion review (to Reader), University of London, May 2004

Promotion review (to Clinical Assistant Professor), Ohio State University, August 2004

Promotion review (to Clinical Assistant Professor), Ohio State University, August 2004

Promotion review (to Clinical Associate Professor), Ohio State University, April 2005

Promotion review (to Professor), University of London, April 2005

PROVINCIAL EXPERT COMMITTEE

Member, Advisory Board, Conseil d'Évaluation des technologies de la santé du Québec, 1999-

NIH CANCER WORKSHOP

Invited attendee, NCI/NIDCFR/NIDCD Head and Neck Cancer Workshop, Bethesda, Maryland, February 21-23, 1999

VISITING LECTURESHIP

Samuel Riven Lectureship, Vanderbilt University, Tennessee, USA, September 1-3, 1999.

TEACHING

a) NATIONAL

Workshop on the Genetics of Cancer, Royal College of Physicians of Canada, Montreal, September 23, 1999.

b) MCGILL UNIVERSITY

- 1) Environmental Carcinogenesis (516-614B MSc program) 1996-1999, 2003, 2005
(One two-hour session)
- 2) Unit 8 small group teaching in medical genetics (medical students) 1997-
(One 2 hour lecture and 4 small group sessions, 3 hours each)
- 3) Genetics course (biology BSc students) 1998-1999
(Six one hour lectures and one 2 hour pre-exam session)
- 4) Unit 1 teaching (medical students) 2001-
(one two hour seminar)

- 5) Special Topics in Epidemiology and Biostatistics: Introduction to genetic epidemiology and statistical methods for human genetics (513-670A, Department of Epidemiology and Biostatistics) (2001-2, one 1 hour seminar)
- 6) ICM whole class oncology teaching: Three lectures on the prevention of Colorectal cancer (2002-2004)
- 7) Experimental and Clinical Oncology #5160635D: Cancer Genetics-1.5 hour seminar (2002-)
- 8) Inherited Cancer Syndromes, 521-690B, Department of Human Genetics: Four 2 hour lectures (2003-)

c) HOSPITAL

- 1) Genetics in Oncology Lecture (Residents) 1998-1999
(1.5 hour teaching session residents, SMBD-Jewish General Hospital)
- 2) Hereditary Breast Cancer (Surgical Residents) November 2005
(1 hour teaching session surgical residents, RVH)
- 3) Hereditary Breast Cancer (Surgical Residents) October 2006
(1 hour teaching session surgical residents, RVH)

HOSPITAL COMMITTEE

Montreal General Hospital Research Ethics Committee member, 1998-2004

PUBLICATIONS (* denotes WF corresponding author if more than one author)

a) Peer Reviewed Articles

1. Levi S, Beardshall K, Swift I, Foulkes WD, Playford R, Ghosh P and Calam, J: Antral Helicobacter pylori, hypergastrinaemia, and duodenal ulcers: effect of eradicating the organism. *Br Med J*, 299: 1504-5, 1989.
2. Campbell IG, Jones T, Foulkes WD, and Trowsdale J: Folate Binding Protein is a marker for ovarian cancer. *Cancer Res*, 51: 5529-5538, 1991.
3. Campbell IG, Freemont PS, Foulkes WD, and Trowsdale J: An ovarian tumour marker with homology to vaccinia virus contains an IgV-like region and multiple transmembrane domains. *Cancer Res*, 52: 5416-5420, 1992.
4. Foulkes WD, Campbell IG, Stamp GWH and Trowsdale J: Loss of heterozygosity and amplification of chromosome 11 in human ovarian cancer. *Br J Cancer*, 67: 268-273, 1993.
5. Foulkes WD, Ragoussis J, Stamp GWH, Allan GJ and Trowsdale J: Frequent loss of heterozygosity on chromosome 6 in human ovarian carcinoma. *Br J Cancer*, 67: 551-559, 1993.

6. Foulkes WD, Black DM, Stamp GWH, Solomon E and Trowsdale J: Very frequent loss of heterozygosity on chromosome 17 in ovarian carcinoma. *Int J Cancer*, 54: 220-225, 1993.
7. Naylor MS, Stamp GWH, Foulkes WD, Eccles DM and Balkwill FR: Tumor Necrosis Factor and its receptors in human ovarian cancer-potential role in disease progression *J Clin Invest*, 91: 2194-2206, 1993.
8. Allan GJ, Cottrell S, Trowsdale J and Foulkes WD: Loss of heterozygosity on chromosome 5 in sporadic ovarian carcinoma is a late event and is not associated with mutations in *APC* at 5q21-22. *Human Mutation*, 3: 283-291, 1994.
9. Foulkes WD, Englefield P and Campbell IG: Mutation analysis of *RASK* and the 'FLR exon' of *NF1* in sporadic ovarian carcinoma. *Eur J Cancer*, 30A: 528-530, 1994.
10. Campbell IG, Nicolai HM, Foulkes WD, Stamp GWH, Senger G, Allan GJ, Boyer CM, Jones K, Bast RC Jr, Solomon E, Trowsdale J and Black DM: A novel gene encoding a B-Box protein within the *BRCA1* region at 17q21.1. *Hum Mol Genet*, 3: 589-594, 1994.
11. Campbell IG, Foulkes WD, Senger G, Trowsdale J, Garin-Chesa P and Rettig WJ: Molecular cloning of the B-CAM cell surface glycoprotein of epithelial cancers: a novel member of the immunoglobulin super-family. *Cancer Res*, 54: 5761-5765, 1994.
12. Englefield P, Foulkes WD and Campbell IG: Loss of heterozygosity on chromosome 22q in ovarian carcinoma is distal to and is not accompanied by mutations in *NF2* at 22q12. *Br J Cancer*, 70: 905-907, 1994.
13. Foulkes WD, Stamp GWH, Afzal S, Lalani N, McFarlane C, Trowsdale J and Campbell IG: *MDM2* amplification is uncommon in ovarian carcinoma irrespective of *TP53* status. *Br J Cancer*, 72: 883-8, 1995.
14. Foulkes WD, Brunet J-S, Kowalski LP, Narod SA and Franco EL: Family history is a risk factor for squamous carcinoma of the head and neck in Brazil: a case-control study. *Int J Cancer*, 63: 769-773, 1995.
15. Campbell, Foulkes WD, Beynon G, Davis M and Englefield P: LOH and mutation analysis of *CDKN2* in primary human ovarian cancers. *Int J Cancer*, 63: 222-225, 1995.
16. Phelan CM, Lancaster JM, Tonin P, Gumbs C, Carter R, Ghadirian P, Perret C, Moslehi R, Dion F, Faucher M-C, Dole K, Karimi S, Foulkes WD, Lounis H, Warner E, Goss P, Anderson D, Larsson C, Narod SA and Futreal PA: Mutation analysis of the *BRCA2* gene in 49 site-specific breast cancer families. *Nature Genetics*, 13:121-123, 1996.
17. Afzal S, Lalani EN, Foulkes WD, Boyce B, Tickle S, Cardillo MR, Baker T, Pignatelli M and Stamp GWH: Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumour cell lines. *Laboratory Invest*, 74: 406-421, 1996.

18. Bryan EJ, Watson RH, Davis M, Hitchcock A, Foulkes WD and Campbell IG: Localization of an ovarian cancer tumor suppressor gene to a 0.5cM region between D22S284 and CYP2D, on chromosome 22q. *Cancer Res*, 56: 719-721, 1996.
19. Davis M, Hitchcock A, Foulkes WD and Campbell IG: Refinement of two chromosome 11q regions of heterozygosity in ovarian cancer. *Cancer Res*, 56: 741-744, 1996.
20. Foulkes WD, Bolduc N, Lambert D, Ginsburg O, Yandell DW, Tonin P and Narod SA: Increased incidence of cancer in first degree relatives of women with double primary carcinomas of the breast and colon. *J Med Genet*, 33: 534-539, 1996.
21. Foulkes WD, Brunet J-S, Sieh W, Shenouda G, Black MJ and Narod SA: Familial risks of squamous cell carcinoma of the head and neck. *Br Med J*, 313: 716-721, 1996.
22. Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner-Costalos J, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Krainer M, Haber DA, Struewing JP, Warner E, Rosen B, Lerman C, Peshkin B, Norton L, Serova O, Foulkes WD, Lynch HT, Lenoir GM, Narod SA and Garber JE: Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. *Nature Med*, 2:1179 -1183, 1996.
23. Milner BJ, Hosking L, Sun S, Haites NE, Foulkes WD: Polymorphisms in $P21^{CIP1/WAF1}$ are not correlated with TP53 status in sporadic ovarian tumours. *Eur J Cancer*, 32A: 2360-2363, 1996.
24. Cutler C, Foulkes WD, Brunet J-S, Flanders T, Shibata H and Narod SA: Cutaneous malignant melanoma is uncommonly associated with a family history of melanoma. *Melanoma Res*, 6: 435-440, 1996.
25. Foulkes WD, Buu PN, Filiatrault D, Leclerc J-M and Narod SA: An excess of congenital abnormalities in French-Canadian children with neuroblastoma: A case series study from Montreal. *Med Pediatr Oncol*, 29: 272-79, 1997
26. Karp SE, Tonin PN, Bégin LR, Martinez JJ, Zhang JC, Pollak MN and Foulkes WD: Influence of BRCA1 mutations on nuclear grade and estrogen receptor status on breast carcinoma in Ashkenazi Jewish women. *Cancer*, 80: 435-441, 1997.
27. Foulkes WD, Wong N, Brunet J-S, Narod SA, Bégin LR, Zhang JC, Martinez JJ, Tonin PN, Karp SE, Pollak MN. Germ-line *BRCA1* mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. *Clin Cancer Res*, 3: 2465-2470, 1997
28. Sun S, Pollock P, Liu L, Karimi S, Jothy S, Milner BJ, Renwick A, Lassam NJ, Hayward NK, Hogg D, Narod SA and Foulkes WD: *CDKN2A* mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. *Int J Cancer*, 73: 531-536, 1997.
29. Bignell GR, Canzian F, Shayeghi M, Stark M, Shugart YY, Biggs P, Mangion J, Hamoudi R, Rosenblatt J, Buu P, Sun S, Stoffer SS, Goldgar DE, Romeo G, Houlston RS, Narod SA, Stratton MR and Foulkes WD: A familial non-toxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial non-medullary thyroid cancer. *Am J Hum Genet*, 61: 1123-1130, 1997.

30. Eeles RA, Simard J, Teare D, Edwards S, Durocher F, Badzioch M, Hamoudi R, Gill S, Biggs P, Dearnaley D, Arden-Jones A, Dowe A, Shearer R, Ford D, Amos C, The CRC/BPG Familial Prostate Cancer Study Collaborators, Ghadirian P, Aprikian A, Norman R, McLellan D, Labrie F, Narod SA, Easton D and Foulkes WD: Linkage analysis of chromosome 1q markers in 136 prostate cancer families. *Am J Hum Genet*, 62: 653-658, 1998.
31. Brunet J-S, Ghadirian P, Rebbeck TR, Lerman CE, Garber JE, Tonin PN, Abrahamson J,
Foulkes WD, Daly M, Wagner-Costalas J, Godwin A, Olopade F, Moslehi R, Liede A, Futreal PA, Weber B, Lenoir GM, Lynch HT and Narod SA: The effect of smoking on breast incidence in BRCA1 and BRCA2 carriers. *J Natl Canc Inst*, 90: 761-766, 1998.
32. Pollock PM, Spurr N, Bishop DT, Newton-Bishop J, Gruis N, Goldstein AM, Tucker MA, Foulkes WD, Barnhill R, Haber D, Fountain J and Hayward NK: Haplotype analysis of 2 recurrent CDKN2A mutations in 10 melanoma families from three continents-evidence for common founders. *Hum Mutation*, 11: 424-431, 1998.
33. Godard B, Foulkes WD, Provencher D, Brunet J-S, Tonin PN, Mes-Masson, A-M, Narod SA and Ghadirian P: Risk factors for familial and sporadic ovarian cancer among French-Canadians: a case-control study. *Am J Obs Gyne*, 179: 403-410, 1998.
34. Kerr B, Foulkes WD, Cade D, Hadfield L, Hopwood P, Serruya C, Hoare F, Narod SA and Evans DG: False family history of breast cancer in the family cancer clinic. *Eur J Surg Oncol*, 24: 275-279, 1998.
35. Tonin PN, Mes-Masson A-M, Futreal PA, Morgan K, Mahon M, Foulkes WD, Cole DEC, Provencher D, Ghadirian P and Narod SA: Founder *BRCA1* and *BRCA2* mutations in French Canadian breast and ovarian cancer families. *Am J Hum Genet*, 63: 1341-1351, 1998.
36. Pal T, Flanders T, Lehman M, McMillan A, Brunet J-S, Narod SA and Foulkes, WD: Genetic implications of double primary cancers of the colorectum and endometrium *J Med Genet*, 35: 978-984, 1998.
37. de Andrade M, Amos, CI and Foulkes WD: Segregation analysis of squamous cell carcinoma of the head and neck: evidence for a major gene determining risk. *Ann Hum Genet*, 62: 505-510, 1998.
38. Wang Z-J, Churchman M, Campbell IG, Xu W-H, Yan Z-Y, McCluggage WG, Foulkes WD and Tomlinson IPM: Allele loss and mutation screen at the Peutz-Jeghers (*LKB1*) locus (19p13.3) in sporadic ovarian tumours. *Br J Cancer*, 80: 70-72, 1999.
39. Pereira P, Stanton V, Jothy S, Tomlinson IPM, Foulkes WD and Rozen R: Loss of heterozygosity of methylenetetrahydrofolate reductase in colon carcinomas. *Oncology Reports*, 6: 597-599, 1999.
40. Warner E, Foulkes WD, Goodwin P, Meschino W, Blondal J, Patterson C, Ozcelik H, Goss_P, Allingham-Hawkins D, Hamel N, Di Prospero L, Contiga V, Serruya C, Klein M, Moslehi R, Honeyford J, Liede A, Glendon G, Brunet J-S and Narod S: Prevalence and penetrance of BRCA1 and BRCA2 mutations in unselected

- Ashkenazi Jewish women with breast cancer *J Natl Cancer Inst*, 91: 1241-1247, 1999.
41. Breast Cancer Linkage Consortium: Cancer risks in *BRCA2* mutation carriers. *J. Natl Cancer Inst*, 91: 1310-1316, 1999 (WDF was one of the many who contributed data to this publication).
 42. Yuan ZQ, Bégin LR, Wong N, Brunet J-S, Trifiro M, Gordon PH, Pinsky L and Foulkes WD: The effect of the I1307K *APC* polymorphism on the clinicopathological features and natural history of breast cancer. *Br J Cancer*, 81: 850-854, 1999.
 43. Jernström H, Lerman C, Ghadirian P, Lynch H, Weber B, Garber J, Daly M, Olopade O, Foulkes WD, Warner E, Brunet J-S and Narod SA. Pregnancy increases the risk of early breast cancer in *BRCA1* and *BRCA2* carriers. *Lancet*, 354:1846-1850, 1999.
 44. Hamel N, Black MJ, Ghadirian P and Foulkes WD: No association between *p53* codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck. *Br J Cancer*, 82: 757-759, 2000.
 45. Xu JF and International Consortium for Prostate Cancer Genetics (ICPCG). Combined Analysis of Hereditary Prostate Cancer Linkage to *1q24-25*: Results from 772 Hereditary Prostate Cancer Families from the International Consortium for Prostate Cancer Genetics. *Am J Hum Genet*, 66: 945-957, 2000 (WDF is a member of the ICPCG writing committee for this paper).
 46. Foulkes WD, Chappuis PO, Wong N, Brunet J-S, Vesprini D, Rozen F, Yuan ZQ, Pollak MN, Kuperstein G, Narod SA and Bégin LR. Primary node negative breast cancer in *BRCA1* mutation carriers has a poor outcome. *Ann Oncol*, 11: 307-313, 2000.
 47. Rahman N, Arbour L, Houlston R, Bonaïti-Pellié C, Abidi F, Tranchemontagne J, Ford D, Narod SA, Pritchard-Jones K, Foulkes WD, Schwartz C and Stratton MR. Penetrance of mutations in the familial Wilms tumor gene, *FWT1*. *J Natl Cancer Inst*, 92: 650-652, 2000.
 48. Liu G, Ghadirian P, Vesprini, D, Hamel N, Paradis A-J, Lal G, Gallinger S, Narod SA and Foulkes WD. Polymorphisms in *GSTM1*, *GSTT1* and *CYP1A1* and risk of pancreatic cancer. *Br J Cancer*, 82: 1646-9, 2000.
 49. Kuperstein G, Foulkes WD, Ghadirian P, Hakimi J and Narod SA. A rapid fluorescent multiplexed-PCR analysis (FMPA) for founder mutations in the *BRCA1* and *BRCA2* genes *Clin Genet*, 57: 213-220, 2000.
 50. Rapley E, Barfoot R, Bonaiti-Pellie C, Chompret A, Foulkes WD, Perusinghe N, Reeve A, Royer-Pokora B, Schumacher V, Shelling A, Skeen J, de Tourreil S, Weirich A, Pritchard-Jones K, Stratton MR, Rahman N. Evidence for susceptibility genes to familial Wilms tumour in addition to *WT1*, *FWT1* and *FWT2*. *Br J Cancer*, 83: 177-83, 2000.
 51. Yuan ZQ, Chong GL, Thompson-May S, Trifiro M, Khandjian EW, Rousseau F, Yandell D, McNamara E, Gordon PH and Foulkes WD. Analysis of the *hMLH1* and *hMSH2* genes in three Quebec families with Hereditary Non-Polyposis Colorectal Cancer. *Ann Roy Coll Phys Surg Canada*, 33: 287-291, 2000.

52. Metcalfe K, Liede A, Hoodfar E, Scott A, Foulkes WD and Narod SA: An evaluation of needs among female *BRCA1* and *BRCA2* mutation carriers undergoing genetic counselling. *J Med Genet*, 37: 866-874, 2000.
53. Chappuis PO, Kapusta L, Bégin LR, Wong N, Brunet J-S, Narod SA, Slingerland J and Foulkes WD: Germline *BRCA1/2* mutations and p27^{Kip1} protein levels independently predict outcome after breast cancer. *J Clin Oncol*, 18: 4045-4052, 2000.
54. Thompson D, Easton D and the Breast Cancer Linkage Consortium. Variations in Cancer Risks by mutation position in *BRCA2* mutation carriers. *Am J Hum Genet*, 68: 410-9, 2001. (WDF was one of the many who contributed data to this publication).
55. Tonin PN, Perret C, Lambert J, Paradis A-J, Kantemiroff T, Benoit M-H, Martin B, Foulkes WD, Ghadirian P. Founder *BRCA1* and *BRCA2* mutations in early-onset French Canadian breast cancer cases unselected for family history *Int. J Cancer*, 95: 189-193, 2001.
56. Manning AP, Abelovich D, Ghadirian P, Lambert JA, Frappier D, Provencher D, Robidoux A, Peretz T, Narod SA, Mes-Masson A-M, Foulkes WD, Wang T, Morgan K, TM Fujiwara, Tonin PN. Haplotype analysis of *BRCA2* 8765delAG mutation carriers in French Canadian and Yemenite Jewish Hereditary Breast Cancer Families. *Human Heredity*, 52: 116-120, 2001.
57. Pal T, Hamel N, Vesprini D, Sanders K, Mitchell M, Quercia N, Ng Cheong N, Murray A, Foulkes WD and Narod SA. Double primary cancers of the breast and thyroid in women: molecular analysis and genetic implications. *Familial Cancer*, 1: 17-24, 2001.
58. Satagopan JM, Offit K, Foulkes WD, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB. The lifetime risk of breast cancer in Ashkenazi Jewish carriers of *BRCA1* and *BRCA2* mutations. *Cancer Epidemiology Biomarkers and Prevention*, 10: 467-73, 2001.
59. Greenblatt MS, Chappuis PO, Bond JP, Hamel N and Foulkes WD. TP53 mutations in *BRCA1/2*-related breast cancer: distinctive spectrum and structural distribution. *Cancer Research*, 61: 4092-97, 2001.
60. Runnebaum IB, Wang-Gohrke S, Vesprini D, Kreienberg R, Lynch H, Moslehi R, Ghadirian P, Weber B, Godwin AK, Risch H, Garber J, Lerman C, Olapade OI, Foulkes WD, Karlan B, Warner E, Rosen B, Rebbeck T, Tonin P, Dubé M-P, Kieback DG, Narod SA. Progesterone receptor variant increases ovarian cancer risk in *BRCA1* and *BRCA2* mutation carriers who were never exposed to oral contraceptives. *Pharmacogenetics*, 11: 1-4, 2001.
61. Chappuis PO, Hamel N, Paradis A-J, Deschênes J, Robidoux A, Potvin C, Cantin J, Tonin PN, Ghadirian P, Foulkes WD. Prevalence of founder *BRCA1* and *BRCA2* mutations in unselected French Canadian women with breast cancer. *Clin Genet*, 59: 418-423, 2001.
62. Bevan S, Pal T, Greenberg CR, Green H, Wixey J, Bignell G, Narod SA, Foulkes WD, Stratton MR and Houlston RS. A comprehensive analysis of MNG1, TCO1,

- fPTC, PTEN, RET, TSHR and TRKA in Familial Non-Medullary Thyroid Cancer: Confirmation of linkage to TCO1. *J Clin Endocrinol Metab*, 86: 3701-4, 2001.
63. Julian-Reynier C, Bouchard L, Evans DGR, Eisinger F, Foulkes WD, Kerr B, Blanquaert, Moatti J-P and Sobol H. Women's attitudes towards preventive strategies for Hereditary Breast/Ovarian cancer risk differ from one country to another: differences between Manchester (UK), Marseilles (F) and Montreal (Ca). *Cancer*, 92: 959-68, 2001.
 64. Elhaji YA, Gottlieb B, Lumbroso R, Beitel LK, Foulkes WD, Pinsky L and Trifiro M. The Polymorphic CAG Repeat of the Androgen Receptor Gene: A Potential Role in Breast Cancer in Women over 40. *Breast Cancer Research and Treatment*, 70:109-16, 2001.
 65. Pal T, Vogl FD, Chappuis PO, Tsang R, Brierley J, Renard H, Sanders K, Kantemiroff T, Bagha S, Goldgar DE, Narod SA and Foulkes WD. Increased risk for non-medullary thyroid cancer (NMTC) in the first-degree relatives of prevalent cases of NMTC: a hospital-based study. *J Clin Endocrinol Metab*, 86: 5307-12, 2001
 66. Jefferies S, Edwards SM, Hamoudi R, A'Hern R, Foulkes WD, Goldgar D, MPT collaborators and Eeles R. No germline mutations in CDKN2A (p16) in patients with squamous cell cancer of the head and neck and second primary tumours. *Br J Cancer*, 85: 1383-6, 2001.
 67. Yuan ZQ, Gottlieb B, Beitel LK, Wong N, Gordon PH, Wang Q, Puisieux, A, Foulkes WD and Trifiro M. Polymorphisms and HNPCC: PMS2-MLH1 protein interactions diminished by 'single nucleotide polymorphisms'. *Human Mutation*, 19: 108-13, 2002.
 68. Ghadirian P, Liu G, Gallinger S, Schmocker B, Paradis A-J, Lal G, Brunet J-S, Foulkes WD and Narod SA. Family history is a risk factor for pancreatic cancer. *Int J Cancer*, 97: 807-810, 2002.
 69. Moustafa A-E, Alaoui-Jamali MA, Batist G, Hernadez-Perez M, Serruya C, Alpert L, Black MJ, Sladek R and Foulkes WD. Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched normal and squamous cell carcinoma cells. *Oncogene*, 21: 2634-2640, 2002.
 70. Hutter P, Wijnen J, Rey-Berthod C, Thiffault I, Verkuijlen P, Farber D, Hamel N, Bapat B, Thibodeau SN, Burn J, Wu J, MacNamara E, Heinimann K, Chong G and Foulkes WD. An MLH1 haplotype is over-represented on chromosomes carrying an HNPCC predisposing mutation in MLH1. *J Med Genet*, 39: 323-327, 2002.
 71. Laazari K, Sutton M, Ghadirian P, Scott A, Paradis A-J, Tonin PN and Foulkes WD. Is there are correlation between the structure of hair and breast cancer or BRCA1/2 mutations? *Phys Med Biol*, 47: 1623-1632, 2002.
 72. Foulkes WD, Thiffault I, Gruber SB, Horwitz M, Hamel N, Lee C, Shia J, Markowitz A, Figer A, Friedman E, Farber D, Greenwood CMT, Bonner JD, Walsh T, Marcus V, Tomsho L, Nafa K, Gebert J, Bressac-de Paillerets B, Gregersen PK, Weitzel J, Macrae FA, Gaff CL, Gordon PH, MacNamara E, King M-C, Hampel H, de la Chapelle A, Boyd J, Offit K, Rennert G, Chong G and Ellis NA. The founder mutation MSH2*1906G>C is an important cause of Hereditary Non-Polyposis

- Colorectal Cancer in the Ashkenazi Jewish population. *Am J Hum Genet*, 71: 1395-1412, 2002.
73. Straume O, Chappuis PO, Salvesen HB, Halvorsen OJ, Goffin J, Bégin LR, Foulkes WD, Akslen LA. Prognostic importance of Glomeruloid Microvascular Proliferation indicates an aggressive angiogenic phenotype in human cancers. *Cancer Res*, 62: 6308-6811, 2002.
 74. Narod SA, Dubé M-P, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Isaacs C, Weber B, Friedman E, Gershoni-Baruch R, Rennert G, Pasini B, Wagner T, Daly M, Garber JE, Neuhausen S, Robson ME, Offit K, Ainsworth P, Olsson H, Evans DGR, Osborne M, Couch F, Foulkes WD, Warner E, Kim-Sing C, Olopade O, Tung N, Saal HM, Weitzel J, Merajver S, Gauthier-Villars M, Jernstrom H, Sun P, Brunet J-S. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 carriers. *J Natl Cancer Inst*, 94: 1773-1779, 2002.
 75. Karakiewicz PI, Foulkes WD, Tanguay S, Elhilali MM, Aprikian AG. Familial prostate and breast cancer in men treated with prostatectomy for prostate cancer: a population based case-control study. *J Urol*, 169: 240-4, 2003.
 76. Goffin JR, Chappuis PO, Bégin LR, Wong N, Brunet J-S, Hamel N, Paradis A-J, Boyd J, Foulkes WD. The impact of germ-line BRCA1 mutations and over-expression of p53 on prognosis and response to treatment following breast cancer: 10 year follow up data. *Cancer*, 97: 527-536, 2003.
 77. Guillem JG, Rapaport BS, Kirchoff T, Kolchana P, Nafa K, Glogowski E, Finch R, Huang H, Foulkes WD, Markowitz A, Ellis NA and Offit K. A636P is associated with early-onset colorectal cancer in Ashkenazi Jews. *J Am Coll Surg*, 196:222-225, 2003.
 78. Goffin JR, Straume O, Chappuis PO, Brunet J-S, Bégin LR, Hamel N, Wong N, Akslen LA and Foulkes WD. Glomeruloid Microvascular Proliferation is associated with p53 overexpression, germ-line BRCA1 mutations and an adverse outcome following breast cancer *Br J Cancer*, 89: 1031-1034, 2003.
 79. Foulkes WD, Metcalfe K, Hanna W, Lynch HT, Ghadirian P, Tung N, Olopade O, Weber B, McLennan J, Olivotto IA, Sun P, Chappuis PO, Bégin LR, Brunet J-S and Narod SA. Disruption of the expected positive correlation between tumor size and nodal status in BRCA1-related breast cancer. *Cancer*, 98: 1569-1577, 2003.
 80. Foulkes WD, Stefansson IM, Chappuis, PO Bégin LR, Goffin JR, Wong N, Trudel M and Akslen LA. Germ-line BRCA1 mutations and the basal epithelial phenotype of breast cancer. *J Natl Cancer Inst*, 95: 1482-1485, 2003.
 81. Pollak MN, Foulkes WD. Challenges to cancer control by screening. *Nat Rev Cancer*, 3: 297-303, 2003.
 82. Halford SE, Sawyer EJ, Lambros MB, Gorman P, Macdonald ND, Talbot IC, Foulkes WD, Gillett CE, Barnes DM, Akslen LA, Lee K, Jacobs IJ, Hanby AM, Ganesan TS, Salvesen HB, Bodmer WF, Tomlinson IP, Roylance RR. MSI-low, a real phenomenon which varies in frequency among cancer types. *J Pathol*, 201: 389-394, 2003.

83. Matakidou A, Hamel N, Polpat S, Henderson K, Kantemiroff T, Harmer C, Clarke SE, Houlston RS, and Foulkes WD. Risk of non-medullary thyroid cancer influenced by polymorphic variation in the thyroglobulin gene. *Carcinogenesis*, 25: 369-73, 2004.
84. Edwards S, Meitz J, Eles R, Evans C, Easton D, Hopper J, Giles G, Foulkes WD, Narod S, Simard J, Badzioch M, Mahle L; International ACTANE Consortium. Results of a genome-wide linkage analysis in prostate cancer families ascertained through the ACTANE consortium. *Prostate*, 57: 270-9, 2003.
85. Hashibe M, Brennan P, Strange RC, Bhisey R, Cascorbi I, Lazarus P, Oude Ophuis MB, Benhamou S, Foulkes WD, Katoh T, Coutelle C, Romkes M, Gaspari L, Taioli E and Boffeta P. Meta and pooled analyses of GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes and risk of head and neck cancer. *Cancer Epidemiol Biomarkers Prev*, 12: 1509-17, 2003.
86. Thiffault I, Hamel N, Pal T, McVety S, Marcus VA, Farber D, Cowie S, Deschenes J, Meschino W, Odefrey F, Goldgar D, Graham T, Narod S, Watters AK, MacNamara E, Sart DD, Chong G, Foulkes WD. Germline truncating mutations in both MSH2 and BRCA2 in a single kindred. *Br J Cancer*, 90: 483-491, 2004.
87. Foulkes WD. BRCA1 functions as a breast stem cell regulator. *J Med Genet*, 41: 1-5, 2004.
88. Al Moustafa AE, Foulkes WD, Benlimame N, Wong A, Yen L, Bergeron J, Batist G, Alpert L, Alaoui-Jamali MA. E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells. *Oncogene*, 23: 350-8, 2004.
89. Bouchard L, Blancquaert I, Eisinger F, Foulkes WD, Evans G, Sobol H, Julian-Reynier C. Prevention and genetic testing for breast cancer: variations in medical decisions. *Soc Sci Med*, 58: 1085-96, 2004.
90. Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C, Roberge D, Norton L, Begin LR, Offit K, Foulkes WD. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. *Breast Cancer Res*, 6: R8-R17, 2004.
91. Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Begin LR, Hamel N, Goffin JR, Wong N, Trudel M, Kapusta L, Porter P, Akslen LA. The Prognostic Implication of the Basal-Like (Cyclin high/p27low/p53+/Glomeruloid-Microvascular-Proliferation+) Phenotype of BRCA1-Related Breast Cancer *Cancer Res*, 64: 830-835, 2004.
92. Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, Tung N, Olopade OI, Weber BL, McLennan J, Olivotto IA, Begin LR, Narod SA. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. *Clin Cancer Res*, 10: 2029-34, 2004.
93. Ghadirian P, Lubinski J, Lynch H, Neuhausen SL, Weber B, Isaacs C, Baruch RG, Randall S, Ainsworth P, Freidman E, Horsman D, Tonin P, Foulkes WD, Tung N,

- Sun P, Narod SA. Smoking and the risk of breast cancer among carriers of BRCA mutations. *Int J Cancer*, 110: 413-6, 2004.
94. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, Olopade OI, Eisen A, Weber B, McLennan J, Sun P, Foulkes WD, Narod SA. Contralateral breast cancer in *BRCA1* and *BRCA2* mutation carriers. *J Clin Oncol*, 22: 2328-35, 2004.
95. Al Moustafa AE, Foulkes WD, Wong A, Jallal H, Batist G, Yu Q, Herlyn M, Sicinski P, Alaoui-Jamali MA. Cyclin D1 is essential for neoplastic transformation induced by both E6/E7 and E6/E7/ErbB-2 cooperation in normal cells. *Oncogene*, 23: 5252-6, 2004.
96. Thiffault I, Foulkes WD, Marcus VA, Farber D, Kasprzak L, MacNamara E, Wong N, Hutter P, Radice P, Bertario L, Chong G. Putative common origin of two MLH1 mutations in Italian-Quebec hereditary non-polyposis colorectal cancer families. *Clin Genet*, 66: 137-43, 2004.
97. Jernstrom H, Lubinski J, Lynch HT, Ghadirian P, Neuhausen S, Isaacs C, Weber BL, Horsman D, Rosen B, Foulkes WD, Friedman E, Gershoni-Baruch R, Ainsworth P, Daly M, Garber J, Olsson H, Sun P, Narod SA. Breast-feeding and the risk of breast cancer in *BRCA1* and *BRCA2* mutation carriers. *J Natl Cancer Inst*, 96: 1094-8, 2004.
98. Brooks-Wilson AR, Kaurah P, Suriano G, Leach S, Senz J, Grehan N, Butterfield YS, Jeyes J, Schinas J, Bacani J, Kelsey M, Ferreira P, MacGillivray B, MacLeod P, Micek M, Ford J, Foulkes WD, Australie K, Greenberg C, LaPointe M, Gilpin C, Nikkel S, Gilchrist D, Hughes R, Jackson CE, Monaghan KG, Oliveira MJ, Seruca R, Gallinger S, Caldas C, Huntsman D. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. *J Med Genet*, 41: 508-17, 2004.
99. Kotar K, Brunet JS, Moller P, Hugel L, Warner E, McLaughlin J, Wong N, Narod SA, Foulkes WD. Ratio of female to male offspring of women tested for *BRCA1* and *BRCA2* mutations. *J Med Genet*, 41: e103, 2004.
100. Thiffault I, Schwartz CE, Der Kaloustian V, Foulkes WD. Mutation analysis of the tumor suppressor PTEN and the glypican 3 (GPC3) gene in patients diagnosed with Proteus syndrome. *Am J Med Genet*, 1: 123-7, 2004.
101. Oros KK, Ghadirian P, Greenwood CM, Perret C, Shen Z, Paredes Y, Arcand SL, Mes-Masson AM, Narod SA, Foulkes WD, Provencher D, Tonin PN. Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 *BRCA1* and *BRCA2* mutations. *Int J Cancer*, 112: 411-9, 2004.
102. Hope Q, Bullock S, Evans C, Meitz J, Hamel N, Edwards SM, Severi G, Dearnley D, Jhavar S, Southgate C, Falconer A, Dowe A, Muir K, Houlston RS, Engert JC, Roquis D, Sinnett D, Simard J, Heimdal K, Møller P, Maehle L, Badzioch M, The Cancer Research UK/British Association of Urological Surgeons' Section of Oncology Collaborators, Eeles RA, Easton DF, English DR, Southey M, Hopper JL, Foulkes WD, Giles GG. Macrophage Scavenger Receptor 1 (MSR1) 999C>T (R293X) mutation and risk of prostate cancer. *Cancer Epidemiol Biomark Prevent*, 14: 397-402, 2005 (WDF is corresponding author).

103. Metcalfe KA, Lynch HT, Ghadirian P, Tung N, Olivotto IA, Foulkes WD, Warner E, Olopade O, Eisen A, Weber B, McClellan J, Sun P, Narod SA. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. *Obstet Gynecol Sur*, 60 (4): 235-6, 2005.
104. Metcalfe KA, Lynch HT, Ghadirian P, Tung N, Olivotto IA, Foulkes WD, Warner E, Olopade O, Eisen A, Weber B, McClellan J, Sun P, Narod SA. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers corresponding. *Gynecol Oncol*, 96 (1): 222-6, 2005.
105. Chappuis PO, Donato E, Goffin JR, Wong N, Begin LR, Kapusta LR, Brunet JS, Porter P, Foulkes WD. Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. *Ann Oncol*, 16 (5): 735-742, 2005.
106. Collett K, Stefansson IM, Eide J, Braaten A, Wang H, Eide GE, Thoresen SO, Foulkes WD, Akslen LA. A Basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. *Cancer Epidemiol Biomarkers Prev*, 14 (5): 1108-12, 2005.
107. Makriyianni I, Hamel N, Ward S, Foulkes WD, Graw S. BRCA1:185delAG found in the San Luis Valley probably originated in a Jewish founder. *J Med Genet*, 42 (5): e27, 2005 (WDF is corresponding author).
108. Arnes JB, Brunet JS, Stefansson I, Begin LR, Wong N, Chappuis PO, Akslen LA, Foulkes WD. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. *Clin Cancer Res*, 11(11): 4003-11, 2005.
109. Weitzel JN, Robson M, Pasini B, Manoukian S, Stoppa-Lyonnet D, Lynch HT, McClellan J, Foulkes WD, Wagner T, Tung N, Ghadirian P, Olopade O, Isaacs C, Kim-Sing C, Moller P, Neuhausen SL, Metcalfe K, Sun P, Narod SA. A comparison of bilateral breast cancers in BRCA carriers. *Cancer Epidemiol Biomarkers Prev*, 14 (6): 1534-8, 2005.
110. Zauber NP, Sabbath-Solitare M, Marotta S, Zauber AG, Foulkes WD, Chan M, Turner F, Bishop DT. Clinical and genetic findings in an Ashkenazi Jewish population with colorectal neoplasms. *Cancer*, 15: 104 (4): 719-29, 2005.
111. Xu J, Dimitrov L, Chang BL, Adams TS, Turner AR, Meyers DA, Eeles RA, Easton DF, Foulkes WD, Simard J, Giles GG, Hopper JL, Mahle L, Moller P, Bishop T, Evans C, Edwards S, Meitz J, Bullock S, Hope Q, Hsieh CL, Halpern J, Balise RN, Oakley-Girvan I, Whittemore AS, Ewing CM, Gielzak M, Isaacs SD, Walsh PC, Wiley KE, Isaacs WB, Thibodeau SN, McDonnell SK, Cunningham JM, Zarfes KE, Hebbiring S, Schaid DJ, Friedrichsen DM, Deutsch K, Kolb S, Badzioch M, Jarvik GP, Janer M, Hood L, Ostrander EA, Stanford JL, Lange EM, Beebe-Dimmer JL, Mohai CE, Cooney KA, Ikonen T, Baffoe-Bonnie A, Fredriksson H, Matikainen MP, Tammela TLj, Bailey-Wilson J, Schleutker J, Maier C, Herkommer K, Hoegel JJ, Vogel W, Paiss T, Wiklund F, Emanuelsson M, Stenman E, Jonsson BA, Gronberg H, Camp NJ, Farnham J, Cannon-Albright LA, Seminara D; ACTANE Consortium. A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. *Am J Hum Genet*, 77 (2): 219-29, 2005.
112. Kotsopoulos J, Lubinski J, Lynch HT, Neuhausen SL, Ghadirian P, Isaacs C, Weber B, Kim-Sing C, Foulkes WD, Gershoni-Baruch R, Ainsworth P, Friedman E, Daly M, Garber JE, Karlan B, Olopade OI, Tung N, Saal HM, Eisen A, Osborne M, Olsson H, Gilchrist D, Sun P, Narod SA. Age at menarche and the risk of breast

- cancer in BRCA1 and BRCA2 mutation carriers. *Cancer Causes Control*, 16 (6): 667-674, 2005.
113. McVety S, Younan R, Li L, Gordon PH, Wong N, Foulkes WD, Chong G. Novel genomic insertion-- deletion in MLH1: possible mechanistic role for non-homologous end-joining DNA repair. *Clin Genet*, 68 (3): 234-238, 2005.
 114. Kotsopoulos J, Olopado OI, Ghadirian P, Lubinski J, Lynch HT, Isaacs C, Weber B, Kim-Sing C, Ainsworth P, Foulkes WD, Eisen A, Sun P, Narod SA. Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res*, 7 (5): R833-R843, 2005.
 115. Sun S, Greenwood CM, Thiffault I, Hamel N, Chong G, Foulkes WD. The HNPCC associated MSH2*1906G-->C founder mutation probably originated between 1440 CE and 1715 CE in the Ashkenazi Jewish population. *J Med Genet*, 42 (10): 766-768, 2005.
 116. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, rebbeck T, Neuhausen SL, Ghadirian P, Foulkes WD, Gershoni-Baruch R, Friedman E, Rennert G, Wagner T, Isaacs C, Kim-Sing C, Ainsworth P, Sun P, Narod SA. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. *J Clin Oncol*, 23 (30): 7491-6, 2005.
 117. Cullinane CA, Lubinski J, Neuhausen SL, Ghadirian P, Lynch HT, Isaacs C, Weber B, Moller P, Offit K, Kim-Sing C, Friedman E, Randall S, Pasini B, Ainsworth P, Gershoni-Baruch R, Foulkes WD, Klijn J, Tung N, Rennert G, Olopade O, Couch F, Wagner T, Olsson H, Sun P, Weitzel JN, Narod SA. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. *Int J Cancer*, 117 (6): 988-91, 2005.
 118. Honrado E, Osorio A, Palacios J, Milne RL, Sanchez L, Diez O, Cazorla A, Syrjakoski K, Huntsman D, Heikkila P, Lerma E, Kallioniemi A, Rivas C, Foulkes WD, Nevanlinna H, Benitez J. Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. *J Clin Oncol*, 23 (30): 7503-11, 2005.
 119. van der Klift H, Wijnen J, Wagner A, Verkuilen P, Tops C, Otway R, Kohonen-Corish M, Vasen H, Oliani C, Barana D, Moller P, Delozier-Blanchet C, Hutter P, Foulkes WD, Lynch H, Burn J, Moslein G, Fodde R. Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC). *Genes Chromosomes Cancer*, 44 (2): 123-38, 2005.
 120. Soravia C, Delozier CD, Dobbie Z, Berthod CR, Arrigoni E, Brundler MA, Blouin JL, Foulkes WD, Hutter P. Double frameshift mutations in APC and MSH2 in the same individual. *Int J Colorectal Dis*, 21 (1): 79-83, 2006.
 121. Barker KT, Foulkes WD, Schwartz CE, Labadie C, Monsell F, Houlston RS, Harper J. Is the E133K allele of VG5Q associated with Klippel-Trenaunay and other overgrowth syndromes? *J Med Genet*, 2006 Jan 27; [Epub ahead of print]
 122. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. *Am J Gastroenterol*, 101 (2): 385-98, 2006.
 123. Nkondjock A, Ghadirian P, Kotsopoulos J, Lubinski J, Lynch H, Kim-Sing C, Horsman D, Rosen B, Isaacs C, Weber B, Foulkes WD, Ainsworth P, Tung N, Eisen A, Friedman E, Eng C, Sun P, Narod SA. Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. *Int J Cancer*, 118 (1): 103-7, 2006.

124. McVety S, Li L, Gordon PH, Chong G, Foulkes WD. Disruption of an exon splicing enhancer in exon 3 of MLH1 is the cause of HNPCC in a Quebec family. *J Med Genet*, 43 (2): 153-6, 2006.
125. Minoo P, Baker K, Goswami R, Chong G, Foulkes WD, Ruskiewicz A, Barker M, Buchanan D, Young J, Jass JR. Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. *Gut*. 2006 Feb 9; [Epub ahead of print]
126. Rudkin TM, Hamel N, Galvez M, Hogervorst F, Gille JJ, Moller P, Apold J, Foulkes WD. The frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populations. *BMC Med Genet*. 2006 Mar 1; 7 (1): 15 [Epub ahead of print]
127. McVety S, Li L, Thiffault I, Gordon P.H, MacNamara E, Wong N, Australie K, Kasprzak L, Chong G, Foulkes WD. The value of multi-modal gene screening in HNPCC in Quebec: three mutations in mismatch repair genes that would have not been correctly identified by genomic DNA sequencing alone. *Familial Cancer*, 5: 21-8, 2006.
128. Oros KK, Leblanc G, Arcand SL, Shen Z, Perret C, Mes-Masson A-M, Foulkes WD, Ghadiran P, Provencher D, Tonin PN. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families. *BMC Medical Genetics*, 7: 23, 2006
129. Li L, McVety S, Younan R, Du Sart D, Gordon PH, Hutter P, Hogervost FBL, Liang P, Chong G, Foulkes WD. Distinct patterns of Germ-Line Deletions in *MLH1* and *MLH2* : the Implication of Alu Repetitive Element in the genetic etiology of Lynch Syndrome (HNPCC). *Hum Mutations*, 27 (4): 388, 2006.
130. Friedman E, Kotsopoulos J, Lubinski J, Lynch HT, Ghadirian P, Neuhausen SL, Isaacs C, Weber B, Foulkes WD, Moller P, Rosen B, Kim-Sing C, Gershoni-Baruch R, Ainsworth P, Daly M, Tung N, Eisen A, Olopade OI, Karlan B, Saal HM, Garber JE, Rennert G, Gilchrist D, Eng C, Offit K, Osborne M, Sun P, Narod SA; the Hereditary Breast Cancer Clinical Study Group. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. *Breast Cancer Res*, 2006 Mar 21;8(2):R15 [Epub ahead of print]
131. Morel CF, Thomas MA, Cao H, O'Neil CH, Pickering JG, Foulkes WD, Hegele RA. A *LMNA* splicing mutation in two sisters with severe Dunnigan-type familial partial lipodystrophy (FPLD2). *J.Clin.Endocrinol.Metab*. 2006 April 24 [Epub ahead of print]
132. Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M, Kim-Sing C, Olsson H, Ainsworth P, Eisen A, Saal H, Friedman E, Olopade O, Osborne M, Weitzel J, Lynch H, Ghadirian P, Lubinski J, Sun P, Narod SA. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. *Int J Cancer*, 118 (9); 2281-4, 2006.
133. Narod SA, Lubinski J, Ghadirian P, Lynch HT, Moller P, Foulkes WD, Rosen B, Kim-Sing C, Isaacs C, Domcheck S, Sun P; for the Hereditary Breast Cancer Clinical Study Group. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case control study. *Lancet Oncol*, 7(5): 402-406, 2006.
134. Tischkowitz MD, Foulkes WD. The basal phenotype of BRCA1-Related Breast Cancer: Past, Present and Future. *Cell Cycle*, 5 (9): 963-7, 2006.
135. Goswami RS, Minoo P, Baker K, Chong G, Foulkes WD, Jass JR. Hyperplastic polyposis and cancer of the colon with gastrinoma of the duodenum. *Nat Clin Pract Oncol*, 3 (5): 281-4, 2006.

136. Galiatsatos P, Kasprzak L, Chong G, Jass JR, Foulkes WD. Multiple primary malignancies in a patient with situs ambiguous. *Clin Genet*, 69 (6): 528-531, 2006.
137. Foulkes WD. BRCA1 and BRCA2: Chemosensitivity, Treatment Outcomes and Prognosis. *Fam Cancer*, 5 (2): 135-142, 2006.
138. Shinto E, Baker K, Tsuda H, Mochizuki H, Ueno H, Matsubara O, Foulkes WD, Jass JR. Tumor Buds Show Reduced Expression of Laminin-5 gamma 2 Chain in DNA Mismatch Repair Deficient Colorectal Cancer. *Dis. Colon and Rectum*. 2006 June 15 [Epub ahead of print]
139. Tischkowitz M, Gologan A, Srolovitz H, Khanna M, Foulkes WD. Muir Torre syndrome and MSH2 mutations: the importance of dermatological awareness. *Br J Cancer*. 2006 Jun 20 [Epub ahead of print]
140. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA, Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube and peritoneal cancers in women with BRCA1 or BRCA2 mutation. *JAMA*, 296 (2): 185-192, 2006.
141. Baker K, Chong G, Foulkes WD, Jass JR. Transforming growth factor-pathway disruption and infiltration of colorectal cancers by intraepithelial lymphocytes. *Histopathology*, 49(4): 371-380, 2006.
142. Oros, KK, Ghadirian P, Maugard CM, Perret C, Paredes Y, Mes-Masson AM, Foulkes WD, Provencher D, Tonin P. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent. *Clin Genet*, 70(4):320-329, 2006.
143. Schaid DJ, McDonnell SK, Zarfes KE, Cunningham JM, Hebring S, Thibodeau SN, Eeles RA, Easton DF, Foulkes WD, Simard J, Giles GG, Hopper JL, Mahle L, Moller P, Badzioch M, Bishop DT, Evans C, Edwards S, Meitz J, Bullock S, Hope Q, Guy M, Hsieh C-L, Halpern J, Balise RR, Oakley-Girvan I, Whittemore AS, Xu J, Dimitrov L, Chang B-L, Adams TS, Turner AR, Meyers DA, Friedrichsen DM, Deutsch K, Kolb S, Janer M, Hood L, Ostrander EA, Stanford JL, Ewing CM, Gielzak M, Isaacs SD, Walsh PC, Wiley KE, Isaacs WB, Lange EM, Ho LA, Beebe-Dimmer JL, Wood DP, Cooney KA, Seminara D, Ikonen T, Baffoe-Bonnie A, Fredriksson H, Matikainen MP, Tammela T LJ, Bailey-Wilson J, Schleutker J, Maier C, Herkommer K, Hoegel JJ, Vogel W, Paiss T, Wiklund F, Emanuelsson M, Stenman E, Jonsson B-A, Grönberg H, Camp NJ, Farnham J, Cannon-Albright LA, Catalona WJ, Suarez BK, Roehl KA. Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. *Human Genetics*. Aug 25 2006 [Epub ahead of print].
144. Kotsopoulos J, Lubinski J, Lynch H.T, Klijn J, Ghadirian P, Neuhausen SL, Kim-Sing C, Foulkes WD, Moller P, Isaacs C, Domchek S, Randall S, Offit K, Tung N, Ainsworth P, Gershoni-Baruch R, Eisen A, Daly M, Karlan B, Saal HM, Couch F, Pasini B, Wagner T, Friedman E, Rennert G, Eng C, Weitzel J, Sun P, Narod SA, Hereditary Breast Cancer Clinical Study Group. Age at first birth and the risk of

breast cancer in *BRCA1* and *BRCA2* mutation carriers. *Breast Cancer Res.*
Submitted, 2006

b) Peer-reviewed brief communications/correspondence (* corresponding author)

1. Hosking L, Trowsdale J, Nicolai H, Solomon E, Foulkes W, Stamp, G, Signer, E and Jeffreys A: A somatic *BRCA1* mutation in an ovarian tumour. *Nature Genetics* **9**:343-344, 1995.
- 2*. Redston M, Nathanson KC, Yuan ZQ, Neuhausen SL, Satagopan J, Wong N, Abrahamson J, Yang D, Nafa D, Antin-Ozerkis D, Ozcelik H, Andrulis I, Daly M, Pinsky L, Schrag D, Gallinger S, Kaback M, King M-C, Woodage T, Brody LC, Godwin A, Warner E, Weber B, Foulkes W and Offit K: The *APC* I1307K allele and breast cancer risk. *Nature Genetics* **20**: 13-14, 1998.
- 3*. Yuan ZQ, Wong N, Foulkes WD, Trifiro M, Alpert L, Manganaro F, Andreutti-Zaugg C, Iggo R, Pinsky L, Gordon P and Lasko D: A missense mutation in both *hMSH2* and *APC* in an HNPCC kindred: implications for clinical screening. *J Med Genet* **36**: 790-792, 1999.
- 4*. Hamel N, Manning A, Black MJ, Tonin PN and Foulkes WD: An absence of founder *BRCA2* mutations in individuals with squamous cell carcinoma of the head and neck. *Int J Cancer (Pred. Oncol)* **83**: 803-804, 1999.
- 5*. Foulkes WD, Brunet J-S, Warner E, Goodwin P, Meschino W, Narod SA, Goss PE and Glendon G. The importance of a family history of breast cancer in predicting the presence of a *BRCA* mutation. *Am J Hum Genet* **65**: 1776-1779, 1999.
- 6*. Hamel N, Karimi S, Brunet J-S, Gilfix B, Ghadirian P, Black MJ, Narod SA and Foulkes WD: Increased risk of head and neck cancer in association with *GSTT1* nullizygosity for individuals with low exposure to tobacco. *Int J Cancer* **87**: 452-454, 2000.
7. Badzioch, M, Eeles R, Leblanc G, Foulkes WD, Giles G, Edwards S, Goldgar DE, Hopper J, Bishop DT, Moller P, Heimdal K, Easton D, the CRC/BPG UK Familial Prostate Cancer Study Group, the EU Biomed Collaborators and Simard J. Suggestive evidence for a site-specific prostate cancer gene on chromosome 1p36. *J Med Genet* **37**: 947-949, 2000.
- 8*. Kasprzak L, Nolet S, Gaboury L, Pavia C, Villabona C, Rivera-Fillat F, Oriola J, Foulkes WD. Familial medullary thyroid carcinoma and prominent corneal nerves associated with the germline V804M and V778I mutations on the same allele of *RET*. *J Med Genet* **38**: 784-787, 2001.
9. Foulkes WD, Brunet J-S, Wong N, Goffin J and Chappuis PO. Change in the penetrance of founder *BRCA1/2* mutations? A retrospective cohort study. *J Med Genet* **39**: 407-409, 2002.
- 10*. Chappuis PO, Goffin J, Perret C, Wong N, Ghadirian P, Tonin PN and Foulkes WD. A significant response to neoadjuvant chemotherapy in *BRCA1/2*-related breast cancer. *J Med Genet* **39**: 608-610, 2002.

11. Maillet P, Bonnefoi H, Vaudan-Vutskits G, Pajk B, Cufer T, Foulkes WD, Chappuis PO and Sappino A-P. Constitutional Alterations of the ATM gene in early-onset sporadic breast cancer. *J Med Genet* **39**: 751-753, 2002.
- 12*. Kotar K, Hamel N, Thiffault I, Foulkes WD. The RNASEL 471delAAAG allele and prostate cancer in Ashkenazi Jewish men. *J Med Genet* **40**: e22, 2003.
13. Hamel N, Kotar K, Foulkes WD. Founder mutations in *BRCA1/2* are not frequent in Canadian Ashkenazi Jewish men with prostate cancer. *BMC Med Genet* **4**: 7, 2003.
14. Galiatsatos P, Kasprzak L, Chong G, Jass JR, Foulkes WD. Multiple primary malignancies in a patient with situs ambiguous. *Clin Genet*, 69 (6): 528-531, 2006.

c) Peer reviewed[#] and non-peer reviewed book chapters and reviews

- 1*. Foulkes W, Stamp G and Trowsdale J: *The molecular genetics of ovarian cancer*. In: Ovarian cancer 2, eds. Sharp, F., Mason, W. P. and Creasman, W.T. pp. 23-33. Chapman and Hall, London, 1992.
2. Campbell IG, Foulkes W, Jones T and Trowsdale J: *Cloning of genes encoding ovarian carcinoma-specific antigens*. In: Ovarian cancer 2, eds. Sharp, F., Mason, W.P. and Creasman, W. T. pp. 73-86. Chapman and Hall, London, 1992.
3. Naylor MS, Stamp GW, Foulkes W, Eccles D and Balkwill F: *Tumor necrosis factor: a role in ovarian cancer?* In: Tumor necrosis factor: molecular and cellular biology and clinical relevance, eds. Fiers W, Buurman WA. Pp.199-202. Karger, Basel, 1993.
- 4*. Foulkes WD and Trowsdale J: *Isolating tumour suppressor genes relevant to ovarian carcinoma-the role of loss of heterozygosity*. In: Ovarian Cancer 3, eds, Sharp, F., Mason WP, Berek J and Blackett AD. Pp. 23-38. Chapman and Hall, London, 1995.
5. Campbell IG, Foulkes W, Jones TA, Poels LG and Trowsdale J: *Cloning and molecular characterisation of monoclonal antibody-defined ovarian tumour antigens*. In: Ovarian Cancer 3, eds, Sharp F, Mason WP, Berek J and Blackett AD. Pp. 53-59. Chapman and Hall, London, 1995.
- 6*[#]. Foulkes WD and Narod SA: Hereditary breast and ovarian cancer. *Clin Invest Med* **18**: 473-484, 1995
7. Foulkes WD: A tale of four syndromes: familial adenomatous polyposis, Gardner syndrome, attenuated APC and Turcot syndrome. *Q J M* **88**: 853-863, 1995
- 8*. Foulkes WD and Narod SA: Screening for cancer in high risk populations. In: *Cancer screening*, ed. Miller AB, Kluwer Academic, Boston, 1996, pp165-182.
- 9*[#]. Flanders T and Foulkes WD: Pancreatic adenocarcinoma: epidemiology and genetics. *J Med Genet* **33**:889-898, 1996
- 10[#]. Foulkes WD: Inherited susceptibility to squamous cell carcinoma of the head and neck. *Ann Cancer Control Res* **7**: 492-498, 1997.
- 11*[#]. Foulkes WD, Flanders TY, Pollock PM and Hayward NK: *CDKN2A* and cancer. *Molecular Med* **3**: 4-19, 1997.
12. Foulkes WD. *BRCA1* and *BRCA2*: penetrating the clinical arena. *Lancet*, **352**: 1325-1326, 1998.

- 13*. Flanders TY and Foulkes WD: Cancers of the digestive system. In: *Inherited susceptibility to cancer: clinical, predictive and ethical perspectives*. Foulkes WD and SV Hodgson (eds). Cambridge University Press, 1998.
- 14*. Foulkes WD and Narod SA: Cancers of the breast, ovary and uterus. In: *Inherited susceptibility to cancer: clinical, predictive and ethical perspectives*. Foulkes WD and SV Hodgson (eds). Cambridge University Press, 1998.
- 15*. Foulkes WD and Hodgson: Late-breaking developments. In: *Inherited susceptibility to cancer: clinical, predictive and ethical perspectives*. Foulkes WD and SV Hodgson (eds). Cambridge University Press, 1998.
- 16*#. Kasprzak L, Foulkes WD, Shelling AN: Hereditary ovarian carcinoma. *BMJ* 318: 786-789, 1999.
- 17#. Jefferies S, Eeles R, Goldgar D, A'Hern R, Henk JM, Gore M, Rhys-Evans P, Archer D, Bishop K, Murkin A, Solomon E, Hodgson S, O'Connell M, Hibbert J, Easton D and Foulkes W. The role of genetic factors in predisposition to squamous cell cancer of the head and neck. *Br J Cancer* 79: 865-7, 1999.
- 18*. Foulkes WD and Shelling AN: Molecular genetics of ovarian cancer: technical overview. In: *Methods in Molecular Medicine-Ovarian Cancer*. Ed Bartlett J. Humana Press, Totowa, New Jersey, pp. 273-290, 2000.
- 19#. Chappuis PO, Rosenblatt J and Foulkes WD: The influence of familial and hereditary factors on the prognosis of breast cancer. *Ann Oncol* 10: 1163-1170, 1999.
20. Chappuis PO, Nethercot V and Foulkes WD: Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. *Semin Surg Oncol* 18: 287-295, 2000.
21. Chappuis PO, Ghadirian P and Foulkes WD: The role of genetic factors in the etiology of pancreatic adenocarcinoma: An update. *Cancer Invest* 19: 63-75, 2001.
- 22#. Wong N, Lasko D, Rabelo R, Pinsky L, Gordon PH and Foulkes W. Genetic counseling and interpretation of genetic tests in hereditary non-polyposis colorectal cancer syndromes *Dis Colon Rectum* 44: 271-9, 2001
- 23#. Rabelo R, Foulkes W, Gordon PH, Wong N, Yuan ZQ, Chong G, MacNamara E, Pinsky L and Lasko D. Genetic testing in high risk, hereditary colorectal cancer syndromes. *Dis Colon Rectum* 44: 437-46, 2001
24. Chappuis PO and Foulkes WD. Risk assessment and genetic testing. In: *Ovarian Cancer*, eds. Stack MS and Fishman D. (Cancer Treatment and Research series, Rosen S, series editor) Kluwer Academic, Boston. Volume 107, pages 29-59, 2002.
25. Singh R, Eeles RA, Durocher F, Simard J, Edwards S, Badzioch, Kote-Jarai Z, Teare D, Ford D, Dearnley D, Arden-Jones A, Murkin A, Dowe A, Shearer R, Kelly J, The CRC/BPG UK Familial Prostate Cancer Study Collaborators, Labrie F, Easton DF, Narod SA, Tonin PN and Foulkes WD. High risk genes predisposing to prostate cancer development: do they exist? *Prostate Cancer and Prostate Diseases* 3, 241-247, 2000.
26. Jefferies S and Foulkes WD. Genetic mechanisms in squamous cell carcinoma of the head and neck. *Oral Oncology* 37: 115-126, 2001

27. Chappuis, PO, Foulkes WD and Provencher, D. Prise en charge du syndrome du cancer du sein et de l'ovaire héréditaire. Deuxième partie: Point de vue de l'oncologue et du gynécologue. *Le Clinicien* 16: 63-71.
28. Foulkes WD, Rosenblatt, J and Chappuis PO. The contribution of inherited factors to the clinicopathological features and behavior of breast cancer. *J Mamm Biol Neoplasia* 6: 453-465, 2001.
29. Shelling AN, Foulkes W. The molecular genetics of ovarian cancer. *Mol Biotechnol* 19: 13-28, 2001.
- 30*. Chappuis PO and Foulkes WD: Overview of clinical genetics of ovarian cancer. In: *Familial Breast And Ovarian Cancer*, eds Morrison P, Hodgson SV and Haites N. Cambridge University Press, 2002, chapter 4: pp43-72.
- 31*. Chappuis PO and Foulkes WD. Management of Hereditary Breast Cancer. In: *Familial Breast And Ovarian Cancer*, eds Morrison P, Hodgson SV and Haites N. Cambridge University Press, 2002. chapter 15: pp237-274.
- 32*. Chappuis PO, Stoppa-Lyonnet D, Asselin B and Foulkes WD. Natural history of hereditary breast cancer. In: *Familial Breast And Ovarian Cancer*, eds Morrison P, Hodgson SV and Haites N. Cambridge University Press, 2002, chapter 6: pp81-107.
- 33*. Foulkes WD, Lanke E, Jefferies S and Chappuis PO. Genetic susceptibility to carcinoma of the head and neck, stomach and pancreas. In: *Genetic predisposition to cancer*, second edition, eds. Eeles, RA, Ponder BA, Easton DF and Eng C. Chapman and Hall, 2004, chapter: pp368-391
34. Foulkes WD. BRCA1 and BRCA2: cancer treatment and outcomes. *Familial Cancer*, in press, 2006

d) Book co-authorship

1. A practical guide to human cancer genetics, third edition: Hodgson SV, Foulkes WD, Eng C and Maher ER. Cambridge University Press, in press.

e) **Book editorship**

1. Foulkes WD and SV Hodgson: Inherited susceptibility to cancer: clinical, predictive and ethical perspectives. Cambridge University Press, 1998.

f) **Invited editorials and commentaries**

1. Foulkes WD. BRCA1 and BRCA2: penetrating the clinical arena. *Lancet*, **352**: 1325-1326, 1998.
2. Chappuis PO, Foulkes WD. Commentary on "Prevalence of BRCA1 and BRCA2 mutations in unselected male breast cancer patients in Canada". *Clinical Breast Cancer* **1**: 64-65, 2000.

3. Foulkes WD. Of mice and women. *Cancer Cell* 1: 11-12, 2002.
4. Foulkes WD. Polygenic or Pollyanna? *Nature Medicine*, 8: 328-330, 2002.
5. Pollak MN, Foulkes WD. Challenges to cancer control by screening. *Nat Rev Cancer*, 3: 297-303, 2003.
6. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. *Nat Rev Cancer*, 4: 665-76, 2004.
7. Rudkin TM, Foulkes WD. BRCA2: breaks, mistakes and failed separations. *Trends Mol Med*. 11(4):145-8, 2005.

g) Peer-reviewed case reports

- 1*. Foulkes W, Rees J and Sewry C: Influenza A and rhabdomyolysis. *J Infect* **21**: 303-304, 1990.
- 2*. Foulkes W, Sewry C, Calam J and Hodgson HJF: Rhabdomyolysis after intramuscular iron-dextran in malabsorption. *Ann Rheum Dis* **50**: 184-186, 1991.
- 3*. Druker HA, Kasprzak L, Bégin LR, Jothy S, Narod SA and Foulkes WD: A family with Graves' disease, multinodular goiter, non-medullary thyroid carcinoma and alveolar rhabdomyosarcoma. *Am J Med Genet*.**72**: 30-33, 1997.
4. Liede A, Tonin PN, Serruya C, Sun CC, Narod SA and, Foulkes WD: Is hereditary site-specific ovarian cancer a distinct genetic condition? *Am J Med Genet***75**: 55-58, 1998.
- 5*. Hébert-Blouin M-H, Koufogianis V, Gillett P and Foulkes WD: Fallopian tube cancer in a *BRCA1* mutation carrier: rapid development and failure of screening. *Am J Obstet Gynecol* **186**: 53-4, 2002.
- 6*. Al-Saffar M and Foulkes WD: Hereditary ovarian cancer due to a non-ovarian cancer cluster region (OCCR) *BRCA2* mutation: Is the OCCR useful clinically? *J Med Genet* 39(11): e68, 2002.
- 7*. Ah Mew N, Hamel N, Galvez M, Al-Saffar M and Foulkes WD: Haplotype analysis of a *BRCA1*:185delAG mutation in a Chilean family supports its Ashkenazi origins. *Clin Genet* 62: 151-156, 2002
8. Kasprzak L, Mesurole B, Tremblay F, Galvez M, Halwani F, Foulkes WD. Invasive breast cancer following bilateral subcutaneous mastectomy in a *BRCA2* mutation carrier: a case report and review of the literature. *World J Surg Oncol* 3:52, 2005.

h) Letters (new data or novel hypotheses, not necessarily peer-reviewed)

- 1*. Foulkes W, Goddard A and Patel K: Retinoblastoma linked with Seascale. *BMJ* **302**: 409, 1991.
- 2*. Foulkes W, Black DM, Solomon E and Trowsdale J: Allele loss on chromosome 17q in sporadic ovarian cancer. *Lancet* **338**: 444-445, 1991.
3. Foulkes W: Tumour suppressor genes in ovarian cancer. *BMJ* **307**: 1009, 1993.
4. Brunet J-S, Narod SA, Tonin P and Foulkes WD. *BRCA1* and ovarian cancer survival. *N Engl J Med* **336**:1256, 1997.
- 5*. Foulkes WD and Narod SA: Re: Family history of cancer and risk of lung cancer among lifetime non-smoking women in the United States. *Am J Epidemiol* **146**: 364, 1997.
- 6*. Foulkes WD, Wong N, Rozen F, Brunet, J-S and Narod SA: Breast cancer survival in *BRCA1* carriers. *Lancet* **351**: 1359, 1998.
- 7*. Yuan ZQ, Kasprzak L, Gordon PH, Pinsky L and Foulkes, WD: I1307K *APC* and *hMLH1* mutations in a non-Jewish family with hereditary non-polyposis colorectal cancer. *Clin Genet* **54**: 368-370, 1998.
8. Chappuis PO, Deschênes J and Foulkes WD. Long-term outcome of invasive breast cancer. *Lancet*, **355**: 1551, 2000.
9. Julian-Reynier C, Evans G, Foulkes W, Sobol H. International variation of women's decisions about prophylactic surgery. *Lancet* **356**: 1687, 2000
- 10*. Chappuis PO, Hamel N, Paradis A-J, Deschênes J, Tonin PN, Ghadirian P, Foulkes WD. Re: Population-based study of *BRCA1* and *BRCA2* mutations in 1035 unselected Finnish breast cancer patients. *J Natl Cancer Inst* **93**:152-153, 2001.
- 11*. Goffin JR, Chappuis PO, Wong N, Foulkes WD: Re: Magnetic Resonance Imaging and mammography in Women with a hereditary risk of breast cancer. *J Natl Cancer Inst* **93**:1754-5, 2001.
12. Andermann A, Thiffault I, Wong N, Gordon P, MacNamara E, Chong G, Foulkes W. Multimodal molecular screening is required to improve the sensitivity of *MLH1* and *MSH2* mutation analysis. *J Clin Oncol* **20**:1705-7, 2002.
13. Foulkes WD, Goffin J, Brunet J-S, Bégin LR, Wong N and Chappuis PO. Tamoxifen may be an effective treatment for *BRCA1*-related breast cancer irrespective of ER status. *J Natl Cancer Inst* **94**: 1504-1506, 2002.

- 14*. Cremin C, Wong N, Buzaglo K, Paradis A-J and Foulkes WD. Non-ovarian pelvic cancers in *BRCA1/2* mutation carriers and BRCAPro statistical model. *J Clin Oncol* **20**: 3937-7, 2002.
15. Foulkes WD. Re: Potential for bias in studies on efficacy of prophylactic surgery for *BRCA1* and *BRCA2* mutation carriers. *J Natl Cancer Inst* **95**: 1344, 2003.
16. Foulkes WD. Re: Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. *J Natl Cancer Inst*; **96**:1040-1, 2004.
17. Foulkes WD, Hamel N, Oros KK, Tonin PN. BRCA mutations and ductal carcinoma in situ. *JAMA* **294**(5):553-4, 2005

i) Letters (commentary, not peer-reviewed)

1. Foulkes W: Breast cancer, desmoid tumours, and familial adenomatous polyposis. *Lancet* **342**: 1560-1561, 1993.
2. Foulkes W: The expanded role of NF1. *Nature Genet* **3**: 282, 1993.
3. Foulkes W: Detection of prostate cancer. *BMJ* **310**: 1139-40, 1995.
- 4*. Foulkes W, Glendon G and Narod S: Screening for ovarian cancer. *JAMA* **274**: 383, 1995.
- 5*. Rosenblatt DS, Foulkes WD and Narod SA: Genetic screening for breast cancer. *N Engl J Med* **334**: 1200, 1996.
6. Foulkes WD: Pitfalls of Genetic Testing. *N Engl J Med* **335**:1235-6, 1996.
- 7*. Foulkes WD and Narod SA: Ovarian cancer risk and family history. *Lancet* **349**: 878, 1997.
8. Foulkes WD: Survival in hereditary breast cancer. *Lancet* **350**: 366, 1997
- 9*. Foulkes WD, Wong N, Brunet J-S and Narod SA: *BRCA* mutations and survival in breast cancer. *J Clin Oncol* **16**: 3206-7, 1998
10. Chappuis PO, Narod SA and Foulkes WD: Screening for ovarian cancer. *Lancet* **354**: 509-510, 1999.
11. Sutton M, Laazari K and Foulkes WD: Response to “the traps and pitfalls inherent in the correlation of changes in the fibre diffraction pattern of hair with breast cancer”. *Phys Med Biol* **48**: L11-L13, 2003.

12. Narasimhadevara R, Pollak MN and Foulkes WD. Re: Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. *J Natl Cancer Inst* **95**: 917, 2003.

j) Technical reports

Foulkes WD. Ovarian cancer in Canada. Laboratory Centre for Disease Surveillance, Health Canada, 1998.

k) Selected abstracts (truncated at 2001)

1. Levi S, Beardshall K, Swift I, Foulkes W, Playford R, Ghosh P, Spencer J and Calam J: *Campylobacter pylori* and duodenal ulcers: the gastrin connection. *Gut* **30**: A1443, 1989.
2. Ghosh P, Beardshall C, Playford RJ, Foulkes W, Levi S, Desa L, and Calam J: Gastrin releasing peptide (GRP) stimulated gastrin release falls after suppression of *Helicobacter pylori* in duodenal ulcer disease. *Gut*, **31**: A597, 1990.
3. Levi S, Goodlad RA, Stamp G, Lee C, Playford R, Ghosh P, Foulkes W, Wright NA and Hodgson HJF: The stomach and the duodenum of patients with arthritis respond to non-steroidal antiinflammatory drug administration by increasing cell turnover. *Gut*, **31**: A599, 1990.
4. Markie D, Foulkes W and Bodmer WF: Three probes recognise the same locus and form part of a linkage group on the long arm of chromosome six. Human Genome Mapping 11, *Cytogenet. Cell Genet.* **58**: nos. 3-4, 1914, 1991.
5. Foulkes W, Ozoa P, Campbell IG, Pignatelli M and Stamp G: Ovarian cancers show selected markedly positive staining with MOv18, an antibody that recognises a high affinity folate binding protein. *J. Pathol.*, **167**: Suppl. 134A, 1991.
6. McFarlane CP, Foulkes WD, Gusterson BA and Spence RP: Characterisation of *c-erbB2* amplification and expression in ovarian tumour samples: evidence for a diagnostic genomic rearrangement. Presented at Annual AACR meeting, San Diego, California, May 1992.
7. Grant SG, Foulkes WD, Sieh W, Narod S and Bigbee WL: Elevated levels of bone marrow somatic mutation in long term cancer survivors. *Proc. Am. Assoc. Cancer Res.*, **36**: A151, 1995.
8. Foulkes WD, Brunet J-S, Kowalski LP, Franco EL and Narod SA: Family history is a risk factor for squamous carcinoma of the head and neck in Brazil: a case-control study. *Am. J Hum. Genet* **57S**: A63; 334, 1995
9. Sun S, Narod SA and Foulkes WD: A p16 mutation in a family with multiple cancers. *Eur. J. Hum. Genet.* 4 Suppl. 1: S11.003, 1996.

10. Foulkes WD, Brunet J-S, Sieh W, Black MJ, Shenouda G and Narod SA: Familial risks of squamous cell carcinoma of the head and neck. *Eur. J. Hum. Genet.* 4 Suppl. 1: 4.020, 1996.
11. Sun S, Narod SA, Jothy J, Kasprzak LZ and Foulkes WD: A p16 mutation in a family with multiple cancers. *Genetique humaine au Quebec: Qui fait quoi? Réseau de médecine génétique appliqués du FRSQ*. Abstract # 46.
12. Evans DGR, Kerr B, Foulkes W, Hadfield LD, Hopwood and Narod SA: Factitious breast cancer history: a new form of Munchausen syndrome. *Am. J. Hum. Genet.* **59S**: A66; 342, 1996.
13. Foulkes W, Flanders T, Lambert D, Narod S: Increased incidence of cancer in first-degree relatives of women with double primary cancers of the colorectum and endometrium. *Am. J. Hum. Genet.*, **59S**:A67; 347, 1996.
14. Bignell G, Sun S, Biggs P, Hamoudi R, Rosenblatt J, Buu P, Druker H, Hudson T, Houlston R, Narod SA, Stratton M and Foulkes W. Non-medullary thyroid cancer: attempts to locate susceptibility genes by linkage in two Canadian families with goitre and non-medullary thyroid cancer. *Am. J. Hum. Genet.* **59S**:A380; 2216, 1996.
15. Eeles RA, Dearnaley DP, Edwards SM, Badzioch M, Easton DF, Arden-Jones A, Dowe A, Ford D, Shearer R, and 103 Collaborators (UK), Labrie F, Tonin P, Durocher F, Simard J, Narod SA and Foulkes W: The contribution of candidate genes to prostate cancer susceptibility. Presented at Winter British Prostate Group Meeting.
16. Provencher D, Godard B, Foulkes WD, Brunet J-S, Tonin PN, Mes-Masson, A-M, Droiun P, Dubuc-Lissoir J, Gauthier P, Audet-Lapointe P, Narod SA and Ghadirian P. Risk factors for familial and sporadic ovarian cancer among French-Canadians: a case-control study. Submitted to la societe des obstetriciens et gynecologues du Canada, 1997 meeting.
17. Eeles R, Simard J, Teare D, Edwards S, Easton D, Dearnaley D, Durocher F, Shearer R, Arden-Jones A, Dowe A, 105 Collaborators (UK), Narod S and Foulkes W. Does the hereditary prostate cancer gene, HPC1, contribute to a large proportion of familial prostate cancer? Published in *Br. J. Cancer* supplement, 1997.
18. Eeles RA, Durocher F, Simard J, Edwards SM, Badzioch M, Ford D, Dearnaley DP, Arden-Jones A, Dowe A, Shearer R, the CRC/BPG UK Familial Prostate Cancer Study Collaborators, Labrie F, Tonin PN, Easton DF, Narod SA, Foulkes WD. Analysis of the contribution of candidate genes to familial prostate cancer. *Br J Urol* 79: Suppl 1; 8-14.
19. Wong N, Brunet J-S, Narod SA, Bégin LR, Zhang JC, Martinez JJ, Tonin PN, Karp SE, Pollak MN, Foulkes WD: Germ-line *BRCA1* mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Presented at Terry Fox Workshop on

Cancer Genetics, Canadian Collaborative Group for Cancer Genetics, Toronto, May 31-June 1 1997. Abstract Poster #8.

20. Pal T, Flanders T, Narod SA, Foulkes W: Implications of Double primary cancers of the colon and endometrium. Presented at Terry Fox Workshop on Cancer Genetics, Canadian Collaborative Group for Cancer Genetics, Toronto, May 31-June 1 1997. Abstract Poster #20.
21. Brunet J-S, Foulkes WD, Tonin P, Ghadirian P, Narod SA: Screening for Hereditary Breast cancer. Presented at Terry Fox Workshop on Cancer Genetics, Canadian Collaborative Group for Cancer Genetics, Toronto, May 31-June 1 1997. Abstract Poster #5.
22. Eeles R, Durocher F, Edwards S, Teare D, Easton D, Dearnley D, Shearer R, Arden-Jones A, Dowe A, UK collaborators, Badzioch M, Amos C, Labrie F, Simard J, Narod S and Foulkes W. Does the hereditary prostate cancer gene, HPC1 contribute to a large proportion of familial prostate cancer?-results from CRC/BPG UK, Texan and Canadian Consortium. *Am J Hum Genet* 61S: A64, 345, 1997
23. Wong N, Brunet J-S, Begin LR, Zhang JC, Martinez JJ, Tonin PN, Narod SA, Karp SE, Pollak MN and Foulkes WD. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. *Am J Hum Genet* 61S: A89, 490, 1997
24. Bignell GR, Canzian F, Shayeghi M, Stark M, Shugart YY, Biggs P, Mangion J, Hamoudi R, Rosenblatt J, Buu P, Sun S, Stoffer SS, Goldgar DE, Romeo G, Houlston RS, Narod SA, Stratton MR and Foulkes WD: A familial non-toxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial non-medullary thyroid cancer. *Am J Hum Genet* 61S: A268, 1561, 1997
25. Kasprzak L, Wong N, Ozaki J, Galvez M, Tonin PN, Rosenblatt DS and Foulkes WD: Ascertainment of familial cancers in McGill Hereditary Cancer Clinics. *Les Journées Genétiques' 98: Réseau de médecine génétique appliqués du FRSQ*. Abstract # 105.
26. Tonin, PN, Mes-Masson A-M, Provencher D, Foulkes W, Morgan K, Narod S and Ghadirian P. Founder BRCA1 and BRCA2 mutations in French-Canadian breast and ovarian cancer families. *Les Journées Genétiques' 98: Réseau de médecine génétique appliqués du FRSQ*. Abstract #22
27. de Andrade M, Amos CI, Foulkes WD. Segregation analysis of squamous cell carcinoma of the head and neck: evidence for a major gene determining risk. Abstract #134, accepted for poster presentation at the seventh international genetic epidemiology society (IGES) meeting, Arcachon, France, Sept 11-12, 1998.
28. Foulkes WD Hamel N, Karimi S, Brunet J-S, Gilfix B, Ghadirian P, Narod SA and Black MJ: Increased risk of head and neck cancer in association with *GSTT1* nullizygoty for individuals with low exposure to tobacco and alcohol. *Am J Hum Genet* 63S: A20, 101, 1998

29. Wong N, Brunet J-S, Bégin LR, Vesprini D, Rozen F, Yuan ZQ, Abrahamson J, Karp SE, Pollak M, Narod SA and Foulkes WD: Axillary node negative primary breast cancer in Ashkenazi Jewish *BRCA1* mutation carriers is associated with P53 over-expression and has a poor prognosis. *Am J Hum Genet* 63S: A47, 248, 1998
30. Dupuis L, Lerner B, Meccas-Faxon S, Berlin B and Foulkes WD. The incidence of cancer in the first degree relatives of women diagnosed with endometrial cancer under the age of 55. *Am J Hum Genet* 63S: A67, 354, 1998.
31. May S, Yuan ZQ, McKinnon W, Lasko D, Greenblatt M, Gordon P, Pinsky L, Yandell D, Rousseau F and Foulkes W. How mutation analysis can link distantly-related families. *Am J Hum Genet* 63S: A78, 420, 1998.
32. International Consortium for Prostate Cancer Genetics (ICPCG). Meta-analysis of 1q24-25 linkage data in 780 prostate cancer families. American Urological Association, 1999.
33. Foulkes WD, Wong N, Brunet J-S, Vesprini D, Rozen F, Yuan, Pollak M, Narod SA, Trudel M and Bégin LR. Novel negative breast cancer in Ashkenazi Jewish women has a very good prognosis if the tumor is both HER2 and BRCA1 germ-line mutation negative. Reasons for Hope, National Scientific Conference, CBCRI, Toronto, Ontario, 17-19 June, 1999.
34. Yuan ZQ, Trifiro M, Wong N, Lasko D, Foulkes WD, Pinsky L, Khandjian E, Rousseau F, Gordon PH. Three novel germ-line mutations of hMLH1/hMSH2 in Montreal families with Hereditary Non-Polyposis Colorectal Cancer. Royal College of Physicians and Surgeons Annual Conference, Montreal, Sept 25, 1999, Abstract 0044.
35. Julian-Reynier CM, Evans G, Bouchard L, Eisinger F, Kerr B, Foulkes W, Blancquaert I, Sobol H. Consultees' attitudes towards preventive strategies for Hereditary Breast Ovarian Cancer risk: Cultural differences between Manchester (UK), Marseilles (F) and Montreal (Ca). *Am J Hum Genet* 65S: A12, 58, 1999
36. Foulkes WD, Wong N, Brunet J-S, Trudel M, Paradis A-J, Kuperstein G, Chappuis PO, Kapusta L, Slingerland J, Narod SA and Bégin LR. Germ-line BRCA mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer: Survival disadvantage depends on nodal status. *Am J Hum Genet* 65S: A62, 322, 1999
37. Chappuis PO, Renard H, Kantemiroff T, Sanders K, MacMillan A, Black MJ, Goldgar DE and Foulkes WD. Increased incidence of thyroid cancer in the first degree relatives of probands with non-medullary thyroid cancer: a case-control-cohort study. *Am J Hum Genet* A121, 643, 1999
38. Kasprzak L, Nolet S, Gaboury L, Gregory W, Pavia C, Villabona C, Rivera-Fillat, Oriola J and Foulkes WD. Familial medullary thyroid carcinoma and prominent corneal nerves associated with a codon 804 germline mutation of the RET gene. *Am J Hum Genet* A132, 706, 1999

39. Foulkes WD, Satagopan JM, Chappuis PO, Wong N, Bégin LR, Boyd J, Offit K and Robson ME. The presence of a germ-line BRCA mutation is an independent poor prognostic marker in breast cancer: a two-center historical cohort study. *Am J Hum Genet* **A105**, 379, 2000
40. Robson ME, Roberge D, Chappuis PO, Offit K and Foulkes WD. Risk of Ipsilateral Recurrence (IBTR) and Metachronous Contralateral Breast Cancer (CBC) after Breast Conservation Therapy (BCT) in Women with Germline *BRCA1* or *BRCA2* Mutations. Slide presentation at the 23rd Annual San Antonio Breast Cancer Symposium. Presented in General Session IV, December 8, 2000.
41. Roberge D, Foulkes W, Wong N, Chappuis P, Bégin L, Chow T. Résultats de la mastectomie partielle suivie de radiothérapie chez les porteuses de gènes *BRCA1/BRCA2* mutants: implications thérapeutiques. Oral communication, 11e congrès national de la société française de radiothérapie oncologique, Paris, 23-24 novembre 2000. *Cancer Radiothérapie* **4**: 1s 10s, 2000.
42. Canil CM, Markin G, Chappuis P, Goshen R, Meschino W, Goss P, Narod S, Foulkes W, Warner E. Comparison of clinical, radiological and pathological features in age-matched Ashkenazi Jewish (AJ) women with breast cancer with and without BRCA1 and BRCA2 mutations. *Am Soc Clin Oncol* **A1649**, 2001.

k) Others

Cervical cancer screening:

Foulkes W: The health of the nation. *Br. Med. J.* **303**: 311-312, 1991.

Conference report:

Foulkes W: Genetics of Cancer. *Lancet* **340**: 1402-1403, 1992.

Castration and Sex:

Foulkes W: Male and female castration. *Br. Med. J.* **308**:416, 1994.

Authorship criteria:

Foulkes WD and Neylon N: Redefining authorship. *Br. Med. J.* **312**: 1423, 1996.

Book review:

Foulkes W. *Hidden Histories of Science* Edited by Robert B Silvers. New York Review Books. *Br. Med. J.* **311**:1101, 1995.

JOURNAL REFEREE

Ad hoc-more than 10 reviews

Journal of Medical Genetics
International Journal of Cancer
British Journal of Cancer

Between 5 and 10 reviews

Nature Genetics
Lancet
Journal of the National Cancer Institute
Cancer Research
Clinical Cancer Research
European Journal of Cancer

Between 1 and 5 reviews

American Journal of Human Genetics
Lancet Oncology
Human Mutation
Oncogene
Gastroenterology
Prostate
Journal of Clinical Pathology
Oncology Research
Molecular and Cellular Probes
Canadian Journal of Oncology

BOOK REFEREE

Cambridge University Press

THESIS DEFENCE/REFEREE/COMMITTEE

PhD, McGill Dept. Biology
Ronald Lafreniere, June 17, 1997.

Ph.D, McGill Dept Biology
Adriana Diaz Anzaluda,
April 1999-current

PhD, McGill Dept Oncology
David Hamilton
May 2000-current

MSc, McGill Dept. Epidemiology and Statistics
Hela Makni, April 2000

MSc, McGill Dept. Biology
Sahar Sibani, January 2001

MSc, McGill Dept. Human Genetics
Andrea Karin Lawrance
May 2001-current

INVITED TALKS and SEMINARS, 1995-2006

Scientific Audience

a) International

September 19, 1995

Title: *Increased risk of squamous cell carcinoma of the head and neck in association with a family history of this cancer.*

Vermont Cancer Center
Burlington, Vermont

May 9, 1996

Title: *Genetics of head and neck cancer*

Epidemiology of head and neck cancer meeting
IARC, Lyon, France

December 9, 1996

Title: *Resolving uncertainty in hereditary breast and ovarian cancer*

Beatson Institute for Cancer Research
Glasgow, Scotland

December 10, 1996

Title: *Developing a Cancer Genetics Service*

Department of Medical Genetics, University of Glasgow,
Yorkhill Hospital
Glasgow, Scotland

February 13, 1998

Title: *Epidemiological and clinical studies of cancer genetics in the Ashkenazi Jewish population.*

Department of Human Genetics Seminar
Schwartz Building, Memorial Sloan-Kettering Cancer Center,
New York, New York.

March 12, 1998

Title: *The genetics of breast cancer in the Ashkenazi Jewish population*

Department of Epidemiology,
MD Anderson Cancer Center,
Houston, Texas.

March 12, 1998

Title: *Familial multinodular goitre and hereditary non-medullary thyroid cancer*

Department of Endocrinology,
MD Anderson Cancer Center,
Houston, Texas.

May 1, 1998

Title: *Endocrine cancers*

Department of Human Genetics
A “genetics of human cancer” course lecture
Memorial Sloan-Kettering Cancer Center,
New York, New York.

September 15, 1998

Title: *Overview of studies of prognosis in familial and hereditary breast cancer*

Breast Cancer Linkage Consortium,
Dublin, Ireland.

September 17, 1998

Title: *Genetics of Breast Cancer*

Division of Investigative Sciences,
Imperial College of Science and Medicine,
Hammersmith Hospital, London

September 18, 1998

Title: *Cancer Genetics: Much Ado about Nothing?*

GlaxoWellcome Medicines Research Centre,
Gunnels Wood Lane
Stevenage, Herts, UK.

October 5, 1998

Title: *Research in progress*

Vermont Cancer Center retreat,
Baldwin’s Creek,
Bristol, VT, USA

May 26, 1999

Title: *The influence of familial and hereditary factors on the clinicopathological features and prognosis of breast cancer*

Department of Epidemiology
Fred Hutchinson Cancer Research Center
Seattle, WA, USA

September 2, 1999

Title: *Recent advances in cancer genetics*

Division of Genetic Medicine, Department of Medicine,
Vanderbilt University
Nashville, TN, USA.

December 3, 1999

Title: *Clinicopathological features and prognosis of hereditary breast cancer*

Netherlands Cancer Institute

Antoni van Leeuwenhoek Huis,
Amsterdam, Netherlands

December 16, 1999

Title: *Clinical, Pathological and Survival studies in hereditary breast cancer*

Duke University Medical Center

Duke University

North Carolina, USA

September 25, 2000

Title: Hereditary breast cancer: genes, risks and outcome

University of Newcastle Medical School

University of Newcastle,

Northumberland, UK

November 28, 2001

Title: Clinicopathological studies of hereditary breast cancer

CHUV,

University of Lausanne

Lausanne, Switzerland

March 27, 2003

Title: Founder populations and cancer genetics: a view from just north of here

NHGRI, Division of Intramural Research Seminar Series,

NIH,

Bethesda, MD, USA

September 22, 2003

Title: *Clinico-pathological features of BRCA1-related breast cancer*

Division of Medical and Molecular Genetics

Guy's Hospital,

London, UK

September 23, 2003

Title: *Five things I learnt about BRCA1-related breast cancer in the last year*

Gjesteforelesning,

Gades Institute,

Haukeland University Hospital

Bergen, Norway

September 24, 2003

Title: *Five things I learnt about BRCA1-related breast cancer in the last year*

Netherlands Cancer Institute

Amsterdam, Netherlands

February 2, 2006

Title: *Genetic Risk Assessment*

5th International “From Gene to Cure” Congress
Vrije Universiteit Amsterdam
Amsterdam, Netherlands

February 2, 2006

Title: *Prevention of Hereditary Breast Cancer*
5th International “From Gene to Cure” Congress
Vrije Universiteit Amsterdam
Amsterdam, Netherlands

April 20, 2006

Title: *Clinico-pathological features of basal-like/BRCA1 tumors*
“Basal-like and BRCA1-associated Breast Cancer” meeting
Harvard Club
Boston, MA, USA

August 16, 2006

Title: *Recent advances in understanding of the inherited susceptibility to cancers of the prostate, pancreas, stomach and colorectum*
Australian Ovarian Cancer Study and the Family Cancer Clinics of Australia
Couran Cove Island Resort
Stradbroke Island, Australia

August 18, 2006

Title: *Hereditary breast cancer: from pathology to treatment and beyond*
Australian Ovarian Cancer Study and the Family Cancer Clinics of Australia
Couran Cove Island Resort
Stradbroke Island, Australia

October 28, 2006

Title: Breakthrough treatments for BRCA1 and BRCA2 mutation carriers
10th Annual Cincinnati Comprehensive Breast Cancer Conference
Cutting Edge Strategies in Breast Cancer: The next decade
Cincinnati, OH, USA

November 9, 2006

Title: Hereditary breast cancer: from pathology to treatment and beyond
Cancer Colloquia IV: Cell and Molecular Biology of Breast Cancer
University of St-Andrews
St-Andrews, Scotland

b) National

April 26, 1996

Title: *Genetics of head and neck cancer*
Cancer Genetic Epidemiology Workshop
Environmental Health Centre

Ottawa, Ontario

February 24, 1999

Title: *Genetics of Breast Cancer: some observations from the study of founder populations in Quebec*

Division of Cancer Biology Research Seminar,
Sunnybrook and Women's College Hospital Health Sciences Centre,
Toronto, ON, Canada

May 19, 1999

Title: *Genetics of Breast and Ovarian Cancer*

"New Developments in prenatal diagnosis and medical genetics"

University of Toronto CME course

Toronto, ON, Canada

June 20, 1999

Title: *Node negative breast cancer in Ashkenazi Jewish women has a very good prognosis if the tumor is both HER2 and BRCA1 germ-line mutation negative*

Reasons for Hope: NCIC/CBCRI conference

Toronto, ON, Canada

June 21, 2001

Title: *Treatment issues in hereditary breast cancer*

Theme: The genetic basis of disease

Canadian Federation of Biological Societies, 44th annual meeting.

Ottawa Congress Centre

Ottawa, ON, Canada

October 7, 2004

Title: *Exons, Introns, Enhancers, Deletions and Founders: an overview of HNPCC in Quebec*

Oncogenetics: Achievements and Challenges,

17ieme entretiens du Centre Jacques Cartier

Crowne Plaza Hotel, Montreal, Quebec

June 15, 2006

Title: *Genetics and Breast Cancer: An update*

Toronto Breast Cancer Symposium 2006

Metro Toronto Convention Center, Toronto, Ontario

c) Local/Provincial

September 28, 1995

Title: *Familial Risks of Squamous Cell Carcinoma of the Head and Neck*

Annual Meeting of Quebec ORL Society

Montibello, Quebec

March 26, 1996

Title: *p16 and Familial Cancer*

Institut de Cancer de Montreal - Hopital Notre Dame
Montreal, Quebec

June 19, 1996

Title: *A p16 mutation in a family with multiple cancers*

Les Journées de Génétique Humaine - Réseau de Médecine Génétique Appliqués du FRSQ
Montreal, Quebec

October 24, 1997

Title: *A gene for familial multinodular goitre maps to chromosome 14q*

Annual Congress of the Quebec ORL Association,
Chateau Frontenac,
Quebec City, Quebec

November 20, 1997

Title: *The genetics of breast cancer*

Annual Scientific Meeting of Clinical Biochemists of Quebec,
Hotel Vogue,
Montreal, Quebec

May 29, 1999

Title: *Hereditary predisposition to breast and ovarian cancer*

Annual Congress of the Quebec Obstetrics and Gynecology Association (AOGQ)
Hotel Delta Sherbrooke,
Sherbrooke, Quebec

September 20, 2002

Title: *Genetic testing for colorectal cancer*

3rd Annual Montreal Colon and GI cancers conference
Queen Elizabeth Hotel
Montreal, Quebec

October 24, 2002

Title: *Genetics of Skin Cancer*

247th Scientific meeting of the Montreal Dermatological Society
Royal Victoria Hospital
Montreal, Quebec

October 4, 2002

Title: *Screening or Risk Reduction?*

1st International Cancer Prevention Symposium-Chagnon Foundation
Ritz Carlton Hotel,
Montreal, Quebec

November 13, 2002

Title: *Genetics of Breast Cancer*
Cité de la Santé Hematology/Oncology Group
Laval, Quebec

June 25, 2004

Title: *Screening of High Risk Patients*
23rd International Congress of Radiology of the International Society of Radiology
Palais des Congrès, Montreal, Quebec

October 7, 2004

Title: *Exons, Introns, Enhancers, Deletions and Founders: an overview of HNPCC in Quebec*
Oncogenetics: Achievements and Challenges,
17ieme entretiens du Centre Jacques Cartier
Crowne Plaza Hotel, Montreal, Quebec

November 25, 2004

Title: *Survivance sur la génétique et la prise en charge du cancer colorectal héréditaire*
Centre intégré de lutte contre le cancer de la Montérégie, Réseau Cancer Montérégie
Hôtel Gouverneur Île Charron, 2405 Île Charron,
Longueuil, Quebec

December 15, 2004

Title : Genetic diseases in the adult: New opportunities
Hôtel Vogue, Montreal, Quebec

September 28, 2005

Title: Genetics of colorectal cancer: What's new?
CCMG 2005 Annual Meeting
Château Bromont
Bromont, Quebec

October 12, 2005

Title: Genetic influence of breast and gynecological cancers in pre-menopausal women
10th McGill International Symposium on Reproductive Endocrinology & Infertility and
Women's Health
Centre Mont-Royal, Montreal, Quebec

October 20, 2005

Title: Overview - 10 years of BRCA1 and BRCA2
BRCA: Today & Tomorrow
First International Symposium on the Hereditary Breast and Ovarian Cancer Susceptibility
Genes
Marriott Château Champlain, Montreal, Quebec

October 20, 2005

Title: Outcome following BRCA1/2 related breast cancer

BRCA: Today & Tomorrow
First International Symposium on the Hereditary Breast and Ovarian Cancer Susceptibility
Genes
Marriott Château Champlain, Montreal, Quebec

d) Institutional

January 11, 1996

Title: *Breast Cancer Syndromes*
Endocrinology Research Seminar - Royal Victoria Hospital
Montreal, Quebec

February 28, 1996

Title: *Familial Breast Cancer*
Oncology Rounds - Royal Victoria Hospital
Montreal, Quebec

February 29, 1996

Title: *Preventive Surgery and the High-risk Patient*
Surgical Grand Rounds - Royal Victoria Hospital
Montreal, Quebec

March 29, 1996

Title: *Germline mutations in p16 and the risk of cancer*
McGill Genetics rounds: Case presentations-Royal Victoria Hospital
Montreal, Quebec

November 8, 1996

Title: *Controversies Surrounding New Genetic Testing* (Panel Discussion)
47th McGill University Annual Refresher Course for Family Physicians
Montreal, Quebec

November 14, 1996

Title: *The role of Preventive Surgery in the High-risk Individual*
Surgical Grand Rounds - Sir M.B. Davis Jewish General Hospital
Montreal, Quebec

November 22, 1996

Title: *Resolving uncertainty in hereditary breast and ovarian cancer*
McGill Genetics Rounds - Montreal Children's Hospital
Montreal, Quebec

November 25, 1996

Title: *Familial Cancer* (with Dr. Patricia Tonin)
Grand Medical Rounds - Sir M.B. Davis Jewish General Hospital
Montreal, Quebec

February 20, 1997

Title: *Genetics and epidemiology of non-medullary thyroid cancer*

Endocrinology rounds,

Montreal General Hospital

Montreal, Quebec.

March 20, 1997

Title: *Methods and recent results in the genetics of cancer susceptibility*

Montreal Cancer Research Group,

McGill Cancer Centre,

Montreal, Quebec.

November 13, 1997

Title: *The genetics of breast cancer*

Department of Epidemiology and Biostatistics,

Fall Seminar Series,

McGill University, Montreal

November 24, 1997

Title: *Female cancer and genetics*

Department of Obstetrics and Gynaecology Grand Rounds

Primrose Amphitheatre, Royal Victoria Hospital,

Montreal, Quebec.

December 5, 1997

Title: *Female cancers and genetics*

Department of Obstetrics and Gynaecology Grand Rounds

Block Amphitheatre, SMBD-Jewish General Hospital,

Montreal, Quebec.

December 10, 1997

Title: *Recent advances in cancer genetics*

Department of Medicine Grand Rounds

JSL Browne Amphitheatre, Royal Victoria Hospital,

Montreal, Quebec.

December 15, 1997

Title: *Breast cancer: endocrine and genetic factors* (with Professors M. Pollak and L. Pinsky)

Department of Medicine Grand Rounds

Block Amphitheatre, SMBD-Jewish General Hospital,

Montreal, Quebec.

February 5, 1998

Title: *Genetics of breast and colorectal cancer*

Department of Surgery Grand Rounds

Osler Amphitheatre, Montreal General Hospital,

Montreal, Quebec.

February 17, 1998

Title: *Cancer genetics: an introduction*
Department of Medicine Grand Rounds
Osler Amphitheatre, Montreal General Hospital,
Montreal, Quebec.

April 24, 1999

Title: *Hereditary ovarian cancer*
4th McGill International Symposium on reproductive endocrinology and infertility
Jeanne Timmins Amphitheatre,
McGill University, Montreal.

May 12, 1999

Title: *Recent advances in breast and ovarian cancer genetics*
Surgical Grand Rounds,
Royal Victoria Hospital,
McGill University, Montreal

August 25, 1999

Title: *The role of BRCA1 and BRCA2 in breast and ovarian cancer*
Obstetrics and Gynecology Rounds
Royal Victoria Hospital,
McGill University, Montreal

December 13, 1999

Title: *Genetics and Adult Onset diseases: A changing role for medical genetics.* (with Prof. D. Rosenblatt)
Medical Grand Rounds,
Sir M.B. Davis-Jewish General Hospital,
McGill University, Montreal

January 12, 2000

Title: *Genetic predisposition and outcome from cancer*
Montreal Cancer Research Group,
McGill Cancer Centre,
Montreal, Quebec.

February 24, 2000

Title: *Non-medullary thyroid cancer*
Endocrinology Grand Rounds
Sir MB Davis-Jewish General Hospital
Montreal, Quebec.

March 15, 2000 (with Ms. Lidia Kasprzak and Dr. Georges Chong)

Title: *Genetics and Cancer: How mutation analysis affects clinical management*

Medical Grand Rounds
Royal Victoria Hospital
MUHC, Montreal, Quebec

April 4, 2000 (with Ms. Lidia Kasprzak)

Title: *Colorectal Cancer Genetics: How mutation analysis affects clinical management*

Medical Grand Rounds
Montreal General Hospital
MUHC, Montreal, Quebec

November 7, 2000

Title: *Management of Hereditary Breast and Ovarian Cancer*

Medical Grand Rounds
Montreal General Hospital
MUHC, Montreal, Quebec

November 8, 2000

Title: *Management of Hereditary Breast and Ovarian Cancer*

Medical Grand Rounds
Royal Victoria Hospital
MUHC, Montreal, Quebec

October 22, 2001

Title: *Management of Hereditary Breast and Ovarian Cancer: Prevention, Early Detection and Treatment*

Medical Grand Rounds
Sir M.B. Davis-Jewish General Hospital,
McGill University, Montreal

November 17, 2001

Title: *McGill Program in Cancer Genetics: Bringing together human genetics and oncology*

McGill Oncology Research Retreat,
November 16-17,
Hotel Days Inn,
Montreal

December 16, 2002

Title: *Genetics of Cancer: an update*

MUHC Radiation Oncology Group
Montreal General Hospital

November 23, 2004

Title: *Clinicopathological features of Hereditary Breast Cancer: Ten years on*

MUHC Clinical and Research Seminar
Meakins Auditorium
McIntyre Building
McGill University

December 15, 2004

Title: *Genetics of Colorectal cancer*

GI residents

Montreal General Hospital

Lectures to Interested Groups and/or the General Public

October 26, 1996

Title: *Risk factors, prevention and early diagnosis in prostate cancer*

First Patient Advocates for Advanced Cancer Treatment (PAACT) Prostate Cancer Conference,

Grand Rapids, MI, USA

May 22, 2001

Title: *Genetics and Cancer: Prevention, Early Diagnosis and Treatment*

Research Governor's Society First Lecture Series

Lady Davis Institute for Medical Research,

Montreal, Quebec.

October 24, 2001

Title: *Genetic Testing for Cancer Susceptibility*

38th Annual André Aisenstadt Clinical Day

The Use of Genetic tests in Medical Diagnosis and Treatment

Sir M.B. Davis-Jewish General Hospital,

McGill University, Montreal

September 18, 2002

Title: *Genetic testing for colorectal cancer*

3rd Annual Montreal Colon and GI cancers pre-conference lay workshop

Queen Elizabeth Hotel

Montreal, Quebec

October 1, 2002

Title: *Genetics of Breast Cancer*

CanSupport Public Lecture

Omni Hotel,

Montreal, Quebec

September 27, 2004

Title: *The Why, Where and How of genes and diseases in the Jewish population*

National Council of Jewish Women of Canada

The power of genealogy

Gelber Conference Center Montreal, Quebec

September 19, 2005

Title: *Role of genetic factors in cancer & familial diseases*

National Council of Jewish Women of Canada
Gelber Conference Centre
Montreal, Quebec

Sabine Mai, Ph.D. CURRICULUM VITAE

*

331 Beaverbrook Street
Winnipeg MB R3N 1M9
Phone: 204-487-1866 (home)

*

Manitoba Institute of Cell Biology
675 McDermot Avenue
Winnipeg MB R3E 0V9
Phone: 204-787-2135
FAX: 204-787-2190
e-mail: smai@cc.umanitoba.ca

websites: http://www.umanitoba.ca/institutes/manitoba_institute_cell_biology/
http://www.umanitoba.ca/institutes/manitoba_institute_cell_biology/GCCRD/Index3.htm
<http://www.itmhrt.ca>

*

EDUCATION

Bachelors	University of Cologne (Germany)	Biology	1981
Masters	University of Cologne (Germany)	Biology	1985
Masters	University of Cologne (Germany)	French	1985
Masters	University of Cologne (Germany)	Pedagogic	1985
Ph.D.	University of Karlsruhe (Germany)	Mol. Biology	1991

RESEARCH TRAINING during Ph.D.

<u>DATES</u>	<u>PLACE</u>	<u>HOST(S)</u>
1986-1988: Waldstein	Tel-Aviv University, Tel-Aviv, Israel	Drs. Y. Koltin, S. Lavi, E.
1990:	Imperial Cancer Research Fund (ICRF), London, U.K.	Dr. H. Land

RESEARCH TRAINING after Ph.D.

1991:	Turku University, Finland
1991-1995	Basel Institute for Immunology, Switzerland
1993/1994:	National Institutes of Health

(NIH/NCI), USA

EMPLOYMENT HISTORY

<u>DATES</u>	<u>PLACE</u>	<u>TITLE</u>
1991-1995	Basel Institute for Immunology, Switzerland	Member
1995-present	Manitoba Institute of Cell Biology	Senior Investigator
1995-2000	Department of Physiology	Assistant Professor
4/98-2001	Department of Human Genetics	Assistant Professor
5/99-present	The Genomic Centre for Cancer Research and Diagnosis (MICB)	Director
3/00-03/05	Department of Physiology	Associate Professor
3/00-03/05	Dept. of Biochemistry and Medical Genetics	Associate Professor
4/05-present	Department of Physiology	Professor
4/05-present	Dept. of Biochemistry and Medical Genetics	Professor

INTERNATIONAL RESEARCH ACTIVITIES

<u>DATES</u>	<u>PLACE</u>	<u>TITLE</u>
4/00-5/00	Dept of Pharmacology, Chiang Mai University	Visiting Prof; Lecturer
12/00	Karolinska Institute, Stockholm, Sweden	Visiting Scientist
12/01-02/02	German Cancer Research Center, Heidelberg	Visiting Scientist
11/03-12/03	Karolinska Institute, Stockholm, Sweden	Visiting Scientist

AWARDS

Bafög stipend	1978-1985
Bafög Auslandsstipendium	1980-1981
Deutscher Akademischer Auslandsdienst (DAAD)	1986, 1987
NCIC Award for New Investigators	1995
Braidwood Jackson Memorial Award	1995
Dr. Saul Highman Memorial Award	1999
Rh Award (Basic Science)	2000
MMSF Basic Science Career Development Award	2000-2003
University of Manitoba Outreach Award	2001
US Army Breast Cancer Concept Award	
(shared with Drs. William Foulkes and Yuval Garini)	2004
University of Manitoba Merit Award (Research and Teaching)	2005

PROFESSIONAL SOCIETIES

American Association for Cancer Research

PROFESSIONAL ACTIVITIES

- 1) External grant reviewer for NSERC, MRC, MHRC, CIHR, Valorisation Recherche Québec, NCIC, MMSF
- 2) External referee for Proc. Natl. Acad. Sci (USA), Oncogene, J. Cell Physiol., Gene, Mol. Cell. Biol., Experimental Cell Research, Genes, Chromosomes and Cancer
- 3) Manitoba Institute of Cell Biology, Recruitment Committee, 1996-present
- 4) Department of Immunology, Recruitment Committee, 1999-present
- 5) Manitoba Institute of Cell Biology Animal Care Committee, 1997-present
- 6) Reviewer of MRC National Graduate Students Research Poster Competition, 1999
- 7) Reviewer of Manitoba Student Poster Competition, Research Day, 2000, 2001.
- 8) Genomic Centre for Cancer Research and Diagnosis: User Committee: 2001-present
- 9) CIHR Strategic Training Program “Innovative Technologies in Multidisciplinary Health Research training” selection committee: 2002-present
- 10) CIHR Strategic Training Program “Innovative Technologies in Multidisciplinary Health Research training” Annual Review Committee: 2003-present
- 11) CIHR Fellowship – Post- Ph.D. (FPF) committee: 2002-2006
- 12) Member of the University of Manitoba Senate: 2003-2006
- 13) Panel J Member NCIC: 2005-

PATENTS:

- 1) Mai, S. "Method and marker for the identification of pre-malignancy and malignancy and their therapeutic intervention". – Serial No. 09489288.
- 2) Mai, S., Chuang, T., Moshir, S, Garini, Y. Method of monitoring genomic instability by 3D microscopy and analysis. – Serial No. 9157-51.
- 3) Garini, Y, Darai, E. and Mai, S. Method and apparatus for genomic analysis.
- 4) Mai, S. Garini, Y, Sarkar R, Vermolen BJ. Methods of detecting and monitoring cancer using 3D analysis of centromeres. # 15502-6

RESEARCH OVERVIEW

Genomic instability is a hallmark of pre-neoplastic and neoplastic cells. The mechanisms underlying the induction of genomic instability in cells have been poorly elucidated.

My laboratory was first to demonstrate that c-Myc deregulation induces locus-specific genomic instability (Mai, 1994) and karyotypic instability (Mai *et al.*, 1996a). This finding was later confirmed by Felsher and Bishop (1999). Using c-Myc-inducible cell lines, we have identified the following genes as targets of c-Myc in genomic instability: *dihydrofolate reductase (DHFR)* (Mai, 1994, 1996b, Taylor *et al.*, 1997, Taylor and Mai, 1998), *ribonucleotide reductase R2* (Kuschak *et al.*, 1999a), *cyclin D2 (CCND2)* (Mai *et al.*, 1999), and *ornithine decarboxylase (ODC)* (Smith *et al.*, 2002, 2003). For review, see Mai and Mushinski, 2003.

Our ongoing work focuses on the initiating mechanisms of c-Myc-mediated genomic instability. This work is important for our understanding of oncogenesis. Furthermore, we apply our knowledge on genomic changes in cancer cells to the analysis of patient samples. Using advanced technologies, we can detect cancer cells earlier than standard procedures. We will apply this knowledge to patient samples with the goal to improve early detection, surveillance and monitoring.

Details on basic research and translational research are given in the two following sections.

Basic research focus.

1) *c-Myc-induced illegitimate DNA replication and re-organization of the genome.*

We have shown that c-Myc deregulation induces illegitimate replication of the mouse *ribonucleotide reductase R2 (R2)* gene (Kuschak *et al.*, 2002). This finding is novel in two ways, i) it shows that replication initiation does not have to occur in fixed regions of the mammalian genome. Rather, replication may occur at different sites. ii) c-Myc can act as a licensing factor for DNA replication. In addition, under conditions of induced c-Myc deregulation, we have observed genome-wide alterations in replication patterns.

To further investigate this process of Myc-dependent DNA replication, we propose to investigate the universal role of c-Myc in DNA replication through i) a genome-wide screen of c-Myc-dependent replication initiation. Our preliminary work has indicated that c-Myc-deregulation affects overall replication patterns throughout the mouse genome. ii) We will examine previously identified c-Myc target genes in genomic instability. We will examine whether or not their replication is altered under conditions of c-Myc deregulation. iii) We propose to study the involvement of c-Myc in the replication machinery at the *R2* and other gene(s).

2) *c-Myc induces genomic instability and apoptosis; mutant Myc proteins, however, have lost this ability and induce genomic instability in the absence of apoptosis.* We have demonstrated that wild-type (wt) c-Myc is able to promote both genomic instability and apoptosis, while mutant (mut) c-Myc proteins, that are common in Burkitt lymphoma patients, do not stimulate apoptosis, but merely promote genomic instability (Fest *et al.*, 2002). Non-random genomic aberrations are caused by the deregulated expression of wild-type vs. myc box II-deleted D106 proteins (Fest *et al.*, 2005). The non-random genomic alterations differ between wt and mut Myc overexpressing cells (Fest *et al.*, 2005). The tumorigenic potential of the cells expressing wt vs. mutant c-Myc was examined in SCID mice: Only wt-Myc overexpressing cells conferred tumorigenic potential, while D106 protein was unable to initiate tumor formation in SCID mice.

3) *c-Myc induces the formation of extrachromosomal elements (EEs).* Work carried out in my laboratory has demonstrated for the first time the induction of extrachromosomal elements (EEs) as a result of c-Myc deregulation. This work allowed us to identify some of the genes that are present on EEs (Mai *et al.*, 1996a,b, Mai *et al.*, 1999, Kuschak *et al.*, 1999, Smith *et al.*, 2003). We are now

analyzing the formation, structure, and function of these EEs. EEs isolated from MycERTM-activated cells are significantly larger than EEs isolated from non-MycERTM-activated control cells. c-Myc-induced EEs are associated with proteins. Immunohistochemistry and western blot analyses using pan-histone-, H3 phosphorylation-, and H4 acetylation-specific antibodies indicate that the majority of EEs isolated from MycERTM-activated cells carry transcriptionally active chromatin. In addition, we were able to show that the c-Myc-activated EEs can replicate autonomously (Smith *et al.*, 2003). While some of the genes on c-Myc-activated EEs have been identified in my laboratory, we wish to assess, in a genome-wide fashion, which other genes are present on these EEs. To this end, we will examine the use of EEs as probes for microarrays.

4) ***Plasmacytoma development in p53-deficient BALB/c mice.*** The induced expression of c-Myc in plasmacytomas (PCTs) in BALB/c mice is regularly associated with non-random chromosomal translocations that juxtapose the *c-myc* gene to one of the immunoglobulin (*Ig*) loci on chromosome 12 (*IgH*), 6(*IgK*) or 16(*IgL*). The most characteristic feature of the PCT-associated chromosomal translocation is that the ratio of the typical [T(12;15)] versus the variant translocation [T(6;15)], which differs significantly depending on the PCT-induction methods. More than 90% of pristane (2,6,10,14-tetramethyl-pentadecane)-induced PCTs carry the typical T(12;15) translocation whereas the percentage of the variant T(6;15) is less than 10% (Wiener *et al.*, 1980; Ohno *et al.*, 1984a; Potter, 1997).

We have described the generation of PCTs in p53-deficient BALB/c mice. Interestingly, p53^{-/-} mice develop PCTs earlier than their wild-type p53^{+/+} littermates. p53^{-/-} mice also show an increase in variant translocations involving *c-myc* and *immunoglobulin* genes (Mai and Wiener, 2002). PCTs that carry variant T(6;15) translocations become as frequent as those with typical T(12;15) translocations (41.66%). In addition, in the absence of p53, the number of translocation-negative PCTs increases from less than 1% to 16.66%. The important issues that need to be answered deal with the generation and survival of the *c-myc/Ig*-carrying B cells. We will address the question whether or not both types of translocations (typical and variant translocation) occur at equal ratios. Usually the typical translocation (T12;15)-carrying B cells would survive, while the variant translocation (T6;15, T15;16)-carrying B cells would be eliminated by p53-dependent apoptosis. However, under conditions of p53 deficiency, both types of translocation-carrying cells would survive at equal ratios.

5) ***The three-dimensional organization of the mammalian nucleus.*** Using high resolution deconvolution microscopy, we have elucidated the three-dimensional (3D) organization of telomeres and chromosomes in the interphase nuclei of normal, immortalized and tumor cells. Here, we have established that the mammalian telomeres are organized dynamically and non-randomly in the 3D nucleus of normal cells around a central telomeric disk. The telomeric disk forms in late G2. On the other hand, 3D nuclei from tumor cells display a disrupted 3D nuclear telomeric organization: telomeres in tumor cell nuclei form aggregates of various numbers and sizes (Chuang *et al.*, 2004). Our ongoing studies focus the mechanism of telomere aggregation and their link to the initiation and/or promotion of genomic instability.

6) ***c-Myc alters the 3D organization of the nucleus and thereby causes chromosomal rearrangements.*** We have recently shown that c-Myc deregulation induces alterations in the 3D organization of telomeres. Telomeres form aggregates of various numbers and sizes. Some of these aggregates represent telomeric fusions. Chromosomes whose ends are fused telomerically often form dicentric chromosomes. These chromosomes break in the subsequent anaphase and generate unbalanced translocations and terminal deletions. The initiation of such breakage-bridge-fusion cycles continues until no more free chromosome ends persist (Louis *et al.*, 2005; Mai and Garini, 2005; Mai and Garini, 2006).

Translational research focus.

Basic research into cancer cell development can be used to examine the nature of cells, *i.e.* to determine whether cells are normal or tumor cells. It is my vision to translate the knowledge gained in my laboratory into clinical applications. This work is ongoing, in collaboration with clinical colleagues, using various cancer models and has led to the filing of three patent applications. Using advanced technologies (such as fluorescent *in situ* hybridization, spectral imaging, three-dimensional imaging and analysis), we identify genomic instability early. This will allow for the early detection of cancer and will also impact on the surveillance of the patient and allow for criteria to assess treatment success.

REFEREED PAPERS:

Sen A, Lichtenzstejn Z, Lichtenzstejn D, Guffei A, **Mai S**. Automatic Classification of Malignant and Non-Malignant Cells based on their Telomeric Organization. In preparation.

Guffei A, Lichtenzstejn Z, Gonçalves dos Santos Silva A, Louis SF, Caporali A, **Mai S**. Mouse Robertsonian chromosome formation following c-Myc deregulation. 2006 Submitted.

*Sarkar R, Guffei A, Vermolen BJ, Garini Y, **Mai S**. Centromere positions in nuclei of normal, immortalized and malignant B cells. 2006 Submitted.*

*Gorrini C, Squatrito M, Wark L, Martinato F, Sardella D, Bennett S, Marchesi F, Scanziani E, **Mai S**, Lough JW, Amati B. Haplo-insufficient tumor suppressor activity of Tip60 in Myc-induced lymphomagenesis through the activation of a DNA damage response 2006. Submitted.*

Kuttler F and **Mai S**. Formation of non-random extrachromosomal elements during development, differentiation and oncogenesis. **Seminars in Cancer Biology** (2006), doi: 10.1016/j.semcancer.2006.10.007.

Caporali A, Wark L, Vermolen B, Garini Y, **Mai S**. Telomeric aggregates and end-to-end chromosomal fusions require myc boxII. **Oncogene** 2006. Sep 4; [Epub ahead of print].

Intasai N, **Mai S**, Kasinrerak W, Tayapiwatana C. Binding of multivalent CD147 phage induces apoptosis of U937 cells. **Int Immunol.** 18(7):1159-69. Epub 2006 Jun 1.

Cao L, Kim S, Xiao C, Wang R-H, Coumoul X, Wang X, Li WM, Xu XL, De Soto JA, Takai H, **Mai S**, Elledge SJ, Motoyama N, Deng C-X. ATM-chk2-p53 activation prevents tumorigenesis at an expense of organ homeostasis upon Brca1 deficiency. **The EMBO J.** 25(10):2167-77. Epub 2006 May 4.

Mai S and Garini Y. The significance of telomeric aggregates in the interphase nuclei of tumor cells. **Journal Cell Biochem.** 97: 904-915. 2006 Jan 11; [Epub ahead of print]. **Article and journal cover.**

Paul JT, Mushinski JF, Henson E, Chuang M, Gibson S, **Mai S**, Johnston J. Cyclin D expression in chronic lymphocytic leukemia. **Leukemia & Lymphoma** 46: 1275-85. 2005

***Mai S** and Garini Y. Oncogenic remodeling of the three-dimensional organization of the interphase nucleus: c-Myc induces telomeric aggregates whose formation precedes chromosomal rearrangements. **Cell Cycle** 4:10, 1327-1331. 2005.*

Vermolen BJ, Garini Y, **Mai S**, Mougey V, Fest T, Chuang TCY, Chuang AYC, Wark L, and Young IT. Characterizing the Three-Dimensional Organization of Telomeres. **Cytometry Part A** 67A: 144-150.2005.

Panigrahi S and **Mai S**. Telomeres, genomic instability, DNA repair and breast cancer. **Curr. Med Chem – Anti-Inflammatory & Anti-Allergy Agents** 4: 421-428. 2005.

Rak M, Gough K, Del Bigio MR, **Mai S**, Westaway D. *In Situ* FTIR Spectromicroscopy of Brain Tissue from a Transgenic Mouse Model of Alzheimer Disease. **Vibr Spectrosc** 38, 133-141. 2005.

Louis SF, Vermolen BJ, Garini Y, Young IT, Guffei A, Zelda Lichtensztejn Z, Fabien Kuttler F, Chuang TCY, Moshir S, Mougey V, Chuang, AYC, Kerr PD, Fest T, Boukamp P, **Mai S**. c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus. **Proc Natl Acad Sci (USA)** 102(27): 9613-8. 2005.

Fest T, Guffei A, Williams G, Silva S, **Mai S**. Uncoupling of genomic instability and tumorigenesis in a mouse model of Burkitt's lymphoma expressing conditional box II-deleted Myc protein. **Oncogene** 24(18):2944-53. 2005.

Guijon FB, Greulich-Bode K, Paraskevas M, Baker P, **Mai S**. Early cervical lesions are characterized by c-Myc overexpression and locus-specific *DHFR* gene amplification. Submitted 2004.

Ermler S, Kronic D, Knoch TA, **Mai S**, Greulich-Bode KM, Moshir S and Boukamp P. Cell cycle-dependent 3D distribution of telomeres and TRF2 in HaCaT and HaCaT-myc cells. **European J of Cell Biol.** Eur J Cell Biol 83: 681-90. 2004.

Louis S, Benedek K, Mowat M, Klein G, Wiener F and **Mai S**. Elongated mouse chromosomes suitable for enhanced molecular cytogenetics. **Cytotechnology** 44(3): 143-149. 2004.

Benedek K, Chudoba I, Klein G, Wiener F, **Mai S**. Rearrangements of the telomeric region of mouse chromosome 11 in Pre-B ABL/MYC cells revealed by mBANDING, spectral karyotyping, and fluorescence *in situ* hybridization. **Chromosome Research** 12: 1-9. 2004.

Chuang TCY, Moshir S, Garini Y, Chuang AYC, IT Young, van den Doel R, Mougey V, M Perrin, M Braun, Kerr DP, Fest T, Boukamp P, **Mai S**. The three-dimensional organization of telomeres in the nucleus of mammalian cells. **BMC Biology** 2: 12. 2004.

Mai S and Mushinski JF. c-Myc-dependent genomic instability. **J. Environ Path Toxicol Oncol** 22: 179-199. 2003.

Abrahams BS, Chong ACO, Nisha M, Milette D, Brewster D, Berry ML, Muratkhodjaev F, **Mai S**, Rajcan-Separovic, Simpsom EM. Metaphase FISHing of transgenic mice recommended: FISH and SKY define BAC-mediated balanced translocation. **Genesis** 36: 134-41. 2003

Smith, G, Dushnicki, L, Smith, S, Wright, JA, **Mai, S**. c-Myc-induced extrachromosomal elements carry active chromatin. **Neoplasia** 5: 110-20. 2003. **Article and journal cover.**

Thierry Fest, T., Mougey, V., Dalstein, V., Hagerty, M.L., Milette, D., Silva, S. and **Mai, S**. c-MYC overexpression in Ba/F3 cells simultaneously elicits genomic instability and apoptosis. **Oncogene** 21: 2981-2990. 2002.

Mai, S. and Wiener, F. The impact of p53 loss on murine plasmacytoma development. **Chromosome Research** 10: 239-251. 2002.

Kuschak, T.I., Taylor, C., Wright, J.A., Wiener, F. and **Mai, S.** c-Myc initiates illegitimate replication of the ribonucleotide reductase R2 gene. **Oncogene** 21: 909-920. 2002.

Mai, S. and Mushinski, J.F. c-Myc-mediated genomic instability. **Critical Reviews in Oncogenesis** 21: 31-47. 2001.

Kuschak, T.I., Kuschak, B., Smith, G., Wright, J.A. and **Mai, S.** Immunoprecipitation of extrachromosomal DNA using anti-histone antibodies. **BioTechniques** 30 (5): 1065-1072. 2001.

Paul JT, Johnston JB, Mushinski JF, **Mai S.** Correlation of the D-type cyclins with clinical features and survival in CLL. **Blood** 98:322 -0. 2001.

Hicks, G.G., Singh, N., Nashabi, A., **Mai, S.**, Bozek, G., Klewes, L., White, E.K., 2, Koury, M.J., Oltz, E.M., Van Kaer, L., and Ruley, H.E. *Fus* deficiency in mice results in defective B lymphocyte development and activation, high levels of chromosomal instability and perinatal death. **Nature Genetics**. 24: 175-179. 2000.

Wiener, F. and **Mai, S.** Banding of mouse chromosomes after spectral karyotyping. **Technical Tips Online**. <http://www.biomednet.com/db/tto>. T01884. 2000.

Wiener, F., Kuschak, T.I., Ohno, S. and **Mai, S.** Deregulated expression of c-Myc in a translocation-negative plasmacytoma on extrachromosomal elements that carry *IgH* and *c-myc* genes. **Proc. Natl. Acad. Sci (USA)**. 96 (24): 13967-13972. 1999.

Kuschak, T.I., Taylor, C., McMillan-Ward, E., Israels, S., Henderson, D.W., Mushinski, J.F., Wright, J.A. and **Mai, S.** The *ribonucleotide reductase R2* gene is a non-transcribed target of c-Myc-induced genomic instability. **Gene**. 238: 351-365. 1999.

Mai, S., Hanley-Hyde, J., Rainey, G.J., Kuschak, T.I., Paul, J.T., Littlewood, T.D., Mischak, H., Stevens, L.M., Henderson, D.W., Mushinski, J.F. Chromosomal and extrachromosomal instability of the *cyclin D2* gene is induced by *Myc* overexpression. **Neoplasia** 1: 241-252. 1999.

Yehualaeshet, T., O'Connor, R. Green-Johnson, J., **Mai, S.**, Silverstein, R., Murphy-Ullrich, J. E., Khalil, N. Activation of rat alveolar macrophage derived L-TGF- β 1 by plasmin requires interaction with TSP-1 and TSP1 cell surface receptor, CD36. **J. Pathol.** 155: 841-851. 1999.

Kuschak, T.I., Paul, J.T., Wright, J.A., Mushinski, J.F. and **Mai, S.** FISH on purified extrachromosomal elements. **Technical Tips Online.** <http://www.biomednet.com/db/tto>. T01669. 1999.

Taylor, C. and **Mai, S.** 1998. c-Myc-associated genomic instability of the *DHFR* locus *in vivo*. **Cancer Detect Prevent.** 22: 350-356. 1998.

Fukasawa, K., Wiener, F., Vande Woude, G. F., **Mai, S.** Genomic instability and apoptosis are frequent in p53 deficient young mice. **Oncogene** 15: 1295-1302. 1997.

Shi, L., **Mai, S.**, Israels, S., Brown, K., Trapani, J. A., Greenberg, A. H. Granzyme B autonomously crosses the cell membrane and perforin initiates apoptosis and granzyme B nuclear localization. **J. Exp. Med.** 185: 855-866. 1997.

Luecke-Huhle, C., **Mai, S.**, Moll, J. c-Myc overexpression facilitates radiation-induced *DHFR* gene amplification. **Int. J. Radiat. Res.** 71: 167-175. 1997.

Mai, S., Fluri, M., Siwarski, D., Huppi, K. Genomic instability in MycER activated Rat1A-MycER cells. **Chromosome Research** 4: 365-371. 1996.

Mai, S., Hanley-Hyde, J., Fluri, M. c-Myc overexpression associated DHFR gene amplification in hamster, rat, mouse and human cell lines. **Oncogene** 12: 277-288. 1996.

Siegel, J., Fritsche, M., **Mai, S.**, Brandner, G., Hess, R.D. Enhanced p53 activity and accumulation in response to DNA damage. **Oncogene** 11: 1363-1370. 1995.

Mai, S., Hanley-Hyde, J., Coleman, A., Siwarski, D., Huppi, K. Amplified extrachromosomal elements containing c-Myc and Pvt 1 in a mouse plasmacytoma. **Genome** 38:780-785. 1995.

Mai, S. and Mårtensson, L. The c-myc protein represses β 5 and TdT initiators. **Nucl. Acid. Res.** 23: 1-9. 1995.

Mai, S. Overexpression of *c-myc* precedes the amplification of the gene encoding the dihydrofolate reductase. **Gene.** 148, 253-260. 1994.

Mai, S. and Jalava, A. C-Myc binds to 5' flanking sequence motifs of the dihydrofolate reductase gene in cellular extracts: role in proliferation. **Nucl. Acid. Res.** 22: 2264-2273. 1994.

Jalava, A. and **Mai, S.** Fos and Jun form cell specific protein complexes at the neuropeptide tyrosine promoter. **Oncogene** 9: 2369-2375. 1994.

Mai, S., Stein, B., Rahmsdorf, H.-J., Kaina, B., Lücke-Huhle, C., Herrlich, P. Damage induced signal transduction in mammalian cells. **J. Cell. Biochem., Suppl.** 14A, p. 59. 1990.

Krämer, M., Stein, B., **Mai, S.,** Kunz, E., König, H., Loferer, H., Grunicke, H. H., Ponta, H., Herrlich, P., Rahmsdorf, H.-J. Radiation induced activation of transcription factors in mammalian cells. **Radiat. Environm. Biophys.** 29: 303-313. 1990.

Lücke-Huhle, C., **Mai, S.,** Herrlich, P. UV-inducible early-domain binding factor as the limiting component of Simian Virus 40 DNA amplification in rodent cells. **Mol. Cell. Biol.** 9: 4812-4818. 1989.

Mai, S., Stein, B., Berg, S. van den, Kaina, B., Lücke-Huhle, C., Ponta, H., Rahmsdorf, H.-J., Krämer, M., Gebel., S., Herrlich, P. Mechanisms of the ultraviolet response in mammalian cells. **J. Cell Sci.** 94: 604-615. 1989.

BOOKS and BOOK CHAPTERS

Kuttler F and **Mai S.** c-Myc, genomic instability and disease. *In:* Volff, J-N. (ed). Genome dynamics. Vol 1: Genome and Disease. Karger Publishers, Wuerzburg, Germany. 171-191. 2006.

Mai S. The three-dimensional organization of the mammalian nucleus in normal and tumor cells. Atlas of Genetics and Cytogenetics in Hematology and Oncology. November 2005. URL: <http://AtlasGeneticsOncology.org/Deep/3DOrganizNuclID20053.html>.

Louis S, Gruhne B, **Mai S.** Towards an understanding of DNA replication in normal and cancer cells: facts and concepts. Review. **Progress in Oncogene Research.** Chapter I, p. 1-56. Nova Science Publishers, Inc. Hauppauge, NY. 2005.

Mai S, Guffei A, Fest T, Mushinski JF. c-Myc Deregulation Promotes a Complex Network of Genomic Instability. *In: Hormonal Carcinogenesis IV* (Eds. Li JJ, Li SA, Llombart-Bosch A). Springer-Verlag, New York, pp 87-97. 2005.

Vermolen B, Young I, Chuang A, Wark L, Chuang T, **Mai S**, Garini Y. Three-dimensional analysis tool for segmenting and measuring the structure of telomeres in mammalian nuclei, *Imaging, Manipulation, and Analysis of Biomolecules and Cells: Fundamentals and Applications III*, D. V. Nicolau, J. Enderlein, R. C. Leif, D. L. Farkas, R. Raghavachari, eds., Proc. of SPIE Vol. 5699. 2005.

Mai, S., Greulich-Bode, K.M., Boukamp. P., Bode, J.G.G. Development of imaging tools for combined protein - FISH analysis (CPFA). *Quantitative Molecular Cytogenetics*. Stockholm. 2002.

Beatty, B, **Mai, S.**, Squire, J. (Eds). FISH: A practical approach. **Oxford University Press**. 2002.

Mai, S. and Wiener, F. Murine FISH. *In: FISH: A practical approach*. **Oxford University Press**. 2002.

Mai, S., Hanley-Hyde, J., Rainey, G. J., Kuschak, T.I., Taylor, C., Fluri, M., Stevens, L. M., Henderson, D. W. and J. F. Mushinski. MYC-induced cyclin D2 genomic instability in murine B cell neoplasms. **Current Topics in Microbiol. Immunol.** 246: 183-189. 1999.

Taylor, C., Jalava, A., **Mai, S.** c-Myc dependent initiation of genomic instability during neoplastic transformation. **Current Topics in Microbiol. Immunol.** 224: 201-207. 1997.

Taylor, C., Jalava, A., **Mai, S.** c-Myc dependent initiation of genomic instability during neoplastic transformation. **Current Topics in Microbiol. Immunol.** 224: **book cover**. 1997.

Luecke-Huhle, C., **Mai, S.**, Moll, J. Correlation of gene expression and gene amplification. **Proc. of the ICRR**. pp. 560-564. 1996.

Mai, S. Genomic instability, chromosomal rearrangements. *In: Mechanisms of B cell neoplasia* 1993. Eds. Melchers, F. and Potter, P. Roche, Basel, Switzerland. pp. 343-349. 1993.

Mai, S., Lücke-Huhle, C., Kaina, B., Rahmsdorf, H.-J., Stein, B., Ponta, H., Herrlich, P. Ionizing radiation induced formation of a replication origin binding complex involving the product of the cellular

oncogene c-Myc. *In: Ionizing radiation damage of DNA: Molecular Aspects.* Wiley-Liss Inc., pp. 319-331. 1990.

Mai, S., Rahmsdorf, H.-J., Lücke-Huhle, C., Ponta, H., Kaina, B., Herrlich, P. Genotoxic agents and the control of gene expression and amplification. *In: Falk Symposium* No. 55. 1989.

Ph.D. THESIS.

Mai, S. 1991. Mechanismen der Mutagen-induzierten zellulären Streßreaktionen: Von DNA-Schädigung zu c-Myc-abhängiger Genamplifikation. Ph. D. thesis. University of Karlsruhe, Germany.

MEETINGS, SYMPOSIA, SEMINARS (1991-present):

- 1) May, 1991. Heidelberg, German Cancer Research Centre, Germany. "Mechanisms of gene amplification".
- 2) September, 1991. 17th Annual Symposium. Molecular Mechanisms of Signal Transduction. Heidelberg, Germany.
- 3) November, 1991. Oncogenes, Suppressor Genes, and Growth Factors. European School of Oncology. San Servolo, Italy. "Molecular steps onto transformation: the involvement of myc protein".
- 4) January, 1992. University of Regensburg, Germany. "Function of c-myc protein complexes".
- 5) February, 1992. Virus Strategies. The Cologne Spring Meeting. Köln, Germany.
- 6) May, 1992. The Cell Cycle. Cold Spring Harbor. USA. "Multifunctional c-Myc mediated protein interactions during cell cycle and after DNA damage".
- 7) September, 1992. Genes, Chromosomes, and Cancer. Heidelberg, Germany. "C-Myc and DHFR".
- 8) February, 1993. Protein-DNA recognition and gene control. Cologne Spring Meeting. Köln, Germany.
- 9) March, 1993. Cancer Detection and Prevention. Nice, France. "Dihydrofolate reductase gene: A c-Myc target gene".

- 10) April, 1993. Workshop on the mechanisms of B cell neoplasia 1993. Basel, Switzerland. Session II: "Genomic instability, chromosomal rearrangements": "C-Myc and genomic instability".
- 11) May, 1993. The Cell Cycle '93: Regulators, Targets and Clinical Applications. XIIIth Washington International Spring Symposium. Washington. USA. "C-Myc mediated DHFR gene amplification in mammalian cells".
- 12) May, 1993. National Cancer Institute, National Institutes of Health, USA. "C-Myc mediated genomic instability".
- 13) May, 1993. National Institutes of Health, Lymphoma Section, USA. "C-Myc mediated genomic instability".
- 14) June, 1993. 25th Annual Meeting of the European Society for Radiation Biology. Stockholm, Sweden. "Mechanisms of gene amplification in mammalian cells".
- 15) July, 1993. University of Regensburg, Germany. Graduiertenkolleg Therapieforschung Onkologie. Cloning and Analysis of Eukaryotic Genes. "Origins of Replication, Overreplication and Genomic Stability".
- 16) September, 1993. Eukaryotic DNA Replication. Cold Spring Harbor. USA. "Transient c-Myc induced DHFR gene amplification".
- 17) March 1994. Basel Institute for Immunology. Basel. Switzerland. "Origins of Replication". (Interactive Immunology Course for Technicians. Part III).
- 18) June 1994. Molecular Genetics of Cancer. Cold Spring Harbor. USA. "Genomic alterations in human carcinoma".
- 19) June 1994. Second European Symposium. Neuroblastoma: recent advances in clinical, cellular, and genetic analysis, Heidelberg. Germany. "Cell-specific transcription control during tumor cell differentiation in vitro."
- 20) September 1994. Genes Chromosomes, and Cancer. Freiburg. Germany. "Myc and genomic alterations at the DHFR locus".

21) November 1994. Biocity Symposium. Turku. Finland. "Cell-specific transcription control during tumor cell differentiation in vitro."

21) December 1994. University of Freiburg. Germany. "c-Myc and genomic instability".

23)-25) January 1995. Keystone Symposium. Oncogenes: 20 years later.

23) Jalava, A. and Mai, S. "Differentiation associated changes in c-Myc/Max complexes at the E-box sequences of two myc target genes: DHFR and NPY."

24) Hanley-Hyde, J., Reed, S. I., Mai, S. "The 5' flanking region of cyclin D2 contains four E-box elements and promotes transcription."

25) Mai, S., Jalava, A., Hanley-Hyde, J. "Myc and genomic alterations at the DHFR locus".

26) April 1995. B Cell Neoplasia Meeting. Basel. Switzerland. "Overexpression of c-Myc precedes specific genomic alterations".

27) August 1995. 10th International Congress of Radiation Research. Würzburg. Germany. "Correlation between gene expression and gene amplification".

28) October 1996. 4th McGill University International Conference on "Regulation of Eukaryotic DNA Replication", Montreal, Quebec, Canada. "DHFR gene amplification following c-Myc deregulation in vivo".

29) October 1996. Predictive Oncology and Therapy. 3rd International Symposium. "Impact of Cancer Biotechnology on diagnostics and prognostic indicators. " c-Myc-associated genomic instability of the DHFR locus in vivo".

30) January 1997. Fred Hutchinson Cancer Centre, Seattle, USA. "c-Myc dependent genomic instability".

31) June 1997. Oncogene meeting Frederick/MD/USA. "c-Myc-dependent genomic instability at the cyclin D2 locus".

32) March 1998. AACR Annual Meeting. New Orleans, LA. "Amplification of the cyclin D2 gene in chronic lymphocytic leukemia (CLL)".

33) June 1998. Cross Cancer Institute. Edmonton, Canada. "c-Myc Dependent Genomic Instability and its Clinical Relevance".

- 34) September 1998. 2nd International Symposium on Minimal Residual Disease. Berlin."Amplification of the cyclin D2 gene in chronic lymphocytic leukemia (CLL)".
- 35) January 1999. National Institute of Cancer (NCI), USA. J. F. Mushinski, D. W. Henderson, L.M. Stevens, T. I. Kuschak, C. Taylor, S. Mai. "c-Myc-induced genomic instability at the cyclin D2 locus in murine B-cell neoplasms."
- 36) January 1999. "The smallest units of c-Myc-dependent genomic instability: Implications for neoplastic transformation". University of Besancon, France.
- 37) January 1999. "The smallest units of c-Myc-dependent genomic instability." Institut Gustav Rossy, Paris, France.
- 38) February 1999. "The role of extrachromosomal elements in c-Myc-dependent genomic instability and neoplasia." Microbiology and Tumor Biology Centre, Karolinska Institute, Stockholm, Sweden.
- 39) March 1999. "N-Myc oncoprotein overexpression and DHFR gene amplification in ameloblastoma". (C. Birek, E. Henson, S. Mai). Annual Meeting of the Int. Ass. of Dental Research (IADR). Vancouver, Canada.
- 40) October 1999. "The use of spectral probes for the early detection of genomic instability." (S. Bal, Y. Garini, J. Johnston, S. Mai). AACR meeting on "Early Detection and Chemoprevention of Cancer", Bal Harbour, Florida.
- 41) October 1999. "Overexpression of c-Myc in a translocation-negative mouse plasmacytoma occurs on extrachromosomal elements". (F. Wiener, T.I. Kuschak, S. Ohno, S. Mai). AACR meeting on "Early Detection and Chemoprevention of Cancer", Bal Harbour, Florida.
- 42) January 2000. "c-Myc-dependent genomic instability". University of Toronto.
- 43) April 2000. "Overexpression of c-Myc in a translocation-negative mouse plasmacytoma occurs on extrachromosomal elements". (F. Wiener, T.I. Kuschak, S. Ohno, S. Mai). AACR, San Francisco.
- 44) April 2000. "c-Myc-Driven Amplification of the Ribonucleotide Reductase R2 Gene". (T.I. Kuschak, C.Taylor, J.A. Wright, and S. Mai). AACR, San Francisco.

- 45) April 2000. "Cyclin D2 mediates Myc-Dependent Cell Cycle Progression. (Lisa M. Stevens, Sabine Mai, Joan Hanley-Hyde, Charles Vinson, and J. Frederick Mushinski). AACR, San Francisco.
- 46) April 7-May 7, 2000. Lectures on basic molecular biology, molecular cancer biology, classical and molecular cytogenetics. Co-supervision of 5 Ph.D. students. Chiang Mai, University, Thailand.
- 47) May 2000. "c-Myc-induced genomic instability". German Cancer Research Centre (DKFZ), Heidelberg.
- 48) November 2000. "c-Myc-mediated locus-specific and karyotypic instability". NIH/Bethesda, Maryland, USA.
- 49) December 2000. "Translocation-negative mouse plasmacytomas as a model for translocation-negative human Burkitt-like lymphomas" AACR special conference. La Jolla, USA.
- 50) March 2001. "Transient excess of wt Myc activity in BAF3 cells can elicit genomic instability, proliferation and apoptosis." AACR, New Orleans (Fest, T., Mai, S.).
- 51) March 2001. "*c-Myc Inducible Chromosomal and Extrachromosomal Amplification of R2 and ODC*. AACR, New Orleans (Smith, G.M, Dushnicky, L., Symons, S., Wright, J.A., and Mai, S.)
- 52) March 2001. "c-Myc-Induced Gene Amplification Over-rides Replication Control." AACR, New Orleans (T. I. Kuschak, F. Wiener, B. C. Kuschak, C. Taylor, J. A. Wright, S. Mai).
- 53) April 2001. "Plasmacytoma development in p53-deficient BALB.cRb6.15 mice". Symposium on Plasma Cell Tumor Formation. NIH/NCI.
- 54) May 2001. D and E cyclin deregulation in chronic lymphocytic leukemia (CLL). (Paul, J.T., Johnston, J.B., Mai, S.). IX IWCLL. Abingdon, Oxfordshire, UK.

55) June 2001. "c-Myc induced *dihydrofolate reductase (DHFR)* gene amplification as genomic biomarker in cervical neoplasia." The Society of obstetricians and gynaecologists of Canada. (Guijon, F, Mai, S., Paraskevas, M.).

56) June 2001. "c-Myc-Induced Gene Amplification Over-rides Replication Control." AACR, New Orleans (T. I. Kuschak, F. Wiener, B. C. Kuschak, C. Taylor, J. F. Mushinski, J. A. Wright, S. Mai). Oncogene Meeting. Frederick, MD, USA.

57) October 2001. "New aspects of c-Myc-dependent genomic instability." Special AACR meeting. Palm Desert. USA.

58) October 2001. *c-MYC overexpression in Ba/F3 cells simultaneously elicits genomic instability and apoptosis. Hematology/Oncology Meeting. France.*

59) March 2002. Les nouveaux aspects de l'instabilité génomique induite par c-myc. Fest, T., Mougey, V., Silva, S., Smith, GM, Kuschak, TI, Kuttler, F, Mai, S. Congrès de la société française d'hématologie. Paris.

60) July 2002. *Development of Imaging Tools for Combined Protein – FISH Analysis (CPFA)*. Sabine Mai, Petra Boukamp, Jörg G. G. Bode. Euroconference on Quantitative Molecular Cytogenetics. Stockholm. www.isbe.man.ac.uk/QMC/

61) November 2002. "Novel aspects of c-Myc-dependent genomic instability". OCI. Toronto.

62) February 2003. "c-Myc-induced genomic instability". Karolinska Institute, Stockholm, Sweden.

63) February 2003. "Genomic instability is defined by the 3D intranuclear space". Karolinska Institute, Stockholm, Sweden.

64) March 2003. "Novel aspects of c-Myc-induced genomic instability". Rennes, France.

65) March 2003. "Genomic instability as a function of the 3D intranuclear space. Example: mouse plasmacytoma." B Cell Neoplasia Meeting. Washington DC, USA.

66) May 2003. "Disruption of the three-dimensional organization of telomeres and chromosomes in tumor cells". Canadian Genetic Disease Network. Kananaskis, Alberta.

67) June 2003. "Aberrations of the three-dimensional organization of telomeres and chromosomes in tumor cells". FASEB conference. "Nuclear Structure and Cancer". Vermont, USA.

68) June 2003. "Novel aspects of c-Myc-dependent genomic instability". Symposium on hormonal carcinogenesis. Valencia, Spain.

69) November 2003. A novel 3D telomeric structure in mammalian cells is disrupted during genomic instability. International Symposium on Minimal Residual Cancer, Oslo, Norway.

70) February 2004. Genomic instability has three dimensions. National Cancer Institute, Advanced Technology Center. USA.

71) March 2004. Genomic instability disrupts three-dimensional (3D) nuclear organization of telomeres and chromosomes in mammalian cells. AACR, Orlando, USA.

72) March 2004. Genomic instability in *v-abl-myc*-induced plasmacytomas. AACR, Orlando, USA.

73) March 2004. A-Max-dependent cellular growth alterations. AACR, Orlando, USA.

74) May 2004. 4th Canadian Symposium on Telomeres and Telomerases. "Alteration of the 3D organization of telomeres and chromosomes in tumor cells and after c- Myc deregulation". Bishop University, Sherbrooke, QC.

75) May 2004. 4th Canadian Symposium on Telomeres and Telomerases. Soumya Panigrahi, Landon Wark, Bart Vermolen, Alice Chuang, Kimberly Kotar, Linda Snell, Peter Watson, Yuval Garini, William Foulkes, Sabine Mai. “3D organization of telomeres in breast cancer cells”. Bishop University, Sherbrooke, QC.

76) May 2004. Canadian Genetic Disease Network Meeting. “Genomic instability has three dimensions”.

77) November 2004. AACR Special Conference on Telomeres and Telomerase in Cancer. San Francisco, USA. “Disorganization of the three-dimensional organization of telomeres in head and neck squamous cell carcinoma”. Chuang T, Chuang A, Vermolen B, Garini Y, Mai S.

78) November 2004. AACR Special Conference on Telomeres and Telomerase in Cancer. San Francisco, USA. “TeloView: a 3D analysis toolbox for measuring the organization and intensities of FISH stained telomeres in interphase nuclei”. Garini Y, Vermolen BJ, Chuang A, Chuang T, Mai S.

79) November 2004. AACR Special Conference on Telomeres and Telomerase in Cancer. San Francisco, USA. “Disruption of the three-dimensional (3D) organization of telomeres during cellular transformation”. Mai S, Garini Y, Vermolen B, Panigrahi S, Louis SF, Guffei A, Begin LR, Chuang A, Chuang T, Hicks G, Foulkes WD.

80) November 2004. AACR Special Conference on Telomeres and Telomerase in Cancer. San Francisco, USA. “Immortalization of human lymphocytes is not sufficient to alter the 3D organization of telomeres”. Louis SF, Andersson K, Henriksson M, Klein G, Mai S.

81) November 2004. Chiang Mai University, Thailand. “The Strategic Training Program “Innovative Technologies in Multidisciplinary Health Research Training” and presentation of our new training program video (www.itmhrt.ca).

82) November 2004. Chiang Mai University, Thailand. “The three-dimensional organization of telomeres - impact on genomic instability and cancer”

83) November 2004. Mahidol University. Bangkok. Thailand.” c-Myc-dependent genomic instability and cancer”

84) November 2004. Thailand Research Fund. Bangkok, Thailand. “The Strategic Training Program "Innovative Technologies in Multidisciplinary Health Research Training" and presentation of our new training program video (www.itmhrt.ca).

85) February 2005. Microbiology and Tumorbiology Center. Karolinska Institute. Stockholm, Sweden. “c-Myc-dependent genomic instability: new insights”.

86) February 2005. University of Technology Delft. Quantitative Imaging Group. “c-Myc-induced genomic instability: pathways to cellular transformation”.

87) March 2005. Lorus Therapeutics, Toronto. The dimensional organization of the nucleus: impact for genomic instability and cancer”.

88) April 2005. AACR Anaheim, California.

Gehrke I, Garini Y, Mai S. “The three-dimensional (3D) analysis of centromeres in interphase nuclei of normal and tumor cells.”

89) April 2005. AACR Anaheim, California.

Kuttler FL, Mushinski JF, Mai S. “ c-Myc-induced genomic instability: characterization of c-Myc-induced extrachromosomal elements.”

90) April 2005. AACR Anaheim, California.

Louis SF, Garini Y, Graves A, Gruhne B, Mai S. “Mechanisms of c-Myc dependent gene amplification.”

91) April 2005. AACR Anaheim, California.

Wark LJ and Mai S. “Three-dimensional (3D) analysis of telomere positioning during the cell cycle”.

92) April 2005. University of Sherbrooke, Quebec. “The three-dimensional organization of the nucleus: role in genomic instability and cancer”.

93) April 2005. Association Cytogenetique du Quebec. Chateau Bromont., Quebec.
“Conformation tridimensionnelle du noyau et emergence de l’instabilite genomique”.

94) May 2005. CIHR Strategic Training Program Meeting. Mont Tremblant. Quebec.
Gehrke I, Garini Y, Mai S. “The three-dimensional (3D) analysis of centromeres in interphase nuclei of normal and tumor cells.”

95) May 2005. CIHR Strategic Training Program Meeting. Mont Tremblant. Quebec.
Louis SF, Garini Y, Graves A, Gruhne B, Mai S. “Mechanisms of c-Myc dependent gene amplification.”

96) June 2005. FASEB Summer Conference. Vermont. USA. “c-Myc deregulation remodels the three-dimensional organization of the nucleus”.

97) June 2005. FASEB Summer Conference. Vermont. USA.
Louis SF, Garini Y, Graves A, Gruhne B, Mai S. “Mechanisms of c-Myc dependent gene amplification.”

98) June 2005. FASEB Summer Conference. Vermont. USA.
Gehrke I, Garini Y, Mai S. “The three-dimensional (3D) analysis of centromeres in interphase nuclei of normal and tumor cells.”

99) September 2005. CCMG Annual Conference. Chateau Bromont, Quebec. c-Myc remodels the three-dimensional organization of the interphase nucleus.”

100) October 2005. Cell, Molecular and Atomic Imaging Symposium. St. Boniface.
“Imaging technologies and training at the Genomic Centre for Cancer Research and Diagnosis”.

101) October 2005. Cell, Molecular and Atomic Imaging Symposium. St. Boniface.
“c-Myc deregulation remodels the 3D organization of the interphase nucleus”.

102) November 2005-December 2005. “FISH and SKY: Theory and Applications”. 1st
international workshop in Chiang Mai, Thailand.

103-105) April 2006. AACR, Washington DC, USA.

c-Myc alters the three-dimensional order of telomeres and chromosomes in the interphase nucleus. *Sherif F. Louis, Bart Vermolen, Fabien Kuttler, Yuval Garini, Sabine Mai*. Proc Amer Assoc Cancer Res 2006;47:[4240]

The three-dimensional order of telomeres impacts on tumorigenesis. *Andrea Caporali, Landon Wark, Sabine Mai*. Proc Amer Assoc Cancer Res 2006;47:[4985]

Three dimensional organization of telomeres in hereditary and non-hereditary breast cancer. *Soumya Panigrahi, Sabine Mai, William Foulkes, Kimberley Kotar, Louis R. Bégin*. Proc Amer Assoc Cancer Res 2006;47:[4991]

106) August/September 2006. Telomeres and Genome Stability. Switzerland.

107) September 2006. Hormonal Carcinogenesis. Montpellier. France.

CURRENT SOURCES OF FUNDING

Investigator: Sabine Mai

Sponsor: CancerCare Manitoba Foundation

Project: The significance of telomeric aggregates in tumor development

Funds authorized: \$50,000/annum (2006-2007)

Investigator: Peter Watson

Co-applicant: Sabine Mai

Sponsor: CIHR Research Resource Grant Award

Project: The Manitoba Tumor Bank - a critical engine for cancer research.

Funds authorized: \$105,065/annum (2006-2011)

Investigator: Sabine Mai

Sponsor: The Susan G. Komen Breast Cancer Foundation

Project: The 3D telomeric signature(s) of DCIS.

Funds authorized: US \$249, 805 (2006-2009)

Investigator: Sabine Mai

Sponsor: CCMF

Project: Live Cell 3D Imaging Station.

Funds authorized: \$191,983 (2006)

Investigator: Sabine Mai

Sponsor: NCIC

Project: Mechanisms of chromosomal rearrangements.

Funds authorized: \$450,000 (2005-2008)

Investigator: William Foulkes

Co-Investigators: Torsten Nielsen and Sabine Mai

Sponsor: CBCRA

Project: BRCA1, CDC4, cyclin E and chromosomal instability in breast cancer.

Funds authorized: \$310,00 (2005-2008)

Investigator: Sabine Mai

Sponsor: NSERC

Project: Tumor progression by c-Myc

Funds authorized: \$60,000 (2005-2007)

Investigator: Sabine Mai

Sponsor: CancerCare Manitoba

Project: Mechanisms of telomeric aggregate formation in mammalian interphase nuclei

Funds authorized: \$48,000 (2005-2006)

Investigator: Sabine Mai

Sponsor: CIHR

Project: Mechanisms of c-Myc-induced genomic instability.

Funds authorized: \$83,826/annum (2005-2008) – declined.

Investigator: Sabine Mai

Sponsor: CIHR IPM

Project: Tumor cell detection through 3D molecular imaging and analysis.

Funds authorized: \$25,000 (1/2005-5/2005)

Investigator: Sabine Mai

Sponsor: CancerCare Manitoba

Project: Genomic instability in three dimensions

Funds authorized: \$50,000 (2004-2005)

Investigators: William Foulkes, Sabine Mai, Yuval Garini

Sponsor: US Army Breast Cancer Concept Award

Project: Breast cancer in three dimensions

Funds authorized: \$ US 80,000 (2004-2005)

Investigator: Patrick C. Choy

Co-applicant: Sabine Mai

Sponsor: Canadian Institutes of Health Research (CIHR)

Project: Maintenance Grant Application in Support of the Multi-User Flow Cytometry Laboratory in the Faculty of Medicine, U of M

Funds authorized: \$ 58,352 (2004-2007)

Investigator: Jan Friedman

Co-applicant: Sabine Mai

Sponsor: Canada Foundation for Innovation (CFI)

Project: Canadian Molecular Cytogenetics Platform

Funds authorized: \$ 4.5 mill. (2004-2009)

Investigator: Sabine Mai

Sponsor: Canadian Institutes of Health Research (CIHR).

Project: Strategic Training Program Grant: “Innovative Technologies in Multidisciplinary Health Research Training”.

Funds authorized: 300,000.00/annum (2002-2008).

Investigator: Sabine Mai.

Sponsor: Canadian Institutes of Health Research (CIHR).

Project: “Mechanisms of genomic instability”.

Funds authorized: \$ 83,826 (2002-2005).

Investigator: Jim Davie

Co-applicant: Sabine Mai

Sponsor: Canada Foundation for Innovation (CFI)

Project title: “Manitoba Breast Cancer Research and Diagnosis Centre”

Funds authorized: \$ 3,795 792

Investigator: Mahesh Chaturvedi

Co-applicant: Sabine Mai

Sponsor: Canada Foundation for Innovation (CFI)

Project title: “200 kV Field Emission Gun Cryo-Transmission/Scanning Electron Microscope”

Funds authorized: \$ 2,994 236

Investigator: Sabine Mai

Sponsor: National Science and Engineering Research Council (NSERC).

Project: “c-Myc-dependent *DHFR* gene amplification”

Funds authorized: \$ 30,000 (2001-2005)

PREVIOUS SOURCES OF FUNDING

Investigator: Sabine Mai

Sponsor: CancerCare Manitoba

Project: "Development and validation of quantitative algorithms that define the position of telomeres in the three-dimensional (3D) mammalian interphase nucleus."

Funds authorized: \$50,000 (2003-2004).

Investigator: Sabine Mai

Sponsor: Paul H. T. Thorlakson

Project: "Application of Comparative Genomic Hybridization (CGH) to Genetic Analysis of Pediatric Acute Lymphoblastic Leukemia (ALL)".

Funds authorized: \$24,000. (2002-2003).

Investigator: Sabine Mai

Sponsor: CancerCare Manitoba

Project: TRF2: An anaphase chromosome stabilizing protein?

Funds authorized: 49,12.00/annum (2002-2003).

Investigator: Sabine Mai

Sponsor: Canadian Institutes of Health Research (CIHR)

Project: CIHR Training Program Development Grant

Funds authorized: \$ 4,000 (2001-2002)

Investigator: Sabine Mai

Sponsor: Canadian Institutes of Health Research (CIHR)

Project: "The impact of p53 on c-Myc-dependent genomic instability and neoplasia"

Funds authorized: \$ 52,500,-/annum (1998-2003)

Investigator: Sabine Mai

Sponsor: Manitoba Health Research Council (MHRC) – University-Industry Collaborative Grant

Project: Early detection of cervical cancer

Funds authorized: 18,750 (2001-2002)

Investigator: Sabine Mai

Sponsor: Applied Spectral Imaging Inc.
Project: Early detection of cervical cancer
Funds authorized: 18,750 (2001-2002)

Investigator: S. Mai, J. B. Johnston
Sponsor: Canada Foundation for Innovation (CFI)
Project: “The Genomic Centre for Cancer Research and Diagnosis”
Funds authorized: \$ 2.25 mill. (1999-2004)

Investigator: Sabine Mai
Sponsor: CancerCare Manitoba
Project: “Extrachromosomal c-Myc activation”
Funds authorized: \$ 50,000 (2001-2002)

Investigator: S. Mai
Sponsor: National Science and Engineering Research Council (NSERC)
Project: Mechanisms of *DHFR* gene amplification upon c-Myc deregulation
Funds authorized: 29.800 (2000-2001)

Investigator: J. B. Johnston, S. Mai, A. Begleiter
Sponsor: Leukemia Research Fund of Canada
Project: “Novel mechanism of action of the nucleoside analogs in chronic lymphocytic leukemia”
Funds authorized: \$ 25.000/annum (1999-2001)

Investigator: S. Mai
Sponsor: Manitoba Medical Service Foundation
Project: “Chromosome 15 rearrangements in AKR lymphomas.

Funds authorized: \$ 20.000,-/annum (2000-2001)

Investigator: Sabine Mai
Sponsor: Leukemia Research Fund of Canada (LCRF)
Project: Identification of candidate genes in non-random rearrangements of chromosome 15 in AKR lymphomas with diploid or trisomic chromosome 15 constitution.
Funds authorized: 45.000 (2000-2001)

Investigator: J. B. Johnston, S. Mai, A. Begleiter

Sponsor: Manitoba Cancer Treatment and Research Foundation

Project: "Identification and functional characteristics of extrachromosomal genes in chronic lymphocytic leukemia"

Funds authorized: \$50.000 /annum (1999-2000)

Investigator: S. Mai

Sponsor: Manitoba Health and Research Council (MHRC) Establishment grant

Project: "Functional interactions between c-Myc and p53 during c-Myc-dependent genomic instability and neoplasia?"

Funds authorized: year 1: \$ 34.000,-; year 2: 33.000,-; year 3: 33.000,- (1997-2000)

Investigator: S. Mai

Source: National Science and Engineering Research Council (NSERC)

Project: "The DHFR gene, a target of c-Myc"

Funds authorized: \$ 30.000,-/annum (1995-2000)

Investigator: J.B. Johnston, A. Begleiter, S. Mai

Sponsor: Berlex Canada Inc.

Project: A novel mechanism of action of fludarabine in chronic lymphocytic leukemia

Funds authorized: \$ 56. 104 (1999).

Investigator: A. Ronald

Co-applicant: S. Mai (one of ten co-applicants)

Sponsor: Medical Research Council

Project: FACS facility

Funds authorized: \$ 350.000 (1999)

Investigator: S. Mai and J. B. Johnston

Sponsor: Leukemia Research Fund of Canada

Project: "Cyclin D2 amplification in Chronic Lymphocytic Leukemia"

Funds authorized: \$ 44,620/annum (1998-1999)

Investigator: S. Mai and J. Johnston

Sponsor: Manitoba Cancer Treatment and Research Foundation (MCTRF)

Project: “Genomic Instability in chronic lymphocytic leukemia”

Funds authorized: \$ 49.970,85/annum (1998-1999)

Investigator: S. Mai

Sponsor: Children Hospital Research Foundation

Project: “Does N-Myc drive DHFR gene amplification in neuroblastoma?”

Funds authorized: \$ 5000,-/annum (1997-1999)

Investigator: S. Mai

Sponsor: Manitoba Medical Service Foundation (MMSF)

Project: “The role of DHFR in tumorigenesis”

Funds authorized: \$ 25.000,-/annum (1998-1999)

Investigator: S. Mai

Sponsor: Manitoba Health Research Council

Project: “The role of c-Myc in gene amplification”

Funds authorized: \$ 48.000,- (1995-1997)

Investigator: S. Mai

Sponsor: Manitoba Cancer Foundation

Project: “The role of c-Myc in neoplasia”

Funds authorized: \$ 31.500,- (1996-1997)

Investigator: S. Mai

Sponsor: Thorlakson Foundation Fund

Project: “Mechanisms of Genomic Instability”

Funds authorized: \$ 15.000,- (1996-1997)

Investigator: S. Mai

Sponsor: Research Development Fund

Project: “Translocation-free juxtaposition of *c-myc* and *immunoglobulin* loci during B cell neoplasia”

Funds authorized: \$ 8.000,- (1997-1998)

ADVISORY COMMITTEES:

1) Christine Vandavelde (MSc.), Department of Biochemistry, 1998-2001

2) Keding Chen (MSc.), Department of Physiology, 1997-2001

- 3) Theodore Kuschak (Ph.D.), Department of Microbiology, 1996-2000
- 4) Greg Smith (Ph.D.), Department of Biochemistry, 1998-2003.
- 5) Slavica Djuric-Ciganovic (MSc.), Department of Human Genetics, 1998-1999.
- 6) James T. Paul, (MSc.), Department of Human Genetics, 1998-2001.
- 7) Gracjan Bozek, Department of Physiology, 1998-2005.
- 8) External Ph.D. reviewer for Chen Delin's Ph.D. thesis on genomic instability and chromosomal fragmentation, The National University of Singapore. 1999.
- 9) External Ph.D. reviewer for the Thai Jubilee Program, Chiang Mai University. 2000.
- 10) External Ph.D. reviewer for Ajay Pandita, University of Toronto. 2000.
- 11) Kendra Caan (M.Sc./Ph.D.). Department of Biochemistry and Medical Genetics, 2000-present.
- 12) Co-advisor of Somchai Awakairt Ph.D., Faculty of Pharmacy, Chiang Mai, Thailand, 2000.
- 13) Karen Poirier, Department of Physiology, September 2000-October 2001.
- 14) Hortense Rabet, Department of Physiology, September 2001-May 2003.
- 15) Michael Lizardo, Department of Oral Biology, July 2002-May 2003.
- 16) Marlon Hagerty, Department of Physiology, July 2002-present.
- 17) Tony Chuang, Department of Physiology, July 2002-present.
- 18) Claire Sevenhuysen, Virology Laboratory, Winnipeg, June 2002-present.
- 19) Margaret Rak, Department of Chemistry, June 2003-present.
- 20) Sherif Louis, Department of Physiology, August 2003-present.
- 21) Soumya Panigrahi, Department of Physiology, January 2004-September 2006.
- 22) Jessica Gietz, Department of Biochemistry and Medical Genetics, January 2005-August 2005.
- 23) S. Maddikka. Department of Biochemistry and Medical Genetics. Candidacy committee. 2005.

STUDENTS AND POST DOCS SUPERVISED

a) M.Sc.

Paul, J.	1998- 2001		MICB, Biochem	M.Sc., 2001
Karen Poirier	2000	MSc student	Physiology/MICB	technician
Marlon Hagerty	2002	MSc. student	Physiology/MICB	MSc. in progress
Tony Chuang	2002	MSc. student	Physiology/MICB	MSc in progress

b) Ph.D.

Figuerola, R.	1995	Ph.D.	Heidelberg, Germany	Ph.D., scientist
Smith, G.	98-02	Ph.D.	MICB, Biochem	MSc, Virol. lab, Wpg
Kuschak, T.I.	96/00	Ph.D. student	MICB, Microbiol	Ph.D.02, Virol. Lab
Hortense Rabet	2001	Ph.D student	Physiology/MICB	technician
Louis, Sherif	2003	Ph.D. student	Physiology/MICB	Ph.D. in progress
Dr. Panigrahi, S	2004	Ph.D. student	Physiology/MICB	Ph.D. in progress

c) Post doctoral fellows (PDFs)

Jalava, A.	1996/7	post doc	MICB	post doc (Auburn)
Thangirala, S.	1996/7	post doc	MICB	post doc (Biochem)
Baijal, P.	1998-	Post doc	MICB	post doc in progress
Santiago Silva	2001	PDF	MICB	PDF (Sweden)
Chat Tayapiwatana	2002	PDF	MICB	PDF (Chiang Mai)
Fabien Kuttler	2004	PDF	MICB	2004-2006
Jun Li	2006	PDF	MICB	06/2006-
Hao Song	2006	PDF	MICB	start date: Oct 2006
Jana Harizanova	2006	PDF	MICB	start date: Nov 1/2006

d) Summer students/rotation students/project students

Narayansingh, R.	1996	summer student	MICB	MD. in progress
Paul, J.	1997	summer student	MICB	MSc. student (MICB)
Kwasnika, A.	1997	summer student	MICB	MSc. student
Landon Wark	2002	Summer student	MICB	Grad student/Brandon
Morgan Jarvis	2002	Summer student	MICB	Grad student/Queens
James Tsang	2002	Summer student	MICB	Grad student/U of M (U of BC)
Beaudin, J.	1997	summer student	MICB	student (U of M)
Marlon L. Hagerty	2000	summer student	MICB	2 nd year student
Marc, J.	1998	student	Dept. Physiology	lecture course student
Guffei, A.	1999	summer student	MICB	high school student
Harwood, P.	1999	summer student	MICB	high school student
Vukovic, B.	1999	project student	MICB	Ph.D. student, U of T
Qing Zhao	2000	project student	MICB	student on probation
Guffei, A.	2000	summer student	MICB	student researcher
Sakar, R.	2000	summer student	MICB	high school student

Tony Chuang	2000	rotation project	MICB	resident
Marlon Hagerty	2001	Summer student	MICB	MSc student
Rahul Sarkar	2001	Summer student	MICB	informatics student
Landon Wark	2003	Summer student	MICB	Grad student/Brandon
Morgan Jarvis	2003	Summer student	MICB	Grad student/Queens
Karen Lumsden	2004	Summer student	MICB	Grad student
Landon Wark	2004	Summer student	MICB	Grad student U of M
Morgan Jarvis	2004	Summer student	MICB	Grad student/Queens
Alexander Graves	2005	Summer student	MICB	stud/Western Ontario
Jeanna Scherzcer	2005	Summer student	MICB	stud/Edinburgh
Sourabh Maiti	2005	Summer student	MICB	stud/U of M
Alexander Graves	2006	Summer student	MICB	stud/Western Ontario
Filip Misev	2006	Summer student	MICB	stud/U of Basel
Adnan Arapovic	2006	Summer student	MICB	stud/ Winnipeg

e) Visiting students and fellows supervised

a) M.Sc.

Mathilde Perrin, University of Besançon, France 2003

b) Ph.D.

Sharareh Moshir, German Cancer Research Center, Heidelberg, Germany 2002, 2003

Sibylle Ermler, German Cancer Research Center, Heidelberg, Germany 2003

Virginie Mougey, University of Besançon, France 2001

Virginie Mougey, University of Besançon, France 2002

Virginie Mougey, University of Besançon, France 2003

Andrea Caporali, University of Parma, Italy 6/8-2004

Andrea Caporali, University of Parma, Italy 6/9-2005

c) Visiting fellow

Martina Braun, EMBL Heidelberg, Germany 2000-2002

d) undergraduate students

Bettina Gruhne, University of Tuebingen, Germany 4/5-2004

f) Visiting PDFs supervised

Dr. Karin Greulich-Bode, German Cancer Research Center, Heidelberg, Germany 2002

*g) CIHR trainees supervised***2002**

Verayuth Praphanphoj, Dr.	Genetic Lab, Rajanukul Hospital, Thailand
Amanda Guffei	MICB
Sharareh Moshir	German Cancer Research Center
Virginie Mougey	University Hospital Jean Minjoz, France
Carolyn Gibbs	Physiology, University of Manitoba (U of M)
Steve Melnyk	Fort Richmond Collegiate
Alex Dibrov	Fort Richmond Collegiate
Shannon Neuman	MICB
Marlon Hagerty	Physiology, U of M
Tony Chuang	Physiology, U of M
Lorie Carriere	Apotex Fermentation Inc
Alicja Kellar	Apotex Fermentation Inc
Eduard Popke	Apotex Fermentation Inc
Michelle McAuley	Apotex Fermentation Inc
Margaret Rak	Chemistry, U of M
Paula Espino	MICB, Biochemistry & Med Genetics
Trung N. Le	MICB, Anatomy
Yasmin Banu	MICB
Shihua He	MICB
Lin Li	MICB, Biochemistry & Med Genetics
Virginia Spencer	MICB, Biochemistry & Med Genetics
Michaela Samek	MICB
Cheryl Taylor	MICB
Sherif Louis	MICB, Microbiology

2003

Dr. Sonia Sachot	University of Rennes1, Medicine
Dr. Mehdi Alizadeh	University of Rennes1, Medicine
Mary Ann George	Toronto
Dr. Chatchai Tayapiwatana	Chiang Mai University, Immunology
Michaela Samek	MICB
Rukmali Mendis	MICB
Dr. Tony Chuang	MICB, Physiology, U of M, HSC
Shibani Bal	Clinical Diagnostics Lab, HSC
Marlon Hagerty	MICB, Physiology, U of M
Cheryl Taylor-Kashton	MICB
Christina Walker	MICB
Margaret Rak	Chemistry, U of M
Trung N Le.	MICB, Anatomy
Lin Li	MICB, Biochemistry & Med Genetics
Sibylle Ermler	German Cancer Research Centre, Germany

Dr. Yasmin Banu
Dr. Malgorzata Burek
Shannon Neumann
Paula Espino
Dr. Watchara Kasinrerak
Dr. Nusra Sittidilokratna
Mike Lizardo
Angela Dawson

MICB
University of Muenster
MICB
MICB, Biochemistry & Med Genetics
Chiang Mai University, Immunology
Mahidol University
MICB, Oral Biology
Clinical Diagnostics Lab, HSC

Atmuri, Vasantha
Balakrishnan, Apoona
Chuang, Alice
Crawford-Young, Susan
Emberley, Ethan
Dunn, Katherine
Fetterman, Christina
Law, Warren
Lee, Debbie
Lewis, Anthony
Sourabh, Maiti
Martelli, Lucia
Morato de Oliveira, Fabio
Park, Ji-Seong
Perrin, Mathilde
Sahai, Beni
Triggs-Raine, Barabara
Versace, Antonietta
Wanichanon, Chaitip

U of M, Biochemistry/Med Genetics
Fort Richmond Collegiate
MICB
Electrical Engineering, U of M
U of M, Pathology
U of M, Biochemistry/Med Genetics
MICB
MICB
St George Hospital, Oncology, UK
U of M, Biochemistry/Med Genetics
Vincent Massey Collegiate
U of Sao Paulo, Brazil
U of Sao Paulo, Brazil
MICB
U of Besançon, France
Cadam Provincial Lab
U of M, Biochemistry/Med Genetics
U of M, Biochemistry/Med Genetics
Science Mahidol University, Thailand

Auditors:

Bal, Shibani
Sahai, Vandama
Wover, Roberta
Drobic, Bojan

HSC, Clinical Cytogenetics Lab
MICB
MICB
MICB

2004

Piranit Kantaputra
Katalin Benedek
Eva Darai
Bart Vermolen
Fabio Morato de Oliveira
Nutjeera Intasai
Vasantha Atmuri
Shan Li
Anna Kania
Silvia Rogatto
Christina Fetterman

Chiang Mai University, Thailand
Karolinska Institute, Stockholm, Sweden
Karolinska Institute, Stockholm, Sweden
Delft University of Technology, The Netherlands
University of Sao Paulo, Brazil
Chiang Mai University, Thailand
University of Manitoba, Biochemistry/Med Genetics
University of Manitoba, Physiology
Munster university, Germany
University of Sao Paulo, Brazil
MICB

Warren Law	MICB
Zhi-Sheng Jiang	University of Manitoba, Physiology
Klaus Wroggeman	University of Manitoba, Biochemistry/Med Genetics
Ji-Seong Park	MICB
Shihua He	MICB
Roberta Wover	MICB
Tanguy Marqueste	University of Manitoba, Physiology
Gary Jones	Laboratory of Genetics, NIH, USA
Katherin Dunn	MICB
Alice Chuang	MICB

Auditors:

Fabien Kuttler	MICB
Soumya Panigrahi	MICB

2004

Betty Engracia	De La Salle University, Philippines
Nehal Patel	University of Manitoba, Winnipeg
Phatchaneeya Thammawong	Chiang Mai University, Thailand
Shauna Loewen	University of Manitoba, Winnipeg
Jinsil Kim	University of Manitoba, Winnipeg
Soumya Panigrahi	University of Manitoba, Winnipeg
Fabien Kuttler	Manitoba Institute of Cell Biology, Winnipeg
Richard Wiens	University of Manitoba, Winnipeg
Meghan Gallant	University of Manitoba, Winnipeg
Jessica Gietz	University of Manitoba, Winnipeg
Morel Rubinger	CancerCare Manitoba, Winnipeg
Mary Lynn Duckworth	University of Manitoba, Winnipeg
Dianna Martin	University of Manitoba, Winnipeg
Shahrzad Jalali	University of Manitoba, Winnipeg
Charlton Cooper	University of Manitoba, Winnipeg
Mohammad Murshedul Alam	University of Alberta, Edmonton
Juliana Cuzzi	University of Sao Paulo, Brazil
Ana Carolina Laus	University of Sao Paulo, Brazil
Andreea Nistor	University of Manitoba, Winnipeg
Tiba Tsafack	University of Yaounde I, Cameroon
M. V. Subba Reddy	University of Manitoba, Winnipeg
Saeid Ghavami	Manitoba Institute of Cell Biology, Winnipeg
Travis Clark	University of Toronto, Toronto
Akira Yamasaki	University of Manitoba, Winnipeg
Carla Jean Thompson	Fort Richmond Collegiate, Winnipeg

Waiting list/auditors

Sirirak Chantakru	Kasetsart University, Thailand
Dina Johar	Manitoba Institute of Cell Biology, Winnipeg
Karol McNeill	University of Manitoba, Winnipeg

Man Ying

Shaftsbury High School, Winnipeg

2005

Dr. Betty Engracia	De La Salle University, The Philippines.
Andrea Caporali	University of Parma, Italy.
Rahul Sarkar	University of Waterloo, Ontario.
Shauna Loewen	University of Manitoba, Winnipeg.
Heidi Dietrich	Delft University, The Netherlands.
Vasantha Atmuri	University of Manitoba, Winnipeg.
Dr. Sabine Hombach	University of Manitoba, Winnipeg.
Sherif Louis	University of Manitoba, Winnipeg.
Iris Gehrke	University of Manitoba, Winnipeg.
Jessica Gietz	University of Manitoba, Winnipeg.
Dr. Helen Tempest	University of Kent, UK.
Ana Carolina Laus	University of Sao Paulo, Brazil.
Antonietta Versace	Manitoba Institute of Cell Biology, Winnipeg.
Landon Wark	University of Manitoba, Winnipeg
Zhenyu Li	University of Manitoba, Winnipeg.
Dr. Fabien Kuttler	Manitoba Institute of Cell Biology, Winnipeg.
Richard Wiens	University of Manitoba, Winnipeg.
Dr. Reena Ray	Children's Hospital of Eastern Ontario, Ontario.
Juliana Cuzzi	University of Sao Paulo, Brazil.
Dr. Sinee Disthabanchong	Mahidol University, Thailand.

2005 Nov-December. 1st international workshop on FISH and SKY in Chiang Mai, Thailand.

Dr. Chotipa Sakulsingharoj	Department of Biology, Faculty of Science Maejo University, Chiang Mai.
Kanokkan Bumroongkit	Department of Anatomy, Faculty of Medicine, Chiang Mai University, Chiang Mai.
Dr. Aprichart Oranratnachai	Department of Obstetrics and Gynaecology, Faculty of Medicine, Chiang Mai University, Chiang Mai.
Chaniporn Puaninta	Department of Anatomy, Faculty of Medicine, Chiang Mai University, Chiang Mai.
Dr. Dalina Tanyong (Itchayanan)	Department of Clinical Microscopy, Faculty of Medical Technology, Mahidol University, Bangkok.
Khajornsak Tragoolpua	Division of Clinical Microbiology Department of Medical Technology Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai.
Dr. Kearkiat Praditpornsilpa	Division of Nephrology Department of Internal Medicine, King Chulalongkorn Memorial Hospital, Bangkok.
Dr. Krai Meemon	Department of Anatomy, Faculty of Science, Mahidol University, Bangkok.
Dr. Krissanapong Manotham	Renal Unit, Department of Medicine, Lerdsin General Hospital, 190, Silom, Bang-Rak.

Dr. Patthama Pongpom Department of Microbiology, Faculty of Medicine, Chiang Mai University. Chiang Mai.

Dr. Piyanuch Boonkumkiao (Niamsup) Department of Biology, Faculty of Science, Maejo University, Sansai, Chiang Mai.

Dr. Prasit Phowthongkum Faculty of Medicine, Chulalongkorn University, Bangkok.

Dr. Rutch Khattiya Food animal clinic, Faculty of Veterinary Medicine, Chiangmai University, Mae-hia, Muang, Chiang Mai.

Dr. Supaporn Suwiwat Department of Pathology, Faculty of Medicine, Prince of Songkla University, Hat-Yai, Songkla.

Dr. Surintorn Boonanuntanasarn School of Animal Production Technology, Institute of Agricultural Technology, Suranaree University of Technology, Nakhon Ratchasima.

Dr. Sutisa Nudmamud-Thanoi Department of Anatomy, and Center for Central Facility and Research Development, Faculty of Medical Science, Naresuan University, Phitsanulok.

Dr. Suvara K. Wattanapitayakul Department of Pharmacology, Faculty of Medicine, Srinakharinwirot University, Bangkok.

Dr. Tewin Tencomnao Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok.

Dr. Tuangporn Suthiphongchai Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok.

Dr. Weerah Wongkham Department of Biology, Faculty of Science, Chiang Mai University, Chiang Mai.

2006 (spring)

Molly Pind U of Manitoba

Dr. Gregory Weitsman MICB, U of Manitoba

Emilia Wiechec University of Aarhus, Denmark

Dr. Yanmin Victor Yang NRC and U of Manitoba

Francisco Mendoza MICB, U of Manitoba

Dr. Soumya Panigrahi MICB, U of Manitoba

Johannes Kohlschutter University of Freiburg, Germany

Sherif Louis MICB, U of Manitoba

Dr. Ludger Klewes MICB, U of Manitoba

Aaron Sen MICB, U of Manitoba

Dr. Raouf Fetni Ste-Justine Hospital, Mc Gill Univ. and U of Montreal, Montreal

Macoura Gadji U of Sherbrooke, Quebec

Nina Thiessen NRC-IBD

Dr. Oumar Samassekou U of Sherbrooke, Quebec

Sawcene Hazourli U of Montreal, Quebec

Dr. Suradej Hongeng Mahidol University, Bangkok, Thailand

Dr. Adriana Szeghalmi U of Manitoba

Dr. Alex Gutsol U of Manitoba

Lisa Manning Canadian Food Inspection Agency/National Centre for Foreign Animal Disease

Dr. Esteban Alberti


Dr. Anna Szeles

International Center of Neurological Restoration,
Havana, Cuba
Karolinska Institute, Sweden


TEACHING AND TRAINING

- "Genomic Instability" Cancer Biology (course #36.720) 1998-present
- New Chromosome Technologies Introduction to Human Genetics (course #125.302) 1998-2002
- MICB and other Departments Use of the FISH facility 1995-present
- Fort Garry School Division No. 5 Science Curriculum for Genetics and Cancer Biology
- Teaching and Training of teachers and student (grades 10-12)
- Students of other schools summer projects for highly motivated students who wish to start careers in science
- 4th Year Radiation Oncologists Seminars on 'RNA', 'DNA', 'Chromosomes' (December 1999)
- Resident Training Research Project on 'Head and Neck' cancer (in collaboration with Drs. C. Birek and P. Kerr).
- Chiang Mai University (Thailand) Co-supervision of 5 Ph.D. students. Laboratory courses and introduction to novel technologies. Visiting lecturer: 4/2000-5/2000.
- Nucleic Acids course (36.724) 2000-present
- CIHR Strategic Training Program "Innovative Technologies in Multidisciplinary Health Research Training". Program funded for 6 years, started in 2002. Our training website: <http://www.itmhrt.ca>
- Organization of workshops and training
- 1) PCR and Cloning November 1999
 - 2) Spectral karyotyping November 2000
 - 3) Advanced Microscopy and Imaging January 2001
 - 4) Gateway Cloning April 2001
 - 5) Principles of FISH September 2001
 - 6) New technologies October 2001 (Medical Hall of Fame students)
 - 7) Development of CIHR Strategic Training Program entitled "Innovative Technologies in Multidisciplinary Health Research" April 2001-present
 - 8) CIHR Strategic training Program workshops since 2002. Details are listed on the training website (<http://www.itmhrt.ca>)


SUPPORTING DATA:



BRCA1-mutant carrier with breast cancer.



BRCA2-mutant carrier with breast cancer



non-BRCA1/2 carrier with breast cancer